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Hydrogen sulfide (H2S), similarly to the other two gasotransmitters 
carbon monoxide (CO) and nitric oxide (NO), plays a fundamental role in 
human (patho)physiology, acting as a signalling molecule at low 
concentrations or exerting toxic effects at higher levels (Wang, 2012). 
Interestingly, H2S plays such a dual role also on mitochondrial function, 
inhibiting cytochrome c oxidase (complex IV) at higher concentrations or 
stimulating mitochondrial respiration at lower concentrations. Sulfide 
oxidation by mitochondria is indeed coupled to electron injection into the 
mitochondrial respirator chain and thus stimulates cellular respiration, while 
preventing toxic accumulation of sulfide (Szabo, 2014). Because H2S is 
crucially involved in the regulation of cellular homeostasis, the 
bioavailability of this gaseous signalling molecule must be finely controlled 
through a correct balance between its synthesis and breakdown (Kabil & 
Banerjee, 2014). H2S biologic effects are interestingly interconnected with O2 
and the action of the other two gasotransmitters CO and NO. Perhaps not 
surprisingly, abnormally increased or decreased H2S levels are widely 
reported to be associated with various pathologies (Hellmich & Szabo, 2015; 
Wallace & Wang, 2015). Hence the relevance of investigating the molecular 
mechanisms that control the cell bioavailability of H2S and its cross-talk with 
O2, CO and NO, as well as the specific role of H2S in human diseases.  
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One of the goal of the present thesis work has been to gain insight 
into the molecular bases of classic homocystinuria. This is a rare metabolic 
disease caused by mutations in the gene of cystathionine β-synthase (CBS), 
one of the major H2S-synthesizing enzymes in humans (Mendes, 2014). CBS 
activity regulates homocysteine levels in humans and was previously shown 
to be fine-tuned by both the allosteric stimulator S-adenosyl-L-methionine 
and the inhibitory action of CO and NO (Vicente, 2014; Vicente, 2016). 
Here, we aimed to investigate the structural and functional properties of a 
CBS variant (p.P49L) causing a mild form of classic homocystinuria. The 
goal was to test if the disease is associated to altered regulatory mechanisms, 
in particular regarding the cross-talk between H2S and CO.  
Endogenously produced H2S has been recently shown to stimulate the 
energy metabolism and proliferation in cancer cells. In light of this 
information, we aimed to evaluate the effect of hypoxia, a common feature in 
the tumour microenvironment, on the ability of cells to dispose H2S. Because 
hypoxic conditions are associated to enhanced H2S synthesis and higher H2S 
levels have been reported to have key protective effects against hypoxia and 
ischemia/reperfusion damage, it seems relevant to assess the effect of 
hypoxia on the H2S breakdown, mostly occurring at a mitochondrial level. To 
this end, we performed high-resolution respirometric measurements on a cell 
model of colon cancer (SW480). 
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Finally, in order to identify new pharmacological interventions 
against colorectal cancer (CRC), we have focused our attention on the study 
of human ferritin (HFt)-based drug delivery systems. HFt can interact with 
and be internalized by the transferrin receptor 1 (TfR1) overexpressed in 
many cancer cells, including colon cancer cells. As HFt-based constructs can 
efficiently entrap chemotherapeutic molecules, these nanodevices represent 
innovative drug delivery systems (Falvo, 2016). In this thesis work we aimed 
to improve HFt as a drug-delivery system and test the efficacy of novel HFt-
based nanocarriers on a suitable cell model of colon cancer progression 
(SW480 and SW620 cells). The long-term of this research is to exploit these 
nanocarriers as delivery systems for drugs with solubility issues or high 
toxicity. 
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1. Physico-chemical properties of H2S 
Hydrogen sulfide is a compound with chemical formula H2S and a 
molecular weight of 34.08. H2S is a colourless, flammable, corrosive and 
water-soluble (~100 mM at 1 atm and 25 °C) gas characterized by a typical 
smell of rotten eggs (Nagy, 2014). The sulfur is a chalcogen element, 
positioned in group 16 of the periodic table. The electron configuration 1s2 
2s2 2p6 3s2 3p4 corresponds to 6 valence electrons and a vacant 3d orbital. 
Therefore, sulfur can have oxidation states from −2 to +6. The oxidation state 
of sulfide sulfur is −2 which makes H2S a reducing species, with a strong 
nucleophilic character (Nagy, 2014). In biological systems, hydrogen sulfide 
reacts with oxidising species, like reactive oxygen species (ROS) and 
reactive nitrogen species (RNS) (Hancock & Whiteman, 2016), and can 
generate persulfides, recently discovered to have signalling biological effects. 
Further, H2S directly or indirectly (via persulfide) promotes protein 
sulfhydration, which consists in the addition of a persulfide moiety on protein 
cysteine residues by reduction of protein-disulfides or oxidation of thiol 
groups by the HS
●
 radical species (Kimura, 2017; Nagy, 2013; Nagy, 2014). 
Persulfides and polysulfides are common contaminants of H2S aqueous 
solutions. Aqueous solutions of H2S are prepared by dissolving sulfide salts. 
The sodium salts NaHS and Na2S are very soluble in water (s ≅ 19g/100g
 
H2O at 20°C) and, for this reason, are often used as H2S donors in biological 
9
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studies. In aqueous solution, H2S dissociates into hydrosulfide anion (HS‒), 
sulfide (S
2-
) and 2 protons (H
+
), according to the following equilibria: 
H2S ⇋ HS− + H
+
    pKa = 7.05 
HS− ⇋ S2− + H+    pKa > 14 
 
Consistently, at physiological pH 7.4 the [H2S]/[HS
‒
] ratio is 0.45 and, 
therefore, one third of H2S is present in the undissociated form (H2S) and two 
thirds as hydrosulfide anion HS
‒
, whereas the amount of the sulfide anion 
(S
2-
) is negligible. 
 
The chemical undissociated specie H2S is highly liposoluble and highly 
volatile, in contrast to HS
‒
 and S
2-
 that can form strong bonds with the 
solvent (Nagy, 2014; Ono, 2014; Wang, 2012).  
 
 
2. H2S, the new gasotransmitter 
Along with carbon monoxide (CO) and nitric oxide (NO), hydrogen 
sulfide (H2S) belongs to a small group of gaseous signalling molecules, 
termed gasotransmitters (Wang, 2002). H2S is able to diffuse across 
biological membranes and dose-dependently regulates multiple physiological 
processes. While displaying toxic effects at high (μM) concentrations, it acts 
10
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as a direct biological mediator (Wang, 2012) and a bioenergetic ‘fuel’ at low 
(nM) concentrations. Additionally, H2S plays a critical role in several 
pathological processes (Kimura, 2014; Wang, 2012). Therefore, the 
bioavailability of this gaseous molecule must be finely regulated through a 
correct balance between its synthesis and breakdown (Kabil & Banerjee, 
2014). Notably, sulfide biosynthesis proved to be regulated by CO and NO 
(Taoka, 1999, Vicente, 2014; Vicente, 2016) suggesting a cross-talk between 
the three gasotransmitters which appears to be fundamental for the 
maintenance of cellular homeostasis (Wang, 2012).   
 
2.1.  Synthesis 
2.1.1 Endogenous H2S production - Enzymes and pathways 
 
In mammals, H2S is enzymatically produced by the pyridoxal 5’-
phosphate (PLP)-dependent enzymes cystathionine β-synthase (CBS) and 
cystathionine γ-lyase (CSE or CGL), and the mitochondrial enzyme 3-
mercaptopyruvate sulfurtransferase (MST) or by the peroxisome-localized D-
amino acid oxidase (DAO) (Kabil & Banerjee, 2014; Shibuya & Kimura, 
2013; Singh & Banerjee, 2012; Shibuya, 2013). CBS and CSE are involved 
in the trans-sulfuration pathway of methionine, a cytosolic metabolic 
pathway leading to the synthesis of cysteine from homocysteine with 
11
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formation of cystathionine as intermediate. H2S is a secondary product of 
these reactions. 
 
 
Figure 1.  Methionine/SAM cycle (blu), folate cycle (yellow) and trans-sulfuration pathway 
(green). 
 
CBS- and CSE- catalysed reactions  
 
The first metabolite in the transulfuration pathway is homocysteine 
(HCy), which is also an intermediate of the SAM/methionine cycle.  Dietary 
methionine provides cells with methyl groups through the generation of S-
adenosylmethionine (SAM or AdoMet) which transfers a methyl group to 
different acceptors generating S-adenosyl homocysteine (SAH or AdoHcy). 
12
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AdoHcy is reversibly hydrolysed to adenosine and homocysteine. HCy has 
then two fates; it can be remethylated by methionine synthase (MS or 
METH) regenerating methionine and thus completing the cycle, or can enter 
the trans-sulfuration pathway (fig.1). In mammals, the trans-sulfuration 
pathway is irreversible; therefore, sulfur exits from methionine cycle and can 
be used to generate cysteine, H2S and other sulfur-containing metabolites. In 
particular, cysteine becomes the limiting substrate for the synthesis of 
glutathione (GSH), coenzyme A (CoA), taurine and sulfate (SO4
2-
). GSH 
together with its oxidized form (GSSG) is an important antioxidant 
compound implicated in the control of cellular redox homeostasis. Coenzyme 
A can transfer acetyl groups and it is involved in energy metabolism (e.g., in 
the Krebs cycle and fatty acids oxidation), while taurine and sulfate are the 
final metabolites derived from the oxidative degradation of the cysteine in 
excess via cysteine dioxygenase (CDO) (Kabil, 2014). The reactions 
involved in the trans-sulfuration pathway and H2S generation are reported 
below (fig. 2). 
 
13
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Figure 2. Reactions involved in the production of H2S and other sulfur metabolites. Trans-
sulfuration pathway (green arrows); CSE-catalysed synthesis of H2S from homocysteine (red 
arrows); Generation of H2S, 3-mercaptopyruvate and other sulfur metabolites from L-
cysteine (violet arrows); MST-catalysed reaction of H2S synthesis (blue arrows); 
Contribution of DAO to H2S synthesis (yellow arrows). 
 
 The first reaction of transulfuration pathway is catalysed by CBS and 
leads to formation of cystathionine. The enzyme uses serine and 
homocysteine as substrates and produces one molecule of water as co-
14
Background 
 
 
product (reaction 1). CBS is a member of the -family of PLP-containing 
enzymes which are typically able to catalyse -replacement or -elimination 
reactions. 
OH
NH3
O
O
NH3
O
O
SH
NH3
O
O
S
NH3
O
O
H2O
L-serine L-homocysteine L-cystathionine  
Reaction 1. Canonical-elimination reaction catalysed by CBS. 
 
Du Vigneaud and co-workers were the first ones to note the production of 
H2S in the presence of homocysteine during his studies on trans-sulfuration 
pathway (Binkley & Du Vigneaud, 1944). CBS can indeed catalyse the 
condensation of homocysteine and cysteine (derived from diet, via 
degradation of endogenous proteins or via trans-sulfuration pathway) 
producing cystathionine and one molecule of H2S (Chen, 2004) (reaction 2).  
 
SH
NH3
O
O
NH3
O
O
S
NH3
O
O
H2S
L-cysteine L-cystathionine
NH3
O
O
SH
L-homocysteine  
Reaction 2. Alternative reaction catalysed by CBS, yielding H2S from cysteine and 
homocysteine.  
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Homocysteine is a substrate of many “accessory” reactions involved in H2S 
generation. In particular, CSE catalyses the synthesis of -ketobutyrate, 
ammonia and H2S from homocysteine and H2O (reaction 3) 
NH3
O
O
SH
L-homocysteine
O
O
O
NH4 H2S
-ketobutyrate
H2O
 
Reaction 3. - elimination reaction catalysed by CSE yielding H2S and -ketobutyrate 
from homocysteine. 
 
or the condensation of two molecules of homocysteine generating 
homolanthionine and H2S (reaction 4) (Singh, 2009). 
 
NH3
O
O
S H2S
L-homolanthionine
NH3
O
O
SH
L-homocysteine
NH3
O
O
SH
L-homocysteine
NH3
O
O
 
Reaction 4. -replacement reaction catalysed by CSE, yielding H2S and homolanthionine 
from homocysteine. Homolanthionine is a biomarker of 
hyperhomocisteinemia/homocystinuria (Chiku, 2009). 
 
The second and last step of the trans-sulfuration pathway is the generation of 
cysteine from cystathionine and H2O catalysed by CSE (react. 5).  
16
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NH3
O
O
S
NH3
O
O
L-cystathionine
O
O
O
2NH4
-ketobutyrate
H2O
SH
O
O
O
L-cysteine  
Reaction 5. Canonical  elimination reaction catalysed by CSE. 
 
Cysteine in turn is a substrate of alternative reactions catalysed by CSE 
yielding H2S and ultimately pyruvate (reaction 6) or L-lanthionine (reaction 
7) (Singh, 2009).  
SHO
O
NH3
H2O OHO
O
NH3
H2S O
O
O
NH4
L-cysteine L-serine Pyruvate  
Reaction 6.  elimination reaction catalysed by CSE. 
 
SHO
O
NH3
SO
O
NH3
H2S
L-cysteine L-lanthionine
SHO
O
NH3
L-cysteine
NH3
O
O
 
 
Reaction 7. - replacement reaction catalysed by CSE. L-lanthionine is a biomarker of 
hyperhomocisteinemia/homocystinuria. (Chiku, 2009). 
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Furthermore, CBS proved to catalyse H2S production through -replacement 
of cysteine by several compounds (-mercaptoethanol, dithiothreitol, 
cysteamine and methanethiol) with formation of the corresponding thioethers 
(Singh, 2009).  
 
MST- and DAO- catalysed reactions 
 
Cysteine can also be converted to 3-mercaptopyruvate via a 
transamination reaction catalysed by cysteine (or aspartate) aminotransferase 
(CAT). In the cytosol and in the mitochondria matrix, 3-mercaptopyruvate is 
desulfurated by 3-mercaptopyruvate sulfurtransferase (MST), which has a 
redox-active cysteine residue in the active site (MST-SH), to generate 
pyruvate and persulfidated enzyme (MST-SSH). Sulfur is then transferred by 
the NADPH-dependent enzyme thioredoxin reductase (TrxR) to the preferred 
reducing acceptor, thioredoxin (Trx) or glutathione (GSH), generating H2S 
(Kabil & Banerjee, 2014). Alternatively 3-mercaptopyruvate can be 
generated through the oxidative deamination of D-cysteine catalysed by D-
amino acid oxidase (DAO) in peroxisomes (Shibuya & Kimura, 2013), 
leading to H2S generation (Shibuya, 2013). 
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Biological relevance 
 
The catalytic promiscuity of the enzymes responsible for H2S 
production may be viewed as a manner to ensure H2S generation from 
different substrates and under several physiological conditions (Singh, 2009). 
The regulation of H2S generation is expected to be a physiological 
mechanism for augmenting or diminishing sulfur metabolites levels on 
demand. Indeed, the physiological relevance of this pathway is both set on 
the production of important cysteine-derived metabolites, such as glutathione 
and H2S, and on the prevention of toxic accumulation of homocysteine 
(Kabil, 2014).   
 
Compound Human plasma levels (Kabil, 2014) 
Methionine 20-100 µM 
AdoMet Low micromolar or trace quantities 
Homocysteine Low micromolar or trace quantities 
Cystathionine Low micromolar or trace quantities 
Cysteine ~100-200 µM 
Taurine ~50-90 µM 
GSH and GSSG ~100-200 µM 
 
H2S 
Low nanomolar  
(*except aorta, 20- to 100-fold higher) 
19
Background 
 
 
 
Table 1. Plasma levels of sulfur compounds derived from the CBS- and CSE-catalysed 
reactions. 
 
Tissue and cellular localization of H2S synthesis enzymes 
 
The relative contribution of CBS, CSE and MST to H2S synthesis 
varies among different tissues, depending on the expression levels of the 
enzymes and the concentration of their respective substrates. In terms of 
tissue localization, CSE is expressed in the cardiovascular system but also in 
the liver, kidney, uterus, placenta, pancreatic islet, lung and gastrointestinal 
tract. CBS is preferentially expressed in the brain and other tissues, such as 
liver, kidney, pancreas, lung and gastrointestinal tract; more recently, it was 
also detected in the cardiac tissue. MST is expressed in the central system, 
mostly in glial cells, but it is also detected in the vascular smooth muscle, 
cardiomyocytes, kidney and liver (reviewed in Wallace & Wang 2015). 
Finally, DAO is localized in brain and kidney (Shibuya & Kimura 2013; 
Shibuya, 2013). In terms of cellular localization, CBS and CSE are mostly 
cytosolic enzymes, whereas MST is present in mitochondria and has a role in 
H2S-based energy production, as confirmed by Szabo and collaborators 
(Modis, 2013) (see Bioenergetics). However, under specific conditions both 
20
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CBS and CSE can be found in mitochondria or nuclei, and MST in the 
cytosol (Fu, 2012; Teng, 2013) (see Hypoxia).  
 
2.1.1.1 Focus on cystathionine β synthase (CBS)  
 
Structure 
 
Human cystathionine β-synthase (hCBS) is a homotetrameric enzyme 
characterized by a complex domain structure and peculiar regulatory 
mechanism. Each 63 kDa subunit contains 551 amino acid residues organized 
in three functional domains (Meier, 2001). The N-terminal domain harbours a 
hexacoordinate heme with cysteine 52 (C52) and histidine 65 (H65) as 
endogenous Fe ligands; the central catalytic domain binds the pyridoxal-5’-
phosphate (PLP) cofactor, whereas the C-terminal domain consists of a motif, 
named “Bateman module” (Bateman, 1997), that binds the positive regulator 
S-adenosyl-L-methionine (AdoMet) and is responsible for CBS 
tetramerization (Ereño-Orbea, 2013). Each CBS subunit binds three different 
substrates (homocysteine, serine and cysteine) and is further regulated 
allosterically by AdoMet, leading to an increase in catalytic activity by 
approximately two- to five-fold (Ereño-Orbea, 2014).   
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Figure 3. Protein domains and crystallographic structure of monomeric hCBS. Image from 
(Ereño-Orbea, 2013). 
 
Limited proteolysis of the full-length enzyme yields the `catalytic 
core' of CBS (amino acid residues 40-413). The reduction in size is 
accompanied by a significant increase in the specific activity of the enzyme 
and a change in its oligomerization state. In particular, removal of the 
regulatory C-terminal regulatory domain leads to a dimer with increased 
activity (four-fold higher kcat) unable to bind AdoMet. The truncated form of 
22
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CBS (45 kDa) lacking the C-terminal domain is a dimer which does not 
exhibit the aggregating properties which make physical studies on the wild-
type full-length protein (63 kDa) difficult (Meier, 2001). 
 
Regulation of enzymatic activity and cross-talk between gasotransmitters 
 
The regulation of the enzymatic activity of hCBS is physiologically 
relevant (see Metabolic disease and Cancer) (Banerjee, 2003). The effectors 
and mechanisms involved in the activity modulation are reported below. 
 
Pyridoxal-5’-phosphate (PLP) 
The pyridoxal-5’-phosphate (PLP) is present under two tautomeric 
forms; enolimine and ketoimine (Garret, 1998). The pyridoxal-5’-phosphate 
(PLP)-dependent enzymes catalyse several metabolically critical 
transformations including trans-aminations and crucial reactions in the 
metabolism of amino acids and amino sugars. Members of this protein family 
share a common first reaction step: the formation of an aldimine intermediate 
(via Schiff base) between the PLP cofactor and the substrate (e.g., the α-
amino group of amino acids) (Toney, 2012). Following this initial step, each 
enzyme catalyses specific reactions, such as α- and β-decarboxylation, 
racemization, transamination, aldolic reaction, β- and γ-elimination, etc. 
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(Toney, 2012). hCBS belongs to the -family of the PLP-containing enzymes 
which are typically able to catalyze -replacement or -elimination reactions 
(Meier et al., 2001). In CBS, the PLP is deeply buried between the N- and C-
terminal domains, and the active site is accessible only via a narrow channel. 
The cofactor is linked to the protein through the -amino group of Lys119 
forming a Schiff base named `internal aldimine' (fig. 4). The nitrogen of the 
pyridine ring generates a hydrogen bond with the O of serine 349 (Ser349). 
Another hydrogen bond is formed between the 3’-hydroxyl group of PLP and 
the N of asparagine 149 (Asn149). The phosphate binding loop is located 
between -strand 8 and -helix 8 and forms an extended hydrogen bonding 
network with several amino acid residues, including threonine 257 (Thr257) 
and threonine 260 (Thr260) (Meier, 2001). 
 
Figure 4. PLP in the CBS catalytic site. 
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In the presence of the substrate (serine or cysteine), the formation of a new 
aldimine intermediate (via Schiff base) between the PLP and the aminoacidic 
substrate (L-homocysteine) takes place. The protonation of the Schiff base, 
stabilized by a hydrogen bond with the oxygen of the ring, leads to increased 
acidity of the proton linked to Cα. The ketoenamine is key to PLP reactivity 
because, when its imine bond is protonated, it facilitates the nucleophilic 
attack by serine or cysteine. (1). The carbanion forming by the loss of 
hydrogen bond to Cα is stabilized by electronic delocalization on the 
pyridinic ring, where the positive charge on the nitrogen atom trapped the 
electrons (2). The -elimination of the  -OH group of serine (or -SH group 
of cysteine) leads to formation of the amino acrylate intermediate and 
elimination of one molecule of H2O (or H2S) (3). The carbon atom in  
position of the amino acrylate intermediate undergoes nucleophilic attack by 
homocysteine generating cystathionine (4) that is eventually released (5) (fig. 
5) (Weeks, 2009) 
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Figure 5. Reaction mechanism of CBS. Image adapted from (Weeks, 2009). 
 
S-adenosyl-L-methionine (SAM or AdoMet) 
Full-length CBS contains a C-terminal regulatory domain of ~140 
residues, including the so-called `CBS domain' or ‘Bateman domain’ of 53 
residues (Bateman, 1977). The C-terminal domain of CBS contains an 
autoinhibitory region harbouring the active site upon binding of the allosteric 
activator AdoMet (Ereño-Orbea et al., 2014). The C-terminal regulatory 
domain occludes the entrance to the catalytic site of the complementary 
monomer (fig. 6). Therefore, removal of the regulatory region in the 
truncated dimeric CBS leads to increased activity (Ereño-Orbea, 2014). 
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Figure 6. Mechanism of CBS allosteric regulation by AdoMet. Image from (Ereño-Orbea, 
2014). 
 
The presence of pathogenic missense mutations in this region often does not 
impair enzyme activity, but typically interferes with the binding of AdoMet 
and/or the enzyme activation by AdoMet (see Metabolic diseases) (Mendes, 
2014).  
 
 
 
Heme 
In hCBS, the heme has been proposed to act not only as a redox 
sensor able to bind exogenous ligands (CO and NO) and modulate CBS 
activity (reviewed in Singh, 2010), but also to structurally stabilize CBS and 
improve its folding (Oliveriusova, 2002). The B-type heme of hCBS is in a 
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hydrophobic pocket located in the N-terminal domain between the α-helices 6 
and 8. The heme iron, both in oxidized (FeIII) and reduced (FeII) state, 
coordinates the four pyrrolic rings of the protoporphyrin IX cofactor, whereas 
axially it binds the imidazolic nitrogen atom of histidine 65 (His65) and the 
thiolate moiety of cysteine 52 (Cys52), generating a low-spin hexacoordinate 
complex with octahedral geometry (Taoka, 2001). The enzyme is fully active 
when the heme is in the ferric state (FeIII), whereas heme reduction has been 
reported to promote a slow inactivation of the enzyme, that has been 
attributed to a ligand switch process (Cherney, 2007). Notably, the CBS 
heme in the reduced state is able to bind the gasotransmitters NO and CO 
resulting in a reversible inhibition of the enzyme (Vicente, 2014; Taoka, 
2001). The communication between the heme and PLP active site has been 
attributed to molecular interactions with the α-helix 8 (Singh, 2010). As 
previously reported, the heme axially binds Hys65 and Cys52. The cysteine 
52 establishes electrostatic interactions with arginine 266 (Arg266) at the end 
of this helix. Upon reduction, the heme increases its affinity for exogenous 
ligands, like CO and NO (Weeks, 2009). Moreover, AdoMet was found to 
further increase the CO affinity of the ferrous heme in human CBS (Vicente, 
2016). Despite the low redox potential (-350mV) of the full-length CBS heme 
(Singh, 2010), in the presence of NADPH the human enzyme methionine 
synthase reductase (MSR) is able to catalyze the reduction of the CBS heme 
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in vitro. This finding shows that reduction of the CBS heme may occur under 
physiological conditions (Kabil, 2001), making the enzyme susceptible to 
inhibition by the other gasotransmitters in vivo. 
 
CO inhibition  
CO binding to ferrous CBS is characterized by two dissociation 
constants, Kd1 =0.7–1.5 μM and Kd2= 45–68 μM (Taoka, 1999), attributed to 
differences in the heme microenvironment (Taoka, 1999) and/or an anti-
cooperative effect between adjacent monomers within a functional CBS 
dimer (Puranik et al., 2009). The reaction follows a biphasic time course with 
a major slow phase, the rate constant of which is hyperbolically dependent on 
CO concentration yielding a limiting value klim= 0.012 – 0.017 s
−1
. This rate 
constant has been attributed to the slow rate-limiting dissociation of the 
endogenous Cys52 thiolate ligand from the ferrous heme iron (Puranik, 
2009). 
 
NO inhibition   
NO binds to ferrous CBS at rates orders of magnitude higher than CO, 
and it dissociates from the ferrous heme iron much more slowly than CO 
(Vicente, 2014). Altogether, these data show that CBS has a higher affinity 
for NO than for CO. The kinetics of NO binding is not limited by the off-rate 
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of the Cys52 ligand and NO was proposed to initially attack the Fe from the 
His65 side, rather than from the Cys52 side (Vicente et al., 2014).  
 
O2 binding  
The ferrous heme [Fe(II)] of CBS can be rapidly oxidized by O2. 
Under normoxic conditions, the protein with ferric heme [Fe(III)] is a target 
of Lon protease, one of the most expressed protease at the mitochondrial 
level involved in the regulation of the mitochondrial protein turnover. Under 
hypoxic condition, the Lon protease does not bind ferrous CBS [Fe(II)], 
determining an accumulation of the CBS inside mitochondria (see Hypoxia 
and Synthesis) (Teng, 2013). 
 
Heme spectral properties 
Upon reduction, the Soret band of the CBS heme shifts from 428 nm 
to 449 nm. On CO binding to the ferrous CBS heme, the band further shifts 
to 422 nm, resulting in a hexacoordinate ferrous-CO adduct with the 
endogenous Cys52 ligand displaced. NO binding to ferrous CBS results 
instead in a notable broadening of the Soret band, accompanied by an 
intensity decrease and a shift to ~395 nm, which have been attributed to 
formation of a high-spin pentacoordinate ferrous- NO adduct with both 
endogenous ligands displaced (Vicente, 2014; Taoka, 2001).  
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2.1.2 H2S production by the gut microbiota 
The gut microbiota is a major source of H2S. In particular, anaerobic 
sulfate-reducing bacteria produce sulfide from the metabolism of dietary 
proteins in the lumen of the human large intestine (reviewed in Blachier, 
2010; Carbonero, 2012). Approximately, one millimolar has been reported 
for the total sulfide content, but a much lower value (60 μM) has been 
reported for free H2S. Due to the potentially toxic sulfide levels, colonocytes 
have been adapted in order to neutralize the sulfide content and, therefore, 
show an unusually high sulfide oxidizing activity (Goubern, 2007; Lagoutte, 
2010; Leschelle, 2005) (see Mitochondrial H2S oxidation in colonocytes). 
Alterations of H2S metabolism in colonocytes are associated to pathological 
condition discussed in H2S and colorectal cancer (Carbonero, 2012). 
 
 
 
2.2. Catabolism  
As H2S is an important signalling molecule exerting dose- and time-
dependent biological effects, the balance between hydrogen sulfide synthesis 
and consumption rates plays a critical role in the maintenance of cellular 
homeostasis (Módis, 2014; Szabo, 2014). H2S, is the only gasotransmitter 
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that is enzymatically catabolised (Hildebrandt & Grieshaber, 2008) by two 
different pathways: it can be oxidized inside the mitochondria (Jackson, 
2012) or it can enter the cytosolic methylation pathway (Weisiger 1980).  
 
2.2.1. Mitochondrial H2S oxidation - Enzymes and pathways 
 
Oxidative phosphorylation: a brief overview 
 
The oxidative phosphorylation takes place at the inner mitochondrial 
membrane where the four complexes (I-IV) of the electron transport chain 
(ETC), as well as the electron transporters coenzyme Q (CoQ) and 
cytochrome c (cyt c), and the ATP synthase, are located. The oxidative 
phosphorylation couples the electron flux derived from the oxidation of 
NADH and succinate, with the ADP phosphorylation, thus generating ATP. 
In a first step, electrons transported by NADH and succinate are transferred 
to Complex I (NADH:ubiquinone dehydrogenase) or Complex II (succinate 
dehydrogenate or SDH) and subsequently, through Complex III (cytochrome 
bc1 or ubiquinol:cytochrome c reductase), cytochrome c and Complex IV 
(cytochrome c oxidase or CcOX), are then transferred to the final acceptor, 
molecular O2. The process is overall accompanied by the vectorial 
translocation of 10 protons (for one molecule of NADH) or 6 protons (for 
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one molecule of succinate or FADH2) from the mitochondrial matrix side to 
the intermembrane space. The electron transport chain contributes to the 
formation of an electro-chemical gradient across the inner membrane which 
generates the proton motive force (PMF) used by ATP synthase (ATPase or 
complex V) to generate ATP from ADP and Pi (2.5 molecules of ATP per 
NADH or 1.5 molecules of ATP per FADH2) (Nicholls & Ferguson, 2013). 
More recent studies have shown that the oxidation of H2S is associated with 
the concomitant injection of electrons into the mitochondrial electron chain, 
thus sustaining the electron flow and promoting the ATP synthesis at lower 
concentrations of sulfide (Goubern, 2007).  
 
Hydrogen sulfide catabolic pathway 
 
The mitochondrial sulfide oxidation pathway is involved in the 
breakdown of sulfide, with the concomitant stimulation of mitochondrial 
respiration (Goubern, 2007) (see Bioenergetics). The pathway has been 
initially identified in the lugworm Arenicola marina (Hildebrandt and 
Grieshaber, 2008). This enzymatic system responsible for H2S metabolism at 
the mitochondrial level, also named sulfide-oxidizing unit (SOU), couples the 
oxidation of 2 sulfide molecules with the consumption of 1.5 molecule of 
oxygen (Goubern, 2007; Lagoutte, 2010). The system comprises the 
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mitochondrial inner membrane-associated enzyme sulfide:quinone 
oxidoreductase (SQR) and the mitochondrial matrix-localized enzymes 
persulfide dioxygenase or ethylmalonic encephalopathy 1 (ETHE1), 
thiosulfate sulfurtransferase or Rhodanese (TST or Rhod) and sulfite oxidase 
(SOx). Overall the pathway oxidizes H2S leading to formation of a variety of 
species, including sulfite (SO3
2-
), thiosulfate (S2O3
2-
), sulfate (SO4
2-
) and 
glutathione persulfide (GSSH) (Kabil & Banerjee, 2014; Libiad, 2014; 
Szabo, 2014).  
The first step of sulfide metabolism is catalysed by sulfide:quinone 
oxidoreductase (SQR). In the catalytic site of SQR, a reactive cysteine 
disulphide transfers a sulfur atom derived from H2S to glutathione (GSH) 
generating glutathione persulfide (GSSH). Concomitantly, the sulfide-derived 
electrons are transferred via a flavin adenin dinucleotide (FAD) moiety to 
coenzyme Q, thus leading to injection of two electrons into mitochondrial 
chain and reduction of 0.5 molecule of O2 to H2O by CcOX. The sulfur-
acceptor has been a topic of discussion in the literature (Jackson, 2012; 
Libiad, 2014): it was proposed to be reduced glutathione (GSH), sulphite 
(SO3
2-
) or an unknown acceptor. Recently, GSH has been proposed as the 
preferred sulfur acceptor for SQR-mediated H2S oxidation under 
physiological conditions (Libiad, 2014). Indeed, increased GSH synthesis by 
administration of the cysteine precursor N-acetylcysteine improves H2S 
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clearance in patients with ethylmalonic encephalopathy caused by mutation 
in the ETHE1 gene, implicating GSH as the persulfide carrier in the sulfide 
oxidation pathway (Tiranti, 2009). 
 
 
 
Subsequently, the persulfide dioxygenase (ETHE1), a mononuclear non-
heme iron enzyme structurally belonging to the family of metallo-β-
lactamases, uses O2 as co-substrate to convert the GSSH into sulfite and 
GSH. GSSH and sulfite are further converted into thiosulfate and GSH by 
thiosulfate sulfur transferase (Rhod). Rhodanese has a single redox-active 
cysteine in the active site and catalyses several reactions involving numerous 
substrates, but the generation of thiosulfate appears to be the most 
catalytically favourable reaction at physiologically relevant substrate 
concentrations (Kabil & Banerjee, 2014; Libiad, 2014). 
 
The last step in the sulfide oxidation pathway is catalysed by sulfite oxidase 
(SOx, Fig. 1B) (Johnson-Winters, 2010).  
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Overall, the mitochondrial SOU couples the oxidation of two H2S with the 
consumption of 1.5 molecules of O2: the stoichiometry is thus 1.5/2 = 0.75, 
as reported by Laguette and co-workers (Lagoutte, 2010). 
 
Figure 7. Hydrogen sulfide synthesizing-enzymes, Sulfide-oxidizing unit (SOU) and 
electron transport chain (ETC). Image from (Szabo, 2014). 
36
Background 
 
 
 
A large variety of mammalian cell types (including colonocytes, 
macrophages, hepatocytes, neurons, etc.) have been assayed for their ability 
to consume H2S at the mitochondrial level (Goubern, 2007; Lagoutte, 2010; 
Mimoun, 2012), revealing a large variability among cell types in terms of 
SOU activity. The activity is high in cells physiologically exposed to 
relatively high H2S levels, such as colonocytes, but absent or hardly 
detectable in other cell types, such as neuroblastoma or other nervous system- 
derived cell lines (Lagoutte, 2010).  
 
2.2.2. Mitochondrial H2S oxidation in colonocytes  
 
The gut microbiota produces sulfide in a concentrations ranging from 
high micromolar to low millimolar as reviewed in (Blachier, 2010) (see H2S 
production by the gut microbiota). The effect of sulfide on the metabolism of 
colonocytes was studied in the HT29 cell line derived from human colon 
cancer (Leschelle, 2005). After 24 hours exposure to high levels of sulfide (1 
mM), HT29 cells have shown a general suppression of mitochondrial 
bioenergetics (decreased CcOX activity and increased proton leak), enhanced 
anaerobic glycolysis (decreased cell proliferation and increased lactate 
release) and unchanged Ki of cytochrome c oxidase (0.3 μM). Therefore, 
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colonocytes appear well adapted to the sulfide-rich colon environment in that 
they are able to neutralize the exogenous sulfide (Leschelle, 2005; Szabo, 
2014). When sulfide exposure is maximal, indeed, complex I, complex II and 
SQR compete for coenzyme Q. However, according to the redox conditions, 
Complex I can work in a reverse mode in the presence of sulfide (Leschelle, 
2005). This process appears to be specific to colonocytes (Lagoutte, 2010). In 
a previous study, reversal of Complex II activity was also suggested 
(Goubern, 2007). When Complexes I or II operate in reverse mode, oxidation 
of sulfide is favoured as these repiratory complexes can accept electrons from 
coenzyme Q, even in the presence of severe CcOX inhibition by high sulfide 
concentrations. The impact of these reverse reactions on ATP production is 
null or negative; indeed, reversal of Complex I activity would cause 
uncoupling (Lagoutte, 2010). However, when complete inhibition of 
Complex IV takes place, the cell must use anaerobic glycolysis to produce 
energy (Szabo, 2014). 
 
3. Physiological and pathological role of H2S 
 
Hydrogen sulfide (H2S) has emerged as an important signalling 
molecule. The lipid-soluble nature of H2S allows it to target a large variety of 
proteins in different cellular compartments. Due to its chemical versatility, 
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H2S can interact with protein sulfhydryl groups and metals (reviewed in 
(Wallace & Wang, 2015). Hydrogen sulfide, therefore, has unique properties 
that make it a selective and powerful modulator of a large range of biological 
targets, with stimulatory or inhibitory effects. 
 
3.1. H2S, a Janus-faced molecule 
 
At low (nM) concentration H2S ensures anti-inflammatory, anti-
oxidant and cytoprotective responses, whereas at higher (μM) concentrations 
it can lead to toxicity and eventually cell death. Indeed, high levels of H2S 
promote pro-inflammatory pathways and inhibit CcOX, thus blocking the 
electron transfer through the respiratory chain with the induction of pro-
oxidant and DNA-damaging effects eventually culminating in cell death 
(Kimura, 2015; Wallace & Wang, 2015). Furthermore, H2S has a very 
interesting dual role on vascular remodelling. It was indeed reported to 
induce smooth muscle relaxation in the portal vein and the thoracic aorta, 
associated with opening of ATP-sensitive K
+
 channels. However, H2S pre-
treatment was also found to induce vasoconstriction by scavenging 
endothelial NO. The response of blood vessels to H2S depends on the vessel 
type, exposure time and concentration. Another variable that influences the 
effects of H2S on the smooth muscle of blood vessels is O2, with low and 
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high concentrations inducing vasodilation and vasoconstriction, respectively 
(see Hypoxia) (Kabil, 2014; Wallace & Wang, 2015). However, the major 
and perhaps most interesting dual role induced by sulfide is the one exerted 
on cell bioenergetics. 
 
3.2. Bioenergetics 
3.2.1. H2S as mitochondrial substrate or inhibitor  
 
In mitochondria, H2S exerts a dual effect on cell bioenergetics. At high 
(high μM) concentration, it blocks mitochondrial respiration by inducing a 
potent, reversible and non-competitive inhibition of complex IV (CcOX) 
(Cooper & Brown, 2008); at the opposite, at lower concentrations (from high 
nM to low μM), H2S is a substrate for most mitochondria (see Mitochondrial 
H2S oxidation) (Goubern, 2007; Lagoutte, 2010), thus stimulating cell 
respiration. H2S has therefore been recognized as the first inorganic substrate 
used by mitochondria to generate ATP (Yong and Searcy, 2001). This makes 
H2S a very interesting molecule from a bioenergetic viewpoint, able to induce 
opposite effects on mitochondrial respiration depending on its bioavailability. 
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H2S as a mitochondrial substrate 
 
The first evidence for mitochondrial sulfide oxidation associated with 
oxygen consumption and ATP synthesis was obtained by investigating the 
invertebrate Solemya reidi (Powell and Somero, 1986). Following this 
observation, Bouillaud and co-workers have reported the first evidence of 
sulfide stimulation of energy metabolism in a human cell model (human 
colon adenocarcinoma cell lines) (Goubern, 2007). As described above (see 
Mitochondrial H2S oxidation), H2S oxidation by the sulfide-oxidizing unit 
(SOU) occurs with the injection of electrons in the ETC. The major 
contribution of this pathway to cellular bioenergetics arises from the SQR-
catalysed reduction of coenzyme Q. 
 
Figure 8. Scheme of sulfide oxidation. Complexes of the mitochondrial respiratory chain are 
numbered with roman numerals. H2S can either induce a stimulation of electron flow via 
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SQR in the SOU or inhibit mitochondrial oxygen binding at Complex IV, thereby stopping 
electron flow. Image from (Szabo et al., 2014). 
 
That sulfide-derived electrons enter the mitochondrial respiratory chain at the 
level of coenzyme Q is demonstrated by the finding that, whereas inhibition 
of Complex I with rotenone has not effect on sulfide catabolism, inhibition of 
Complex III or Complex IV by antimycin A or cyanide, respectively, blocks 
mitochondrial sulfide oxidation (Goubern, 2007). Complexes I and II 
therefore compete with SQR for the reduction of coenzyme Q, while 
complexes III and IV are required for sulfide oxidation. Interestingly, the 
maximal rate of sulfide oxidation was found to increase with cell 
differentiation (Mimoun, 2012) and a maximal rate of sulfide oxidation 
approaching the theoretical limit was observed, under which condition all the 
electrons travelling in the respiratory Complexes III–IV are expected to come 
from H2S via SQR. 
 
Biological relevance  
 
Compared to other substrates of the mitochondrial respiratory chain, 
H2S oxidation has a relative low energetic yield, due to the relatively high 
cost in terms of oxygen [injection of electrons into coenzyme Q is associated 
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with the consumption of additional O2 by ETHE1 (Hildebrandt and 
Grieshaber, 2008)] and the low contribution in terms of electrons injected 
into respiratory chain. On the other hand, H2S diffuses freely across cell 
membranes, it does not need any ‘biochemical preparation’ (which has an 
energy cost), the affinity of SQR for sulfide is high and, in addition, in the 
gut an abundant sulfide production occurs with no energy cost. All that 
guarantees that sulfide oxidation takes place with high efficiency at low 
concentrations of sulfide, thereby preventing its toxic accumulation (Szabo, 
2014). Additionally, sulfide was suggested to serve as an ‘emergency’ 
substrate. Indeed, although in terms of quantitative bioenergetics it is clearly 
inferior to carbon metabolism, under physiological or stress conditions, H2S 
production by endogenous enzymes can contribute to cellular bioenergetics 
(Fu, 2012; Goubern, 2007). A bioenergetic role has been clearly 
demonstrated for 3-MST, the enzyme that is responsible for the majority of 
mitochondrial H2S production, which shows preferential mitochondrial 
localization as described above (see Synthesis). The role of 3-MST in the 
regulation of cellular bioenergetics is supported by a large body of evidences 
(Módis, 2013). SQR silencing suppresses both basal and 3-MP mediated 
stimulation of bioenergetic function (Módis, 2013). Interestingly, oxidative 
stress impairs the bioenergetic role of 3-MST (Módis, 2013). Also CSE and 
CBS contribute to the physiological regulation of bioenergetic function, since 
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the H2S produced in cytosol by these enzymes can freely diffuse across the 
cell. Additionally, since the distribution of both CSE and CBS is cell type- 
and tissue-dependent, effects of CBS/CSE are also cell type- and organ-
dependent. Under conditions of cell dysfunction (such as hypoxia), CSE 
sustains cellular bioenergetics by translocating to the mitochondria (Fu, 
2012), while in colon cancer cells (HCT116 cell model) it is the endogenous 
H2S production by CBS that supports cellular bioenergetics and cell 
proliferation (Szabo, 2013). Intriguingly, CBS was also found to accumulate 
in mitochondria under hypoxic/ischemic conditions (see Cancer and 
Hypoxia), although the physiological relevance of this process needs to be 
established. 
 
H2S as a mitochondrial inhibitor 
 
Sulfide inhibition of isolated mitochondrial CcOX is reversible, 
potent (Ki = 0.2 μM at pH 7.4) and non-competitive in that H2S affects the 
enzyme Vmax, but not the KM for O2 (Petersen, 1977). Interestingly, sulfide 
inhibition of CcOX is pH dependent, the Ki dropping from 2.6 μM to 0.07 
μM as the pH decreases from 8.05 to 6.28 (Nicholls, 1982). Consistently, 
CcOX inhibition by sulfide is more effective under acidosis conditions 
(Szabo, 2014), probably because under these conditions H2S prevails over the 
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HS− form. The active site of CcOX, being located in an apolar environment, 
is expected to preferentially bind electroneutral species, such as H2S, or 
proton-neutralized anionic species (HS
−
 + H
+
) (Rich, 1996), both favoured at 
lower pH. (Nicholls, 2013). H2S inhibits CcOX with a low Ki value. This 
notwithstanding, inhibition of respiration in isolated mitochondria or intact 
cells requires much higher H2S concentrations (µM, see (Leschelle, 2005). 
The sulfide-mediated inhibition of CcOX leads to decreased electron flow 
through the ETC and thus to a decline in ATP production (Hill, 1984). This 
effect has been well documented both in vivo and in cell models (Leschelle, 
2005). The inhibitory effect has been observed at 10-100 µM H2S depending 
on the experimental approach. Indeed, quantitative information on sulfide 
oxidation and related bioenergetic effects was often obtained in these studies 
by supplying sulfide at selected injection rates rather than as a single bolus, 
an approach reviewed in (Abou-Hamdan, 2015). After tissue homogenates 
exposure to a single bolus of NaHS, the complex I activity has been shown to 
return to its original level within 10-30 min. Due to the opposite effects of 
sulfide on mitochondrial respiration, stimulation of oxygen consumption and 
mitochondrial energization is best appreciated at low sulfide concentrations, 
non-inhibitory towards CcOX (Abou-Hamdan, 2015). 
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3.3.  Cancer  
Recent studies revealed increased expression of various hydrogen 
H2S-producing enzymes in colon, ovarian, prostate and breast cancer cells 
(reviewd in Szabo, 2013), and a new role of H2S in cancer has emerged 
(Chao 2016; Hellmich & Szabo, 2015; Szabo, 2015). H2S seems to have a 
dual role also in the cancer, promoting angiogenesis and proliferation and 
sustaining cellular bioenergetics or, at the opposite, displaying a cytotoxic 
effect and becoming deleterious for the tumour cell at higher concentration 
(Szabo, 2014a) (see H2S metabolism as drug target).  
 
3.3.1.  H2S in colorectal cancer (CRC) 
Colonocytes are exposed to high levels of H2S produced by the gut 
microbiota (Blachier, 2010). These cells therefore show efficient systems to 
metabolize H2S (Lagoutte, 2010). On the other hand, high levels of H2S in 
the gut have been associated to ulcers, chronic inflammation, DNA damages 
and colon cancer (CRC- colorectal cancer) (Carbonero, 2012). In particular, 
tissues isolated by patients with CRC display a reduced expression of Rhod, 
one of the enzymes involved in sulfide catabolism, underlining the 
importance of the role of H2S metabolism in CRC (Ramasamy, 2006). More 
recent studies have shown in cancer cells an over-expression of the H2S-
generating enzyme CBS and a functional role of CBS-derived H2S, which 
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promotes proliferation through the stimulation of cellular bioenergetic at both 
mitochondrial and cytosolic level (Hellmich & Szabo, 2015; Szabo, 2013; 
Szabo & Hellmich, 2013). In the mitochondrion, H2S acts as a metabolic 
‘fuel’ injecting electrons into mitochondrial chain (Szabo, 2013; Szabo & 
Hellmich, 2013), whereas in the cytosol, hydrogen sulfide stimulates the 
glycolytic activity (Mustafa, 2010).  
Additionally, inhibition (with aminooxiacetic acid, AOAA) or silencing of 
CBS in colon cancer cells HCT116 decreases bioenergetic functions in vitro. 
Implantation into the mice of CBS-silencing colon cancer cells, reduces 
tumour growth and inhibits peritumour angiogenesis (Szabo, 2013) in vivo. 
Furthermore, interestingly, inhibition (with AOAA) or silencing of CBS also 
sensitizes the cancer cells to chemotherapy (Chao & Zatarain, 2016; Chao, 
2014). In colon cancer cell lines SW480, instead, high expression levels of 
CSE were observed. Inhibition (with propargylglycine, PAG) or silencing of 
CSE in SW480 cell lines reduces the proliferation in vitro and tumour growth 
in vivo (Fan, 2014). 
Therefore, H2S produced by CBS or CSE promotes bioenergetics, 
proliferation, migration, invasiveness, and neoangiogenesis, thus creating the 
ideal conditions for tumour cell survival (Cai, 2010; Hellmich & Szabo, 
2015; Szabo & Hellmich, 2013). Following these studies, scientific interest in 
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H2S metabolism has increased in the perspective of developing new 
pharmacological interventions in the therapy of cancer (Hellmich, 2015). 
 
3.4.  Hypoxia  
Hypoxia is a common factor of the microenvironment of solid 
tumours that is associated to drug-resistance and malignancy (reviewed in 
Muz, 2015). Under hypoxic conditions a central role is played by the hypoxia 
inducible factor (HIF) which appears to be directly involved in the up- or 
down-regulation of key enzymes in pathways implicated in cancer 
metabolism and thus in cell survival (Semenza, 2013). The relationship 
between hypoxia and metabolic reprogramming in cancer has been widely 
reported and is reviewed in (Masson & Ratcliffe, 2014).  
 
3.4.1. H2S as an oxygen sensor 
The interplay between the two gaseous molecules H2S and O2 has 
been thoroughly investigated (reviewed in Olson, 2015; Wu, 2015). H2S 
mimics hypoxia-induced responses like vasodilation (Zhao, 2001), neo-
angiogenesis (Papapetropoulos, 2009) and the expression of HIF-1a 
(Beaumont, 2016). Furthermore, the H2S levels proved to be regulated by the 
O2 concentration in tissues. Olson et al. proposed a model in which both 
cytosolic synthesis and mitochondrial oxidation of sulfide are regulated in an 
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O2-dependent manner (Olson, 2015). The higher H2S levels in 
hypoxic/ischemic conditions is primarily due to the over-expression and/or 
activity stimulation of the H2S-synthesizing enzymes (Takano, 2014; 
Kolluru, 2015). Under hypoxic conditions both CBS and CSE were shown to 
display increased activity due to release of CO inhibition, following activity 
down-regulation of the isoform 2 of heme-oxygenase (enzyme involved in 
the heme degradation generating CO) (Morikawa, 2012; Yuan 2015). 
Hypoxia also leads to the translocation of CSE from the cytosol to 
mitochondria, where CSE uses approximately three-fold higher 
concentrations of L-cysteine to produce H2S (Fu, 2012). In addition, whereas 
under normoxic conditions CBS is degraded inside mitochondria by Lon 
protease, upon hypoxic stress Lon protease cannot recognize the 
deoxygenated/ferric haem group in CBS, and therefore CBS is not degraded. 
This leads to accumulation of CBS in the mitochondrion and increased 
mitochondrial H2S levels (Teng, 2013). The enhanced production of H2S 
occurring under hypoxia may be interpreted as a mechanism to ensure H2S-
mediated protection against ischemia injuries and against the cytotoxic and 
inflammatory damages induced by hypoxic conditions (Takano, 2014; 
Kolluru, 2015; Morikawa, 2012; Hine, 2016). Enhanced H2S levels proved to 
be a compensatory response to hypoxia promoting vasodilation (Yuan, 2015; 
Morikawa, 2012) in many O2 sensitive tissues. On the other hand, hypoxia 
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makes complex IV more sensitive to H2S inhibition (Matallo, 2014; Abou-
Hamdan, 2016) and induces notable metabolic changes: it enhances 
anaerobic glycolysis and reduces mitochondrial mass and activity (as a result 
of enhanced mitophagy and reduced mitochondrial biogenesis) (Solaini, 
2010; Zhang 2008, Wu 2015), thus shifting the action of H2S from protective 
to detrimental.  
 
3.5.  Metabolic diseases  
Alterations of H2S metabolism are also involved in pathological 
metabolic dysfunctions (Wallace & Wang, 2015), like lipid metabolism 
disorders, liver diseases, diabetes and homocystinuria. The role of hydrogen 
sulfide metabolism in homocystinuria is reported below.  
 
3.5.1. H2S in hyperhomocysteinaemia and homocystinuria 
Hyperhomocysteinemia is a clinical metabolic condition characterized 
by elevated homocysteine plasma levels which have been linked to a variety 
of human diseases, including heart attack, stroke and osteoporosis. The major 
causes of hyperhomocysteinaemia are deficiencies in vitamins B4, B9 and 
B12 and mutations in the genes encoding 5-methyltetrahydrofolase or CBS 
(Maron and Loscalzo, 2009). CBS is involved in the trans-sulfuration 
pathway of methionine and H2S metabolism and regulates both homocysteine 
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and H2S levels in the human body (see Synthesis). Banerjee and 
collaborators, have demonstrated that the H2S generation catalysed by 
cystathionine γ-lyase (CSE) increases progressively with the grade of 
hyperomocysteinemia. Indeed, at severely elevated homocysteine (200 mM), 
both -elimination (reaction 5) and the replacement (reaction 4) 
reactions of homocysteine catalysed by CSE lead to the generation of H2S 
with concomitant production of homolanthionine and lanthionine, 
respectively. The elevated H2S production by CSE may contribute to the 
hyperhomocysteinemia-associated cardiovascular disturbances. Based on 
these data, the inhibition of CSE has been suggested as a pharmacological 
strategy to treat hyperhomocysteinemia, and homolanthionine and 
lanthionine were proposed as novel biomarkers of the disease (Chiku, 2009) 
 
Figure 9. Proposal mechanism for the CSE selective affinity for homocysteine. Image from 
(Chiku, 2009). 
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Classical homocystinuria (OMIM#236200) is an inborn error of 
metabolism associated with mutations in the in CBS gene. It has a variable 
incidence of 1:1.800 to 1:900.000 and is biochemically detected by markedly 
high homocysteine and methionine levels in plasma and urine. The clinical 
presentation includes complications in the vascular, neurological and skeletal 
systems (Mudd, 1975) and an oxidative stress condition due to the high 
plasmatic levels of homocysteine. The major therapeutic approach for 
classical homocystinuria consists in dietary methionine restriction and 
administration of pyridoxine (vitamin B6), a precursor of the PLP cofactor 
essential for CBS activity (Mudd, 1975). However, a significant part of 
patients (approximately half) does not respond to this treatment (Schiff & 
Blom, 2012). The CBS mutations identified in patients with classical 
homocystinuria are often missense mutations resulting in single amino acid 
substitutions which often affect the enzyme folding and/or activity (Hnízda, 
2012). Additionally, some of these mutations have been shown to affect the 
positive allosteric regulation of CBS by AdoMet, pointing to such 
dysregulation as a new pathogenic mechanism in classical homocystinuria 
(Mendes, 2014). A novel therapeutic approach is currently under 
development based on enzyme replacement therapy using PEGylated 
recombinant CBS (Bublil, 2016). 
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4. New pharmacological strategies in cancer 
4.1.  H2S metabolism as drug target 
 
CBS has recently emerged as a drug target in cancer (Druzhyna, 
2016). CBS-derived H2S was indeed shown to play a key role in the survival 
and proliferation of tumour cells. Different strategies have been proposed for 
the treatment of cancer, based on the dual effect of sulfide on cell 
bioenergetics. The dose-dependent effect of H2S on cancer has been 
demonstrated in colon adenocarcinoma cell lines using increasing 
concentration of H2S in the presence or absence of aminooxiacetic acid 
(AOAA), an inhibitor of CBS (fig. 10). These studies showed enhanced cell 
proliferation induced by H2S, the effect being related to the balance between 
endogenous and exogenous H2S. 
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Figure 10. Biphasic (bell-shaped) dose-response of H2S on tumour cell proliferation. Image 
from (Hellmich, 2015). 
 
Based on these studies two possible pharmacological approaches, both 
aiming to reduce the cell proliferation, seem applicable: i) increasing the H2S 
production using either H2S-donors or inhibitors of the H2S-consuming 
enzymes, or ii) reducing the H2S generation using inhibitors of H2S-synthesis 
enzymes (Chao, 2016, Chao, 2014; Asimakopoulou, 2013; Druzhyna, 2016; 
Hellmich, 2015).  
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4.2.   Ferritin-based nanoparticles as a new drug delivery system  
 
Ferritin 
 
Ferritin (Ft) is a member of the iron storage protein family with 
ubiquitous distribution among all life forms, except in yeast (Crichton & 
Boelaert, 2009). Ft consists of 24 subunits forming a globular shell-like 
protein containing a cavity with external and internal diameters of 12 nm and 
8 nm, respectively (Harrison & Arosio, 1996). Each subunit is folded in four-
helical bundle, formed by four antiparallel helices (A-D, named in order from 
the amino terminus) and a shorter helix on the top (E). 
 
Figure 11. Monomeric subunit fold of human H ferritin. 
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The N-terminal ends of each subunit are located on the ferritin surface, with 
the C-termini pointing toward the inner cavity of the protein.  
The protein coat is perforated by several small channels, formed by subunits 
with 3- or 4-fold symmetry, which traverse the protein cage and allow the 
passage of ions and small molecule. 
 
Figure 12. Quaternary structure of ferritin from Pyrococcus furiosus (PDB code: 2JD7). 
A. View along the four-fold axis. B. View along the three-fold axis. 
 
In particular, three-fold pores are involved in the uptake of ferrous iron [Fe 
(II)]. The pores expose negatively charged residues generating a negative 
electrostatic gradient thanks to which iron enters the channel and binds the 
catalytic sites, named ferroxidase sites, where it is oxidized by molecular 
oxygen (O2) to ferric iron [Fe (II)]. Ferric iron then moves to the iron 
nucleation sites where Fe(III)-mineral formation takes place. When the 
Fe(III)-mineral reaches a sufficient size, Fe(II) atoms can also be oxidized 
directly on the surface of the growing mineral. The cavity may contain up to 
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4.000 iron atoms, often stored as ferric oxy-hydroxide mineral, while the 
ferritin without loaded iron is also referred as apoferritin (Ceci, 2012).   
All animal ferritins are assembled from two subunit types, the heavy (H 
chain; 21 kDa) and light chains (L chain; 20 kDa); H chains contain the 
catalytic centres and are more abundant in tissues with an active iron 
metabolism. L chains contain many nucleation sites and are more abundant in 
iron storage tissues like spleen. 
 
Drug delivery and Ferritin-based nanoparticles (NPs) 
 
Heavy human protein ferritin (HFt) is an intriguing system for 
biotechnology applications for the outstanding features described below 
(Heger, 2014; Lee, 2016; Truffi, 2016).  
 
HFt is an ideal nanocarrier for human applications in vivo, being a 
natural self-constituent present both inside the cells and in the bloodstream; 
therefore, it shows high solubility, biocompatibility, biodegradability and, 
additionally, a high stability in a large range of temperature (up 80°C) and pH 
(2-10) (Jain, 1999). Moreover, HFt dimensions (<20 nm) increase the 
chances of passing human body barriers and reaching specific targets since 
HFt is small enough to penetrate tumor capillary fenestrations and large 
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enough to avoid rapid clearance through the kidney. Of particular relevance, 
especially in view of potential applications in cancer therapy, is the ability of 
HFt to be easily internalized by many types of protein- and iron-avid cancer 
cells. (Li, 2010). Additionally, HFts are an ideal template for encapsulation 
of several compounds inside their internal cavity (Zhen, 2013; Falvo, 2013; 
Fan, 2012, Vannucci, 2012; Uchida, 2006; Fantechi, 2014). HFt can be 
produced at low cost and high yield through recombination techniques, the 
uniformity of the quaternary structure guarantees a high homogeneity in both 
size and shape and, furthermore, the interior of the cage provides an isolated 
environment, protected from bulk solution, where chemical reactions can take 
place. Generally, the method used for nanoparticles (NPs) formation is based 
simply on the addition of various ions or small molecules to apoferritin under 
specific oxidizing (O2 or H2O2) or reducing (NaBH4) conditions, allowing the 
diffusion inside the protein. An alternative approach was reported to 
incorporate metal particles and other compounds that cannot pass through the 
ferritin channels. According to this method, the protein cage is reversibly 
disassembled in acidic conditions (~ pH 2.0) and the compounds are 
passively encapsulated within the cavity by raising the pH to neutral values 
(Kim, 2011). Using this method, several diagnostic agents (Truffi, 2016; Fan, 
2012) and drug molecules were encapsulated in ferritin, such as cisplatin, 
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doxorubicin, curcumin, methylene blue, etc (Xing, 2009; Blazkova, 2013; 
Ma-Ham, 2011; Simsek & Kilic, 2005; Cutrin, 2013). 
 
 
Figure 13. Schematic illustration of nanoparticles synthesis using ferritins as nano-reactors. 
 
HFt possesses all features necessary to operate as an appropriate 
platform for specific cell targeting/delivery discriminating healthy from 
cancerous cells (Schoonen, 2014). HFt has indeed an exterior surface which 
can be easily functionalized through genetic engineering and/or chemical 
conjugation. For instance, short peptide and antibodies recognizing specific 
cell receptors, can be genetically conjugated with the N-terminal region of 
HFt (Vannucci, 2012). A breakthrough in the ferritin-based drug delivery 
field was recently reported by Li et al. (Li, 2010). They discovered that HFt 
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(but not LHFt) has the ability to effectively bind cancer cells and be 
internalized using the transferrin receptor 1 (TfR1) (Li, 2010). TfR1 is up-
regulated on the surface of many cancer types (such as colon, liver, lung, 
pancreas, cervical, ovarian, prostate, breast, sarcoma and thymus cancer), 
reaching up to 100-fold higher levels than in normal cells. HFt was shown to 
be internalized by TfR1 in more than 474 clinical tissue specimens and 
specifically recognize several types of tumor over non-tumor tissues with 
98% sensitivity and 95% specificity (Fan, 2012). The high expression of 
TfR1 in cancer could arise from the high demand of DNA synthesis in these 
rapidly dividing cells through the ribonucleotide reductase enzyme. This 
enzyme needs iron as a cofactor providing a plausible explanation for the 
high expression of TfR1 in tumor cells (Daniels, 2006). In addition, two 
papers by (Zhang, 2015) and (Bellini, 2014) underline the selective capability 
of HFt, but not LFt, to shuttle doxorubicin (DOXO) molecules to the cell 
nucleus. In this case, HFt nanocages loaded with DOXO could behave like a 
“Trojan horse”: called back within the nucleus for the purpose of defense 
given its the well-known HFt antioxidant activity, HFt releases instead the 
cytotoxic anticancer drug directly into the most effective site of action 
(fig.14). 
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Figure 14. Schematic representation of the nuclear delivery of DOXO by HFt complexes. 
 
Despite the several advantageous features, HFt half-life in plasma after 
systemic injection may be too short (i.e., ~ 2 hours; Worwood, 1982) to attain 
sufficient accumulation at the tumour level. Although HFt was reported to 
bind and encapsulate some types of drugs, both the yields and stability of the 
resulting ferritin-drug complexes were not satisfactory. During the last three 
years ferritin-doxorubicin complexes have been obtained by several groups, 
mostly by performing reversible, pH-dependent HFt dissociation (pH 2) and 
reassociation (pH 7.5) in the presence of the drug. Typically, this process 
resulted in the loss of more than 50% of the starting protein material and an 
average of 25-30 doxorubicin molecules encapsulated within each protein 
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cavity. Moreover, more than 30% of the drug leaked by the first week of 
storage, indicating that the stability of the ferritin-doxorubicin complexes is 
quite low for drug development purposes. (Zhen, 2013; Liang, 2014; Bellini, 
2014; Gumulec, 2014; Zhang, 2015; Kilic, 2012). Recently, Falvo et al. have 
developed a novel HFt-based construct in order to increase the in vivo half-
life and the stability of HFt-drug complexes, called HFt-MP-PAS, suitable 
for drug delivery. In this construct the N-terminus of each HFt subunit is 
genetically fused to: i) a PAS polypeptide sequence, i.e., a sequence rich in 
proline (P), alanine (A) and serine (S) residues; (Fracasso, 2016; Falvo, 2016) 
and ii) a tumor-selective sequence (MP) responsive to proteolytic cleavage by 
tumour proteases (MMPs), inserted between each HFt subunit and the outer 
PAS polypeptide (Fracasso, 2016). The exposed unstructured polypeptide 
PAS was used to increase ferritin stability during the pH jump (2.0-7.5) step 
occurring in the drug-encapsulation reaction, and has also the advantage of 
extend the HFt plasma half-life, eliminating the disadvantages occurring in 
the case of protein-PEGylation for following biopharmaceutical development 
and production (Schlapschy, 2013; Harari, 2014). The PAS shield was aimed 
at hampering the interaction between drug-loaded HFt and TfR1 in healthy 
tissues and reducing internalization by normal cells, already limited by the 
low expression of the receptor. The MP sequence allows the PAS shield to be 
selectively removed by stimuli present in the tumour microenvironment, i.e., 
62
Background 
 
 
metalloproteinases (MMPs) specific for this sequence. In particular, MMP-2 
and MMP-9 have been recognized as key MMPs over-expressed at the tumor 
microenvironment and involved in tumor angiogenesis, invasion, and 
metastasis (Rundhaug 2003) so that the resulting unmasked HFt can freely 
interact with and be internalized by TfR1 overexpressed in cancer cells. The 
HFt-MP-PAS constructs proved to i) encapsulate in the internal cavity three 
times more doxorubicin (DOXO) than wild-type HFt, ii) form more stable 
complexes (i.e., drug leakage was negligible) and iii) possess higher in vivo 
circulation time. Importantly, DOXO-loaded HFt-MP-PAS (HFt-MP-PAS-
DOXO) displayed excellent therapeutic efficacy in a human pancreatic 
cancer model in vivo, significantly increasing overall animal survival (Falvo 
2016). The nanocarriers efficacy was even superior to the novel albumin-
based DOXO delivery system (INNO-206), currently in phase III clinical 
trials, ascribing to the PAS shield the increase in DOXO encapsulation, 
protein-drug complex stability and circulation time with respect to HFt. The 
higher in vivo efficacy of HFt-MP-PAS-DOXO with respect to other DOXO 
delivery systems is likely due to both effective PAS removal by tumour 
specific MMPs and efficient DOXO delivery into the cell nucleus, as 
revealed by confocal microscopy studies (Falvo, 2016). 
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Figure 15. HFt-MP-PAS40-DOXO.  Image from (Falvo 2016). 
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Abstract 
Merely considered as a toxic gas in the past, hydrogen sulfide (H2S) is 
currently viewed as the third ‘gasotransmitter’ in addition to nitric oxide 
                                                 
1
 Abbreviations: H2S, hydrogen sulfide; NO, nitric oxide; CO, carbon monoxide; CcOX, 
cytochrome c oxidase; CBS, cystathionine β-synthase; AdoMet, S-adenosyl-L-methionine; 
CGL, cystathionine γ-lyase; PLP, pyridoxal 5’-phosphate; MST, 3-mercaptopyruvate 
sulfurtransferase; CAT, cysteine aminotransferase; 3-MP, 3-mercaptopyruvate; SOU, sulfide 
oxidizing unit; SQR, sulfide:quinone oxidoreductase; GSH, reduced glutathione, GSSH, 
glutathione persulfide; ETHE1, persulfide dioxygenase; Rhod, rhodanese; SOx, sulfite 
oxidase; FCCP, p-trifluoromethoxyphenylhydrazone, MSR, methionine synthase reductase; 
AOAA, aminooxyacetic acid; AdoHcy, S-adenosyl-L-homocysteine.  
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(NO) and carbon monoxide (CO), playing a key signalling role in human 
(patho)physiology. H2S can either act as a substrate or, similarly to CO and 
NO, an inhibitor of mitochondrial respiration, in the latter case by targeting 
cytochrome c oxidase (CcOX). The impact of H2S on mitochondrial energy 
metabolism crucially depends on the bioavailability of this gaseous molecule 
and its interplay with the other two gasotransmitters. The H2S-producing 
human enzyme cystathionine β-synthase (CBS), sustaining cellular 
bioenergetics in colorectal cancer cells, plays a role in the interplay between 
gasotransmitters. The enzyme was indeed recently shown to be negatively 
modulated by physiological concentrations of CO and NO, particularly in the 
presence of its allosteric activator S-adenosyl-L-methionine (AdoMet). These 
newly discovered regulatory mechanisms are herein reviewed. 
  
 
Keywords 
Sulfide metabolism, gasotransmitters, mitochondrial respiration, cytochrome 
c oxidase, cystathionine -synthase, heme chemistry 
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1. Hydrogen sulfide synthesis and breakdown in human physiology 
Hydrogen sulfide (H2S) has emerged in the past decades as the third 
recognized ‘gasotransmitter’ in human physiology. Much like its 
‘predecessors’ nitric oxide (NO) and carbon monoxide (CO), H2S was 
historically considered a poisonous gas that was subsequently discovered to 
be endogenously synthesized to fulfil a myriad of signalling and regulatory 
functions [1-4]. This colourless gas with a strong characteristic odor (the 
smell of rotten eggs) is slightly polar, which allows it to freely diffuse across 
biological milieu, including membranes. In aqueous solution, H2S 
equilibrates with hydrosulfide (HS
-
) and sulfide (S
2-
), according to the pKa1 
~7.0 (H2S/HS
-
) and pKa2 ~19 (HS
-
/S
2-
) measured at 25°C. At a 
‘physiological’ pH of 7.4, HS- is the predominant species (70-80%) and H2S 
occurs at 20-30%, whereas S
2-
 is supposedly present in negligible amounts 
[3, 5, 6]. Unless otherwise stated, the terms ‘H2S’ and ‘sulfide’ are herein 
employed interchangeably to collectively indicate the H2S/HS
-
 pair.  
H2S has a dose-dependent effect on multiple physiological processes, 
acting as a signalling molecule (mostly resulting in persulfidation of cysteine 
residues in proteins [4, 5, 7]) and a bioenergetic ‘fuel’ at low concentrations, 
and displaying deleterious effects at high concentrations. Although the in 
vivo free H2S levels in mammalian physiology are difficult to estimate and 
remain a matter of debate, it is presently accepted that high nanomolar to low 
micromolar concentrations may occur under non-pathological conditions [8]. 
Disturbances in H2S metabolism either impairing or enhancing H2S 
production and/or breakdown are currently and growingly associated with 
many pathological conditions, ranging from cardiovascular [9] and 
neurodegenerative diseases [10] to cancer [11].  
H2S is generated in humans via two major routes: ubiquitous 
endogenous enzymes (described below) and the gut microbiota, particularly 
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sulfate-reducing bacteria. The three major human enzymes recognized as 
endogenous H2S sources are the methionine cycle transsulfuration pathway 
enzymes cystathionine β-synthase (CBS) and cystathionine γ-lyase (CGL), 
and the 3-mercaptopyruvate sulfurtransferase (MST) (Figure 1A) [1, 12]. 
Whereas CBS and CGL are both pyridoxal 5’-phosphate (PLP)-dependent 
enzymes, MST has a single redox-active cysteine residue in the active site. 
As mentioned above, both CBS and CGL participate in the transsulfuration 
pathway of methionine metabolism. Therefore, their physiological relevance 
is both set on homocysteine homeostasis and on H2S generation [13]. Indeed, 
both enzymes produce H2S via reactions that are ‘alternative’ to their 
historically-considered canonical activities. The CBS canonical activity 
concerns the condensation of serine and homocysteine into cystathionine and 
water, but the enzyme can also use cysteine alone or together with 
homocysteine to generate H2S and different co-products [13] (Figure 1A). 
Similarly, CGL, whose canonical reaction is the conversion of cystathionine 
into cysteine with the production of α-ketobutyrate and ammonia, can 
generate H2S from cysteine and/or homocysteine [13] (Figure 1A). This 
seemingly catalytic promiscuity may be viewed as a robust system to ensure 
H2S generation from different substrate combinations and under several 
physiological conditions. MST functions together with another enzyme, 
cysteine aminotransferase (CAT), which converts cysteine and α-
ketoglutarate into glutamate and 3-mercaptopyruvate (3-MP), the latter used 
as a substrate for the MST-catalyzed H2S production [1]. An additional 
pathway has been recently demonstrated involving MST, where 3-MP 
alternatively derives from D-cysteine and a D-amino acid oxidase [14]. In 
terms of cellular localization, the classical view is that CBS and CGL are 
cytosolic enzymes, whereas MST is located in the mitochondria. However, 
there are numerous exceptions where both CBS and CGL can be found in 
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mitochondria and MST in the cytosol, which preclude taking a firm position 
in this regard. Examples of CBS localization in the mitochondria and its 
impact on cellular bioenergetics and mitochondrial function are detailed 
below.  
As any other potentially toxic gaseous molecule endogenously 
synthesized with signalling purposes, H2S levels must be kept under strict 
control. Indeed, as reviewed in [1, 15], human cells are equipped with an H2S 
breakdown enzymatic system associated to the mitochondria (Figure 1B), 
initially identified in the lugworm Arenicola marina [16], and more recently 
denoted as ‘sulfide oxidizing unit’ (SOU) [17]. The enzymatic unit comprises 
a sulfide:quinone oxidreductase (SQR), a persulfide dioxygenase (also 
known as ETHE1 or sulfur dioxygenase), a thiosulfate sulfurtransferase 
(rhodanese) and a sulfite oxidase (SOx), that overall catalyze the breakdown 
of H2S to thiosulfate and sulfate, the main sulfide catabolites (Figure 1B). A 
more detailed description of the mitochondrial SOU is given in section 2.3,  
 
2. Hydrogen sulfide and mitochondrial respiration  
As a common feature, the three gasotransmitters NO, CO and H2S can 
all inhibit mitochondrial cytochrome c oxidase (CcOX), causing a decline in 
the electron flux of the respiratory chain and thus in ATP synthesis (reviewed 
in [18], Figure 2). NO can also inhibit Complex I via S-nitrosation [19-22], 
the inhibition being dependent on a reversible conformational change of the 
enzyme [23]. More recent studies, however, have shown that, unlike the other 
two gasotransmitters, at low concentrations (nanomolar to low micromolar) 
H2S can also stimulate mitochondrial respiration by acting as a mitochondrial 
electron donor [17, 24-30] (Figure 2). This makes H2S a very interesting 
molecule from a bioenergetic viewpoint, able to induce opposite effects on 
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mitochondrial respiration depending on its bioavailability (reviewed in [8, 15, 
31, 32]).   
 
 
2.1 H2S as an inhibitor of mitochondrial respiration 
Cytochrome c oxidase (CcOX), considered as the main target of 
gasotransmitter-mediated inhibition of mitochondrial respiration, is inhibited 
by the three gasotransmitters with different kinetics [18]. CO acts a simple 
competitive inhibitor, lowering the enzyme KM for O2 by binding at the O2-
reactive, fully-reduced heme a3-CuB active site ([33], Figure 3). CcOX 
inhibition by NO is more complex (reviewed in [34-39]). It can proceed 
through two alternative reaction pathways [40-45], one competitive and the 
other uncompetitive towards O2, i.e., leading to a decrease of both Vmax and 
KM for O2 yet keeping their ratio unchanged [46, 47]. The O2-competitive 
pathway, prevailing at higher electron flux and lower O2 levels, leads to an 
adduct of CcOX with NO bound to ferrous heme a3, whereas the O2-
uncompetitive one, favoured at lower electron flux and higher O2 levels, 
results into the formation of an inhibited state of the enzyme with nitrite 
bound to ferric heme a3 ([18, 44, 46, 48], Figure 3).  
Differently from CO and NO, H2S was reported to be a non-
competitive inhibitor of isolated mitochondrial CcOX [49], i.e., affecting the 
enzyme Vmax, but not the KM for O2. The inhibition is reversible, potent (Ki = 
0.2 μM at pH 7.4) and independent of oxygen concentration [49]. 
Interestingly, sulfide inhibition of CcOX is pH dependent, the Ki dropping 
from 2.6 μM to 0.07 μM as the pH decreases from 8.05 to 6.28 [50]. 
Consistently, CcOX inhibition by sulfide is more effective under acidosis 
conditions (see [8, 31] and references therein). Although the effect of pH has 
not been investigated in mechanistic details, the enhanced inhibition is likely 
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related to the fact that H2S, with its pKa of ~ 7.0, prevails over HS
-
 in acidic 
conditions. The active site of CcOX, being located in an apolar environment, 
is indeed expected to preferentially bind electroneutral species, such as H2S, 
or proton-neutralized anionic species (HS
-
 + H
+
) [51], both favoured at lower 
pH. Sulfide inhibition of isolated mitochondrial CcOX is not only effective, 
but also relatively fast, proceeding with an initial rate constant of 2.2×10
4
 
M
−1
 s
−1
, as measured at pH 7.4 with the enzyme in turnover with O2 in the 
presence of ascorbate and cytochrome c [52]. Unlike NO and CO [53], H2S 
does not bind ferrous heme a3. The inhibited enzyme displays sulfide bound 
to ferric heme a3 (Figure 3), preventing the reaction with O2 and thus leading 
to electron accumulation at the CuA and heme a sites [54, 55]. Based on 
electron paramagnetic resonance (EPR) spectroscopy [56], CuB in sulfide-
inhibited CcOX was suggested to be in the cuprous state, possibly bound to a 
second H2S molecule (Figure 3), with a substantial increase of the reduction 
potential. The mechanism of inhibition is only partly understood. H2S was 
suggested to bind the enzyme in turnover at cupric or cuprous CuB to be 
transferred intramolecularly to ferric heme a3, leading to enzyme inhibition 
[52].  
  
 
2.2 H2S oxidation by mitochondrial cytochrome c oxidase 
Somewhat similarly to the other two gasotransmitters, H2S is not only 
an inhibitor, but it can also serve as a reducing substrate for CcOX [50, 52, 
57]. Besides being able to slowly oxidize CO to CO2 [58, 59] and much more 
quickly NO to nitrite [42, 60, 61], CcOX can also oxidize sulfide probably to 
a persulfide species [50, 52, 57]. Sulfide directly reacts with the oxidized 
heme a3-CuB active site in the so-called ‘pulsed’ state of the enzyme [52]. 
This state is obtained by subjecting to a reduction/oxidation cycle the 
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‘resting’ enzyme, much less reactive with external ligands. This ‘pulsing’ 
procedure has been discovered in 1977 by Antonini and co-workers [62]. It 
remains to be demonstrated whether the enhanced reactivity of ‘pulsed’ 
CcOX towards H2S arises from Cl
-
 dissociation from the active site, as 
previously shown for NO [63]. With pulsed CcOX, in the absence of 
reducing substrates, the heme a3-CuB site is directly reduced by low sulfide 
levels and the produced ferrous heme iron under aerobic conditions is 
promptly converted into a ferryl state, optically resembling the ‘P’ catalytic 
intermediate [52]. This species eventually decays slowly (tens of seconds) 
into the ‘F’ ferryl form of the enzyme by reacting with residual sulfide or by 
auto-reduction [52]. The physiological relevance of this CcOX-mediated 
oxidative degradation of H2S remains to be determined, because 
mitochondrial SQR seems to provide a very effective H2S dissimilatory 
pathway, probably out-competing the H2S-metabolizing activity of CcOX. 
Finally, it is worth mentioning that H2S can also directly reduce cytochrome 
c [50]. The reaction, however, is probably too slow and with too low affinity 
to have a physiological relevance, although to our knowledge it has not been 
investigated yet with cardiolipin-bound cytochrome c, much more reactive 
towards external ligands [64]. 
 
2.3 H2S as an effective substrate of the mitochondrial respiratory chain 
Despite the low Ki value measured with isolated CcOX (Ki = 0.2 μM 
at pH 7.4 [49]), inhibition of respiration in isolated mitochondria or intact 
cells requires much higher H2S concentrations (micromolar to tens of 
micromolar, see for instance [65, 66]). This finding is fully consistent with 
the observation that H2S at relatively low concentrations (nanomolar to low 
micromolar) also acts as an effective substrate of the mitochondrial 
respiratory chain. Evidence for mitochondrial sulfide oxidation associated 
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with oxygen consumption and ATP synthesis was first obtained by 
investigating the invertebrate Solemya reidi [24]. This is the first study in 
which the dual effect of H2S on mitochondrial respiration, inhibitory at 
higher concentration and stimulatory at lower levels, was demonstrated. 
These initial observations were expanded in more recent studies conducted 
on isolated mitochondria as well as on permeabilized or intact cells from 
higher organisms, including human cell lines [17, 25-30]. Quantitative 
information on sulfide oxidation and related bioenergetic effects was often 
obtained in these studies by supplying sulfide at selected infusion rates rather 
than as a single bolus, an approach reviewed in [32]. Due to the opposite 
effects of sulfide on mitochondrial respiration, stimulation of oxygen 
consumption and mitochondrial energization is best appreciated at low 
sulfide concentrations, non-inhibitory towards CcOX.  
 Electrons derived from sulfide oxidation are accepted by coenzyme Q 
(Figure 2). Sulfide-stimulated oxygen consumption is indeed blocked by 
inhibitors of the bc1 complex (antimycin) or of CcOX (cyanide), being 
unaffected by rotenone inhibition of Complex I [26, 65, 67, 68], except in 
colonocytes where Complex I has been suggested to work in a reverse mode 
[17, 26] (see section 2.4). Based on this and other evidence [16], the 
existence of a mitochondrial sulfide oxidizing unit (SOU) was envisaged 
[17]. In such unit the primary sulfide oxidizing enzyme is the membrane-
associated sulfide:quinone oxidoreductase (SQR), having a cysteine 
disulphide in its active site and harboring a non-covalent flavin adenine 
dinucleotide moiety from where sulfide-derived electrons are transferred to 
coenzyme Q [69] (Figure 1B). H2S oxidation by human SQR involves the 
transfer of a sulfur atom to an acceptor which has been a topic of discussion 
in the literature [70, 71]: it was proposed to be i) reduced glutathione (GSH) 
yielding glutathione persulfide (GSSH), ii) sulphite (SO3
2-
) yielding 
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thiosulfate (S2O3
2-
) or iii) an unknown acceptor. Recently, it has been 
proposed that at physiological GSH and sulfite concentrations, GSH is the 
preferred sulfur acceptor for SQR-mediated H2S oxidation [71]. The next 
step in the sulfide oxidation pathway is catalyzed by the persulfide 
dioxygenase ETHE1 (Figure 1B), a mononuclear non-heme iron enzyme 
structurally belonging to the metallo-β-lactamase family, which uses oxygen 
as a co-substrate for generation of sulfite from GSSH [71-73]. GSSH and 
sulfite are further converted into thiosulfate and GSH by rhodanese (Rhod, 
Figure 1B), having a single redox-active cysteine in its active site [71, 74]. 
Rhodanese catalyzes a myriad of reactions involving numerous substrates, 
but the transfer of a sulfur atom from GSSH to sulfite to generate thiosulfate 
appears to be the most catalytically favourable reaction at physiologically 
relevant substrate concentrations [71]. The last step in the sulfide oxidation 
pathway is catalyzed by sulfite oxidase (SOx, Figure 1B), a multi-domain 
cytochrome b5 containing a molybdenum cofactor [75]. Electrons derived 
from sulfite are intramolecularly transferred through the heme cofactor to 
cytochrome c, while the oxygen atom is supplied by water, with concomitant 
production of sulfate (SO4
2-
) [75]. Overall, the mitochondrial SOU couples 
the oxidation of H2S to thiosulfate and sulfate with the injection of electrons 
into coenzyme Q, leading to consumption of 0.79 O2 per H2S molecule 
oxidized, as reported by Goubern and co-workers [26]. 
Despite the apparent simplicity of the sulfide oxidation pathway 
herein described, the intricate sulfur chemistry and the remarkable substrate 
promiscuity of this pathway’s enzymes allows one to envisage a number of 
alternative reaction pathways occurring under different (patho)physiological 
conditions. Irrespectively of the fate of sulfide-derived species, the major 
contribution of this pathway to cellular bioenergetics arises from the SQR-
catalyzed reduction of coenzyme Q. 
76
Results and Discussion – Paper 1 
 
 
 
2.4 H2S and cellular bioenergetics 
A large variety of mammalian cell types (including colonocytes, 
macrophages, hepatocytes, neurons etc.) have been assayed for their ability to 
consume H2S at the mitochondrial level [17, 26-29], revealing a large 
variability of this sulfide oxidizing activity between cell types. The activity is 
high in cells physiologically exposed to relatively high H2S levels, such as 
colonocytes, but absent or hardly detectable in other cell types, such as 
neuroblastoma or other nervous system-derived cell lines. Moreover, for yet 
unknown reasons, in mitochondria isolated from animal organs, the SOU 
activity relative to the basal respiratory oxygen consumption is typically 
much less than measured in intact cultured cells. As discussed in [8], this has 
been tentatively ascribed to an up-regulation of the SOU enzymes and/or to a 
down-regulation of the respiratory enzymes in cultured cells, typically 
relying on glycolytic metabolism .   
 Particularly interesting is the case of colonocytes. It has long been 
known that the intestinal microbiota, especially abundant in the colon, 
represents a major source of sulfide. Consistently, in this tract of our gut, 
sulfide reaches particularly high levels: up to 60 μM free H2S was reported in 
equilibrium with up to one millimolar total sulfide-derived species [76-79]. It 
is therefore not surprising that colonocytes exhibit a high sulfide oxidizing 
activity, even at such high sulfide levels inhibitory for CcOX [17, 26]. In 
these cells, when sulfide is oxidized, Complex I has been reported to work in 
a reverse mode, thus making oxidized coenzyme Q available for reduction by 
SQR, even in the presence of a severe CcOX inhibition [17, 26]. Thus, 
colonocytes appear well adapted to the sulfide-rich colon environment: they 
are able to extract energy from a bacterial metabolic waste (H2S) and are 
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suitably equipped with an efficient dissimilatory system to prevent sulfide 
toxicity [76]. 
 From the bioenergetic point of view and particularly in comparison 
with NADH oxidation, sulfide oxidation doesn’t seem to be very efficient in 
terms of energy yield. This is not surprising as the oxidation of H2S, while 
injecting electrons into coenzyme Q, is associated with the consumption of 
additional (with respect to the respiratory chain) O2 by ETHE1 [16] (Figure 
1B). Despite this low energy yield, as discussed in [8], H2S has several 
advantages, namely over NADH. It freely diffuses across the membranes, 
without the need to be synthesized or transported inside mitochondria to feed 
the respiratory chain with electrons. In addition, H2S is used with high 
affinity by SQR which ensures H2S to be an effective respiratory ‘fuel’ at 
low, non-toxic concentrations. Last but not least, H2S bioavailability inside 
the cell can be rapidly and finely controlled through regulation of the H2S-
synthesizing and -consuming enzymes (see below). Based on these 
properties, sulfide was suggested to serve as an ‘emergency’ substrate, 
particularly in some body regions and under specific physiological or stress 
conditions [8]. In this regard, it is intriguing that CGL, preferentially located 
in the cytosol, under cell dysfunction conditions translocates into the 
mitochondrion [80] and that under hypoxic conditions CBS does the same, 
exerting mitochondrial protective effects, as shown in cultured hepatocytes 
and liver tissue [81].       
Several lines of evidence show that endogenously produced H2S can 
contribute to cellular bioenergetics [29, 80, 82], but more work is needed in 
this direction. A bioenergetic role has been clearly demonstrated for MST 
[29]. Using cultured hepatoma cells and isolated rat liver mitochondria, low 
concentrations of the MST substrate, 3-MP, proved to lead to H2S production 
and bioenergetic enhancement, and these effects proved to be mediated by 
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MST and SQR by gene silencing [29]. In contrast, under normal conditions, 
at least in vascular smooth-muscle cells, CGL does not seem to support 
cellular bioenergetics. It is worth noticing, however, that upon intracellular 
calcium loading, the enzyme translocates to the mitochondrion where it 
exerts positive bioenergetic effects under hypoxic conditions [80]. Regarding 
CBS, an in vivo bioenergetic role was envisaged in Caenorhabditis elegans, 
whose basal and maximal carbonyl cyanide p-
trifluoromethoxyphenylhydrazone (FCCP)-stimulated oxygen consumption 
was shown to be attenuated by silencing a CBS homologue, the main H2S-
producing enzyme in this model organism [83, 84].    
 More recently, endogenous H2S production by CBS was found to 
support cellular bioenergetics and cell proliferation in HCT116 colorectal 
cancer cells [82]. In these cells, CBS is selectively up-regulated (like in 
human colon adenocarcinoma specimens) and a significant fraction of the 
enzyme is associated to mitochondria. Moreover, as shown by CBS silencing 
or inhibition with aminooxyacetic acid (AOAA), the CBS-generated H2S 
enhances cell proliferation and energy metabolism. Both oxidative 
phosphorylation and glycolysis proved to be stimulated by CBS-produced 
H2S, the glycolytic pathway being presumably enhanced in response to 
sulfhydration and consequent activation of glyceraldehyde 3-phosphate 
dehydrogenase [85, 86]. Interestingly, AOAA, which has been reported to 
inhibit both CBS and CGL [87], decreased the migration and invasion of 
cancer cells, reduced the migration of endothelial cells co-cultured with colon 
cancer cells and, notably, affected the growth rate of both HCT116 and 
patient-derived tumour xenografts [82]. None of the effects described above 
was observed upon CGL silencing or pharmacological inhibition with the 
CGL-selective inhibitor propargylglycine, pointing to a specific role for CBS 
in colorectal cancer cell bioenergetics. 
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 In summary, there is growing evidence that H2S, depending on its 
bioavailability, can impact cellular bioenergetics by stimulating or inhibiting 
the mitochondrial respiratory chain and, under certain conditions, enhancing 
glycolysis. These functions of H2S are interestingly intertwined with the 
action of the other two gasotransmitters CO and NO. Hence the relevance of 
shedding light into the molecular mechanisms controlling the cell 
bioavailability of H2S and its cross-talk with the other gasotransmitters. 
 
3. Gasotransmitters interplay at human cystathionine β-synthase  
3.1. Cellular localization and structure of human CBS 
CBS is a key enzyme of the transsulfuration branch of methionine 
metabolism, that plays a key role in mammalian physiology both contributing 
to homocysteine homeostasis and acting as a source of H2S [13, 88, 89]. 
Whereas CBS is typically considered a cytosolic enzyme, its localization has 
been shown to vary in different (patho)physiological contexts. Microvascular 
endothelial cells and hepatocytes have been reported to secrete CBS and 
CGL, which circulate as part of the plasma proteome, generating H2S from 
homocysteine, particularly when its concentration rises in human blood [90]. 
In endothelial cell models, exogenous H2S afforded higher cell viability and 
decreased DNA oxidative damage upon serum starvation and 
hypoxia/reoxygenation. Moreover, immunoprecipitation of CBS and CGL 
from serum prior to its supplementation with homocysteine makes the serum 
more stressful for endothelial cells. These observations led to the proposal 
that secreted CBS and CGL ensure both the clearance of elevated 
homocysteine and the production of H2S to exert a protective role in the 
endothelium [90]. CBS has also been shown to be a target for sumoylation, 
leading to accumulation of the protein in the nucleus, as associated with the 
nuclear scaffold [91]. Of greater relevance for the effect of H2S on cell 
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bioenergetics and respiration, CBS can translocate to mitochondria in 
different (patho)physiological conditions. Teng and co-workers [81] reported 
partial localization of CBS to liver mitochondria, transiently enhanced under 
hypoxia/ischemia to protect mitochondria from oxidative stress through H2S 
generation. CBS levels are restored upon return to normoxia, the protein 
degradation being mediated by the mitochondrial Lon protease, targeting 
specifically the CBS heme-binding domain in the oxidized (ferric) form [81]. 
Moreover, in the HCT116 colorectal cancer cell line, a significant fraction of 
the total cellular CBS is localized to the mitochondria, particularly associated 
with the outer mitochondrial membrane, where it was proposed to stimulate 
mitochondrial functions [82], as described above. Increased accumulation of 
CBS concurrent with elevated H2S has been recently reported in 
mitochondria isolated from the spinal cord of a mouse model of amyotrophic 
lateral sclerosis, where the increased H2S production was proposed to be 
associated with impaired cytochrome c oxidase-dependent respiration [92]. 
Each CBS monomer comprises a PLP-binding core catalytic domain 
and two flanking regulatory domains: an N-terminal heme-binding domain 
and a C-terminal domain which binds the allosteric activator S-adenosyl-L-
methionine (AdoMet) (Figure 4) [93]. The PLP-binding catalytic core is 
characteristic of type II PLP-dependent enzymes [93, 94]. The C-terminal 
domain, structurally also known as “Bateman” module, comprises a pair of 
so-called CBS motifs able to accommodate AdoMet [94-96]. This domain 
has been suggested to be also responsible for enzyme tetramerization, its 
removal resulting in stabilization of a dimeric form of CBS unresponsive to 
AdoMet and displaying increased basal activity [97].   
 
3.2. Properties of the heme moiety of human CBS 
81
Results and Discussion – Paper 1 
 
 
The heme in CBS constitutes an evolutionary milestone, since its 
harbouring domain is absent in protein homologues from unicellular 
eukaryotes. This low-spin hexacoordinate B-type heme, axially bound to 
His65 imidazole and Cys52 thiolate moieties (human CBS numbering), has 
been proposed to act not only as a redox sensor able to bind exogenous 
ligands (CO and NO), but also to structurally stabilize CBS and improve its 
folding [97]. Whereas the enzyme is fully active when the heme is in the 
ferric state, heme reduction by excess sodium dithionite (a strong reductant) 
has been reported to promote a slow enzyme inactivation (>20 minutes at 
37°C), attributed to a ligand switch process [98]. Notably, the CBS heme in 
the reduced state is able to bind the ‘gasotransmitters’ NO and CO, resulting 
in a reversible enzyme inhibition (detailed below) [99-101]. The CBS heme 
has thus been considered a redox and ligand sensor able to modulate CBS 
activity (reviewed in [102]). The communication between the heme and PLP 
active site has been attributed to molecular interactions at either end of the α-
helix 8 [103-105]. While at the heme end of this helix Arg266 establishes 
electrostatic interactions with the Cys52 thiolate, on the opposite end Thr257 
and Thr260 are involved in a hydrogen-bond network with the PLP 
phosphate moiety (Figure 4). The role of these residues in communicating the 
heme redox and ligand state to the PLP site has been confirmed by functional 
and spectroscopic studies on clinically relevant site-directed variants of 
Arg266, Thr257 and Thr260 [103-105]. Although the CBS heme has a low 
reduction potential (ca. -350 mV, [103]), in the presence of NADPH the 
human enzyme methionine synthase reductase (MSR) has been shown to be 
able to catalyze its reduction in vitro and generate both the ferrous-CO and 
the ferrous-NO adducts [106, 107]. 
The UV-visible spectral changes associated with heme reduction and 
CO or NO binding to the reduced heme are depicted in Figure 5A. Upon 
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reduction, the Soret band of the oxidized heme centered at 428 nm is shifted 
to 449 nm (Figure 5A), similarly to the heme thiolate-containing 
cytochromes P450. Upon CO binding to the ferrous CBS heme, the band 
shifts to 422 nm (Figure 5A), resulting in a hexacoordinate ferrous-CO 
adduct with the endogenous Cys52 ligand displaced, as confirmed by Raman 
spectroscopy [108]. NO binding to ferrous CBS results instead in a notable 
broadening of the Soret band, accompanied by an intensity decrease and a 
blue shift to ~395 nm (Figure 5A), which have been attributed to formation 
of a high-spin pentacoordinate ferrous-NO adduct with both endogenous 
ligands displaced, as confirmed by EPR spectroscopy [101]. Despite the 
inhibitory effect of CO and NO on CBS, the enzyme activity is restored upon 
reoxidation by O2 or potassium ferricyanide, both converting the CO or NO 
ferrous adducts to the ferric state [99, 101].  
The kinetics of this interplay between the three ‘gasotransmitters’ has 
been investigated by a combination of static and stopped-flow absorption 
spectroscopy [100, 101, 106, 107, 109-111] . 
  
3.3 Physiological relevance of CBS inhibition by NO and CO 
The physiological relevance of CBS regulation by NO and CO has 
been attested by different lines of in vivo evidence. In mice experiencing 
renal ischemia-reperfusion, elevated NO levels have been shown to inhibit 
CBS, yielding an increase in homocysteine deleterious for the kidney [112]. 
Increased NO production by endothelial cells and macrophages during 
endotoxemia has been shown to result in mitochondrial dysfunction and 
elevated oxidative stress in adrenocortical cells, leading to adrenal 
insufficiency, whereas the adverse effects of increased NO were suppressed 
upon supply of an exogenous H2S donor [113]. It was proposed that NO-
mediated inhibition of CBS contributes to mitochondrial dysfunction and 
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impaired steroidogenesis in adrenal cortex during endotoxemia [113]. 
Cerebral vasodilation in a mouse model of hypoxia was reported to be 
associated with CO-mediated CBS regulation [114]. Under hypoxic 
conditions, the CO-producing oxygen sensor heme oxygenase HO-2 is down-
regulated. The resulting decreased CO levels alleviate the CO inhibitory 
effect on CBS-catalyzed H2S production, contributing to mediate 
vasodilation of precapillary arterioles [114]. Increased CO in the liver has 
been shown to cause a decrease in H2S levels and a concomitant increase of 
bile output. These effects were observed in wild-type but not in heterozygous 
CBS knockout mice, leading to the proposal that CO inhibition of CBS-
mediated H2S production affords a control mechanism of bile excretion, at 
least in stressful and/or pathological conditions [115]. The relevance of CO 
inhibition of CBS activity has been attributed not only to its H2S-generating 
ability, but also to its ‘hinge’ role between the remethylation and the 
transsulfuration pathways (reviewed in [116]). CBS inhibition by CO diverts 
homocysteine to the remethylation pathway (Figure 1A), making AdoMet 
more available for protein and nucleic acid methylation. On the other hand, 
an opposing effect produced by CBS inhibition arises from the accumulation 
of S-adenosyl-L-homocysteine (AdoHcy), an inhibitor of specific 
methyltransferases. This imbalance caused by CO inhibition of CBS has been 
shown to affect the global protein methylation status (e.g. causing hyper-
methylation of histone H3), leading to the hypothesis that CBS inhibition by 
CO plays a role in the regulation of cancer cell survival [116, 117]. 
 
3.3.1 CO binding to human CBS  
In the past few years, several groups (including ours) have thoroughly 
investigated in vitro CO and NO binding to the heme moiety of human CBS, 
to bring together the data acquired on the isolated enzyme with the in vivo 
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data supporting the physiological relevance of this regulatory mechanism. 
CO binding to ferrous CBS is characterized by two dissociation constants, 
Kd1 = 0.7-1.5 µM and Kd2 = 45-68 µM  [100, 110, 111], attributed to 
differences in the heme microenvironment [100] and/or an anti-cooperative 
effect between adjacent monomers within a functional CBS dimer [108]. 
Overall CO binding has been reported to proceed with a C50 value of 29 ± 4 
µM [111] and >30 µM (estimated from Figure 2 in [100]). The kinetics of 
CO binding to ferrous CBS was investigated by time-resolved spectroscopy 
[108, 110, 111]. Upon mixing ferrous CBS with CO solutions, formation of 
the ferrous-CO adduct occurs without optical evidence for reaction 
intermediates, as judged by global fit analysis. The reaction time course is at 
least biphasic (Figure 5B), with a major slow phase the rate constant of which 
is hyperbolically dependent on CO concentration, yielding a limiting value 
klim = 0.012-0.017 s
-1
 [108, 110]. As confirmed by laser flash photolysis time-
resolved Raman spectroscopy, this rate constant has been attributed to the 
slow rate-limting dissociation of the endogenous Cys52 thiolate ligand from 
the ferrous heme iron [108]. The koff of CO was found to be 0.5 ± 0.1 s
-1
 in 
stopped-flow
 
displacement experiments carried out mixing the ferrous-CO 
adduct with an excess (0.1-1.9 mM, before mixing) of authentic NO [110].  
 
3.3.2 NO is a quick and tight ligand of human CBS 
NO binding to the reduced heme of human CBS has been initially 
reported to be characterized by a very low affinity (Kd value of 281 ± 50 
µM), incompatible with a physiological relevance of this reaction [101]. In 
that study, however, the Kd for NO was likely overestimated because 
measurements were carried out using a slow NO releaser (diethylamine 
NONOate) in the presence of large excess of dithionite, which is known to 
promptly react with free NO. Using a different reduction system, involving 
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NADPH and human MSR, a ~10-fold lower Kd value was reported (30 ± 5 
µM), still considered an upper limit for this dissociation constant, as it was 
measured in the presence of multiple equilibria (NADPH ↔ MSR ↔ CBS ↔ 
CBS-NO) [107]. More recently, employing authentic NO stock solutions and 
low dithionite concentrations to reduce CBS, a Kd ≤ 0.23 µM was measured 
[110], fully compatible with a physiological role of this molecular 
interaction. Reduced human CBS, therefore, displays a much (>100-fold) 
higher affinity for NO than for CO.  
Interestingly, NO binds ferrous CBS much more quickly than CO 
(Figure 5B). The kinetics of NO binding to ferrous heme in human CBS was 
analyzed by stopped-flow absorption spectroscopy [110]. No reaction 
intermediates were detected during the conversion of hexacoordinate ferrous 
CBS into the pentacoordinate ferrous-NO species. Overall, the reaction of 
reduced CBS with NO was significantly faster than with CO. As shown in 
Figure 5B, 500 µM CO requires ~10 minutes for conversion of ferrous CBS 
into the ferrous-CO adduct, whereas formation of the ferrous-NO adduct is 
complete within ~3 seconds after mixing ferrous CBS with 400 µM NO. Also 
differently from CO, the observed association rate constant for NO is linearly 
dependent on [NO] up to ~800 µM, yielding kbim = 8 x 10
3
 M
-1 
s
-1
 [110]. NO 
dissociation kinetics was analyzed by the Moore and Gibson method [118], 
by mixing ferrous-NO CBS with a CO-saturated 200 mM dithionite solution. 
In accordance with the high affinity for NO, dissociation of this ligand 
occurred slowly, with a kobs = 0.003 s
-1
 more than 100-fold slower than the 
CO off rate constant (0.5 ± 0.1 s
-1
) [110].  
Thus, NO binds to ferrous CBS at rates orders of magnitude higher 
than those observed for CO binding and it dissociates from the ferrous heme 
iron much more slowly than CO. Altogether, these data neatly fit with the 
much higher affinity for NO with respect to CO. From a mechanistic 
86
Results and Discussion – Paper 1 
 
 
viewpoint, the fact that kinetics of NO binding is not limited by the off-rate 
of the Cys52 ligand was taken as the evidence that NO initially attacks the Fe 
from the His65 side, rather than from the Cys52 side [110] (Figure 6). 
Moreover, since that reaction yields a pentacoordinate ferrous-NO adduct as 
the final product [101] with no evidence for a transiently generated 
hexacoordinate Cys-Fe-NO adduct, NO binding to the His side was 
suggested to cause a concomitant displacement of Cys52, at rates much 
higher than its intrinsic off rate (that instead limits CO binding). It remains to 
be established whether the NO bound in the final pentacoordinate adduct lays 
on the His or the Cys side. For NO to end up on the Cys side, an obligate 
hexacoordinate ferrous-dinitrosyl (NO-Fe-NO) species should form 
transiently during the reaction, as observed with other hexacoordinate heme 
proteins (e.g. bacterial cytochrome c’ and heme NO/O2 sensor, and soluble 
guanylate cyclase) where high affinity for NO is attained by sequential NO 
binding steps preceding formation of the final pentacoordinate NO-bound 
species [119-123]. However, direct spectroscopic evidence for the formation 
of such a hexacoordinate ferrous-dinitrosyl intermediate during the reaction 
of CBS with NO is lacking. For this reason, these yet hypothetical reactions 
are depicted inside a dashed box in Figure 6. Irrespectively of the NO binding 
mechanism, it remains to be understood why in human CBS NO initially 
binds to the His side, whereas CO to the Cys side. In bacterial cytochrome c’, 
binding of NO and CO on opposite sides of the heme has also been reported 
[121, 124-126]. The affinity for either gas in heme proteins has been assigned 
to the chemical nature of the endogenous iron axial ligands and to the 
properties of the heme pocket environment, as a cumulative effect of steric 
hindrance, electrostatic interactions and H-bonds [119, 120, 123].  
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3.3.3 Effect of S-adenosyl-L-methionine on CO and NO inhibition of human 
CBS  
As a follow-up of the investigations described above, a thorough 
analysis of the effect of the allosteric activator AdoMet on the heme 
chemistry of human CBS has been recently undertaken, focusing on the CO 
and NO binding properties of the enzyme [111]. Structural studies have 
elucidated the molecular basis of AdoMet stimulation of CBS activity [94, 
96]. In the AdoMet-free state, the C-terminal domain from one monomer 
hinders substrate accessibility to the active site of the adjacent monomer. 
Upon AdoMet binding, a large conformational change takes place and the C-
terminal domains from the two monomers associate in a disk-like shape, 
thereby unblocking the entry to the substrate pocket and facilitating its access 
to the PLP active site.  
Despite the significant distance between the C-terminal AdoMet-
binding and the N-terminal heme-binding domains (>30 Å between adjacent 
monomers and >50 Å within one monomer in AdoMet-free CBS), the 
question was raised as to whether AdoMet binding at the C-terminus 
promotes a distal communication with the heme site [111]. Indeed, by 
analyzing H2S production by reduced CBS as a function of CO concentration 
in the absence or presence of AdoMet, we estimated a Ki = 9.5 ± 1.0 μM for 
AdoMet-free CBS and a Ki = 0.7 ± 0.1 μM for the AdoMet-bound enzyme 
(Figure 7A) [111]. These data not only provided the first report of a Ki for 
CO regarding CBS-catalyzed H2S production, but also revealed a marked 
functional effect of AdoMet on the heme-mediated CO inhibition of the 
enzyme.  
Prompted by these observations, a thorough characterization of the 
CO and NO binding properties of human CBS in the presence or absence of 
AdoMet has been undertaken [111]. As shown in Figure 7B and in line with 
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the effect of AdoMet on CO inhibition, by performing anaerobic CO 
titrations of reduced CBS monitored by UV-visible absorption spectroscopy, 
AdoMet proved to significantly increase the affinity of the enzyme for CO. 
Particularly, AdoMet binding resulted in an overall ~5-fold decrease of the 
C50 value, from 29 ± 4 μM to 6 ± 1 μM. Carrying out control titrations with a 
truncated CBS form lacking the C-terminal AdoMet-binding domain, a C50 of 
12 ± 1 μM was estimated both in the absence and presence of AdoMet, ruling 
out an unspecific direct effect of AdoMet on the heme [111].     
The effect of AdoMet on CO binding kinetics was then evaluated by 
stopped-flow mixing AdoMet-free or AdoMet-bound ferrous CBS with CO 
solutions. In accordance with the increased affinity measured in the presence 
of AdoMet, CO association to the AdoMet-bound was markedly faster than 
to the AdoMet-free enzyme (Figure 7C) [111]. Indeed, incubation with 
AdoMet resulted in an overall ~10-fold faster association (t1/2 = 5.5 s and t1/2 
= 55 s for AdoMet-bound and AdoMet-free CBS, respectively). The effect of 
AdoMet on CO binding was then analyzed at saturating CO concentrations 
and varying the AdoMet concentration [111]. The reaction followed a 
characteristic biphasic timecourse and both CO binding rate constants 
showed a hyperbolic dependence on AdoMet concentration, characterized by 
a C50 values of 12 ± 4 μM and 18 ± 3 μM for the fast and slow kinetic phase, 
respectively, showing a nearly saturating effect at physiological AdoMet 
concentrations (50-80 μM, [127]). Altogether, the acquired data show a 
significant functional impact of AdoMet on CO binding to ferrous human 
CBS resulting in an increased propensity towards CO inhibition of H2S 
synthesis. 
The effect of AdoMet was further evaluated on the binding affinity 
and association kinetics of NO [111]. As compared to CO, AdoMet exhibited 
a less pronounced effect on NO binding. Affinity for NO increased by ~2-
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fold in the presence of AdoMet, consistent with a ~1.5-fold increase in the 
association bimolecular rate constant and ~1.3-fold decrease in the 
dissociation observed rate constant [111]. Notably, the association observed 
rate constants at a fixed NO concentration displayed a hyperbolic dependence 
on AdoMet concentration, yielding a C50 of 16 ± 2 μM for AdoMet, fully 
consistent with those determined for CO and with a modulation of NO 
binding to CBS at physiological AdoMet concentrations. As with CO, a 
truncated version of CBS lacking the C-terminal AdoMet-binding domain 
proved to be insensitive to AdoMet both in terms of NO binding affinity and 
kinetics [111].  
The fact that AdoMet affects differently CO and NO binding is fully 
consistent with the proposal that NO and CO attack initially the CBS heme 
iron from different sides (Figure 6). Since AdoMet affects more 
pronouncedly CO binding, it is likely that AdoMet binding at the C-terminal 
regulatory domain results into a selective weakening of Fe-Cys52 bond. It 
remains to be determined whether this functional communication between 
distant regulatory sites within CBS also involves the catalytic core domain. 
Irrespectively of the mechanistic details entailing this functional and 
structural communication between the CBS domains, it is remarkable that an 
allosteric effector that increases the enzyme activity, at the same time makes 
the enzyme more prone to inactivation by the exogenous ligands CO and NO. 
Despite this seemingly paradoxical regulatory conundrum, it is not surprising 
that CBS, being a major source of H2S, exhibits such intricate switching 
mechanisms to quickly, effectively and reversibly modulate H2S production, 
although the reflection on bioenergetics of the gasotransmitters interplay at 
the level of CBS remains to be elucidated. 
   
90
Results and Discussion – Paper 1 
 
 
In conclusion, growing evidence suggests that endogenous H2S can 
impact cellular bioenergetics by modulating (either positively or negatively) 
mitochondrial respiration and, under certain conditions, enhancing glycolysis. 
Depending on its concentration, H2S can either act as an effective substrate 
or, similarly to CO and NO, as an inhibitor of the mitochondrial respiratory 
chain, targeting CcOX. This dual function of H2S, while crucially depending 
on the bioavailability of this gaseous signalling molecule, is interestingly 
intertwined with the action of the other two gasotransmitters CO and NO. It 
is therefore important to increase our knowledge on the molecular 
mechanisms underlying H2S metabolism, its regulation and the intricate 
cross-talk between the three gasotransmitters, all contributing to a correct 
balance between H2S synthesis and breakdown. In this light, a key role could 
be played by human CBS, an enzyme sitting at the crossroad between the 
signalling pathways of the three gasotransmitters. The field is in its infancy 
and clearly deserves in the future more efforts to answer the many as yet 
open questions.  
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FIGURES AND LEGENDS 
 
Figure 1 
 
Figure 1. H2S metabolism in human physiology. Panel A, H2S biosynthetic 
pathway. Homocysteine (Hcy) is generated through the methionine cycle, 
involving the sequential conversion of methionine (Met) into S-adenosyl-L-
methionine (AdoMet), followed by AdoMet demethylation into S-adenosyl-
L-homocysteine (AdoHcy) and production of Hcy by hydrolysis. 
Cystathionine β-synthase (CBS) catalyzes the condensation of serine (Ser) 
and Hcy into cystathionine (Cysth) and water. Alternative reactions catalyzed 
by CBS, using cysteine (Cys) alone or Cys and Hcy, result in H2S production. 
The next step in the transsulfuration pathways is catalyzed by cystathionine 
γ-lyase (CGL), which converts Cysth into Cys. Alternative reactions 
catalyzed by CGL, using Hcy and/or Cys as substrates, yield H2S. Cys is 
converted by cysteine aminotransferase (CAT) into mercaptopyruvate (3-
MP), which is used as a substrate by mercaptopyruvate sulfurtransferase 
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(MST) for H2S production. Panel B, sulfide oxidizing unit: H2S is oxidized 
by sulfide:quinone oxidoreductase (SQR), with reduced glutathione (GSH) as 
the preferred sulfur acceptor, yielding glutathione persulfide (GSSH) and 
reduced quinone (Q). GSSH is catabolized by persulfide dioxygenase 
(ETHE1) into sulfite, using O2 as co-substrate. GSSH and sulfite are 
converted by rhodanese (Rhod) into thiosulfate. Finally, sulfite is oxidized to 
sulfate by sulfite oxidase (SOx). Reduced quinone (Qred) supplies electron 
equivalents via Complex III to accomplish Complex IV-mediated oxygen 
respiration.  
 
Figure 2 
 
 
Figure 2. H2S and mitochondrial respiration. Dual effect of H2S on 
mitochondrial respiration depending on its bioavailability. At low 
concentrations, H2S supplies the mitochondrial electron transfer chain, being 
oxidized by sulfide:quinone oxidoreductase (SQR) with concomitant 
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reduction of coenzyme Q. Reduced quinone (also derived from NADH 
oxidation by Complex I) is then oxidized by Complex III to generate reduced 
cytochrome c, finally used by Complex IV as the electron source for O2 
reduction to water. Proton translocation by complexes I, III and IV contribute 
to Complex V-mediated ATP production. At high H2S concentrations, 
cytochrome c oxidase (Complex IV) is directly inhibited by H2S, blocking 
respiration and concomitant ATP synthesis.   
 
Figure 3 
 
 
Figure 3. Inhibition of cytochrome oxidase by the three 
‘gasotransmitters’ CO, NO and H2S. Redox active metal centres of 
cytochrome oxidase (CcOX): the binuclear CuA centre is the electron entry 
point, heme a mediates electron transfer to the O2-reducing binuclear active 
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site, composed by heme a3 and CuB. CO inhibits CcOX by tight reversible 
binding to ferrous heme a3. The CcOX inhibition pathway by NO varies 
depending on the electron flux and O2 level. At high electron flux and low 
[O2], NO binds to ferrous heme a3. At low electron flux and high [O2], the 
inhibited adduct has nitrite bound to ferric heme a3. Sulfide-inhibited CcOX 
has H2S bound to ferric heme a3 and possibly another H2S molecule bound to 
cuprous CuB. 
 
Figure 4 
 
Figure 4. Structure of human cystathionine β-synthase. Cartoon 
representation of the ‘full-length’ human CBS homodimer (PDB ID: 4COO; 
Δ516-525; 2.0 Å resolution), where the C-terminal domain of each monomer 
(coloured cyan or light orange) hinders the substrate entrance to the active 
site of the opposite monomer. AdoMet binding causes the C-terminal 
domains to associate in a disk-like form, de-repressing the enzymatic activity. 
Red sticks, regulatory heme b with its Cys52 and His65 ligands, where NO or 
CO bind, resulting in enzyme inhibition. Green sticks, active site PLP 
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moiety, where H2S production occurs. Bright blue and bright orange helices 
(residues T257-G258-G259-T260-I261-T262-G263-I264-A265-R266) communicate the 
heme redox and ligand binding state to the PLP active site. Figure generated 
with Pymol. 
 
Figure 5 
 
 
 
Figure 5. Spectroscopic and kinetic analysis of NO and CO binding to 
human CBS. Panel A, UV-visible absorption spectra of human CBS (in 50 
mM phosphate buffer, 300 mM KCl, 10% glycerol, pH 7.0) in the oxidized 
(black line), dithionite-reduced (red line), ferrous-CO bound (dotted green 
line) and ferrous-NO bound (dashed blue line) states. Panel B, kinetic traces 
acquired after stopped-flow mixing ferrous human CBS with NO (400 μM 
after mixing) or CO (500 μM after mixing) at 25 °C. Adapted from [110].   
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Figure 6 
 
 
 
Figure 6. Proposed mechanisms for NO and CO binding to human CBS. 
Whereas CO binding to ferrous CBS appears to be rate-limited by the 
displacement of Cys52, NO is proposed to displace first the His65 ligand and 
end-up as a pentacoordinate ferrous-NO adduct with both endogenous axial 
ligands displaced and NO laying on either the His or the Cys side. In the 
latter case, an obligate hexacoordinate ferrous-dinitrosyl (NO-Fe-NO) species 
should form transiently. As there is no direct evidence for the occurrence of 
such a dinitrosyl intermediate in the reaction of CBS with NO, these yet 
hypothetical reactions are depicted inside a dashed box.  
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Figure 7. 
 
 
 
Figure 7. AdoMet enhances CO binding to human CBS and inhibition of 
H2S production. Panel A, CO inhibition of H2S production by human CBS 
in the absence or presence of S-adenosyl-L-methionine (AdoMet), assayed at 
37 °C. Data fitting yielded Ki = 9.5 ± 1.0 μM and Ki = 0.7 ± 0.1 μM in the 
absence and presence of AdoMet, respectively. Panel B, CO titration profiles 
obtained by global fit of the UV-visible spectral data acquired in the absence 
(blue circles) or presence (red squares) of 500 μM AdoMet. Data fitting 
yielded C50 = 6 ± 1 μM and C50 = 29 ± 4 μM for AdoMet-bound and 
AdoMet-free CBS, respectively. Panel C, Reaction time courses obtained by 
stopped-flow mixing ferrous human CBS with 1 mM CO in the absence (blue 
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line) or presence (red line) of AdoMet (500 μM before mixing). Data fitting 
yielded t1/2 = 5.5 s and t1/2 = 55 s for AdoMet-bound and AdoMet-free CBS, 
respectively. Reaction conditions and data analysis detailed in [111]. 
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ABSTRACT 
The human disease classical homocystinuria results from mutations in the 
gene encoding the pyridoxal 5’-phosphate (PLP)-dependent cystathionine β-
synthase (CBS), a key enzyme in the transsulfuration pathway that controls 
homocysteine levels and is a major source of the signaling molecule 
hydrogen sulfide (H2S). CBS activity, contributing to cellular redox 
homeostasis, is positively regulated by S-adenosyl-L-methionine (AdoMet), 
but fully inhibited upon CO or NO• binding to a non-catalytic heme moiety. 
Despite extensive studies, the molecular basis of several pathogenic CBS 
mutations is not yet fully understood. Here we found that the ferrous heme of 
the reportedly mild p.P49L CBS variant has altered spectral properties and 
markedly increased affinity for CO, making the protein much more prone 
than wild type (WT) CBS to inactivation at physiological CO levels. The 
higher CO affinity could result from the slightly higher flexibility in the heme 
surroundings revealed by solving the crystallographic structure of a truncated 
p.P49L at 2.80-Å resolution. Additionally, we report that p.P49L displays 
impaired H2S-generating activity, fully rescued by PLP supplementation 
along the purification, despite a minor responsiveness to AdoMet. Altogether, 
the results highlight how increased propensity to CO inactivation of an 
otherwise WT-like variant may represent a novel pathogenic mechanism in 
classical homocystinuria.  
 
ABBREVIATIONS 
AdoMet, S-adenosyl-L-methionine; CBS, cystathionine β-synthase; CBSΔ409-
551, truncated cystathionine β-synthase lacking the C-terminal 143 residues; 
CBS p.P49L, cystathionine β-synthase variant harboring a proline-to-leucine 
substitution at residue 49; CO, carbon monoxide; CSE, cystathionine γ-lyase; 
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EDTA, ethylenediaminetetraacetic acid; H2S, hydrogen sulfide; KPi, 
potassium phosphate; MME, monomethyl ether; MST, mercaptopyruvate 
sulfurtransferase; NO•, nitric oxide; PEG, polyethylene glycol; PLP, 
pyridoxal 5’-phosphate; r.m.s.d., root mean square deviation; SDS-PAGE, 
sodium dodecyl sulfate polyacrylamide gel electrophoresis; WT, wild-type 
 
INTRODUCTION  
Hydrogen sulfide (H2S) has emerged as a key signaling molecule in 
human physiology and pathophysiology, being implicated in the regulation of 
several processes such as neuromodulation, angiogenesis, vasorelaxation, 
bioenergetics/respiration, cell survival and proliferation, among others [1-4]. 
The gas has a pivotal role in the control of cellular redox homeostasis and 
prevention of oxidative stress, modulating the expression of key antioxidant 
enzymes [2]. Similarly to other relevant gaseous signaling molecules like CO 
and NO•, at low concentrations H2S can exert cytoprotective effects or 
become cytotoxic at higher concentrations. 
At least three human enzymes have been identified as key 
endogenous sources of H2S: cystathionine β-synthase (CBS) and 
cystathionine γ-lyase (CSE), both occurring in the transsulfuration pathway 
of methionine metabolism, and mercaptopyruvate sulfurtransferase (MST) 
[1]. Beyond enabling conversion of homocysteine to cysteine through their 
historically recognized canonical activities, CBS and CSE catalyze a number 
of ‘alternative’ reactions leading to H2S synthesis, which has brought these 
enzymes into the limelight [1,5,6]. Indeed, a growing number of human 
pathologies, from cardiovascular and neurodegenerative diseases to different 
cancer types, are reportedly associated with disturbances of H2S metabolism 
related to CBS, CSE and/or MST [7]. CBS, in particular, has been shown to 
be overexpressed in colorectal, ovarian and breast cancer, among other 
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cancer types (reviewed in [8,9]), as well as in neurodegenerative diseases, 
such as amyotrophic lateral sclerosis [10]. The enzyme is therefore currently 
recognized as a drug target [8]. 
CBS catalyzes the condensation of homocysteine and serine (or 
cysteine) leading to formation of cystathionine and H2O (or H2S). The human 
enzyme is a 551-amino acid protein with a central catalytic domain, 
harboring a pyridoxal 5’-phosphate (PLP) cofactor, flanked by a C-terminal 
domain with a binding site for the allosteric positive regulator S-adenosyl-L-
methionine (AdoMet) and an N-terminal domain, harboring a hexacoordinate 
heme with C52 and H65 as endogenous Fe ligands [11]. Structural studies 
have shown that, whereas the AdoMet-binding domain occludes the substrate 
entry site in the catalytic core, AdoMet binding induces a conformational 
change clearing the path for substrates access to the active site [11-13]. In the 
presence of AdoMet enzymatic activity thus increases 2-5 fold, as measured 
with isolated proteins and bacterial or human cell lysates. Another interesting 
regulatory mechanism concerns the B-type heme moiety in the N-terminal 
domain. While the enzyme is fully active when the heme is in the oxidized 
state, reduction to the ferrous state negatively impacts enzyme activity, 
possibly through a ligand exchange mechanism involving the replacement of 
C52 by a yet unknown neutral ligand [14,15]. Such change in the Fe 
coordination is accompanied by a notable shift in the CBS heme Soret band 
from 449 to 424 nm, leading to an inactive protein species commonly 
referred to as ‘C-424’ [15]. Even more striking is that binding of NO• or CO 
to the ferrous heme results in enzyme inhibition [16-20], with different lines 
of evidence pointing to a physiological role of this regulatory mechanism in 
vivo [21-27]. According to structural and mutagenesis studies, changes in the 
heme redox and ligation state are communicated to the PLP active site 
through α-helix 8 [15,28,29]. This regulatory mechanism places CBS at the 
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crossroad between the signaling pathways of the three gasotransmitters (H2S, 
CO and NO•) in human physiology [30]. More recently, it has been shown 
that AdoMet enhances CBS sensitivity to CO and NO•, further highlighting 
an intricate interplay between the three domains in the protein [20].  
Classical homocystinuria (OMIM #236200) is an inborn error of 
metabolism associated with mutations in the CBS gene. With a variable 
incidence of 1:1,800 to 1:900,000, classical homocystinuria is biochemically 
detected by markedly high homocysteine and methionine levels in plasma 
and urine, with clinical presentation involving mental impairment, vascular 
complications, dislocated lenses and skeletal abnormalities [31]. Notably, 
elevated homocysteine levels are associated with oxidative stress conditions, 
well known to contribute to the onset and progress of a broad spectrum of 
diseases. Thus far, besides dietary methionine restriction, the major 
therapeutic approach for classical homocystinuria consists of administration 
of pyridoxine (vitamin B6), a precursor of the PLP cofactor [31], although a 
significant part of patients (approximately half) do not respond to this 
treatment [32]. The vast majority of the mutations identified in patients with 
classical homocystinuria are missense mutations resulting in single amino 
acid substitutions. Whereas most mutations affect the enzyme folding and/or 
activity [15,28,33-39], some of them have been shown to affect enzyme 
regulation by AdoMet, pointing to such dysregulation as a new pathogenic 
mechanism in classical homocystinuria [40]. The fact that several variants 
have impaired activity due to protein misfolding is underlined by the 
demonstration that some of them are amenable to be functionally rescued by 
chemical chaperones [34,36,38,39,41,42]. A novel therapeutic approach is 
currently under development based on enzyme replacement therapy using 
PEGylated recombinant CBS, which has been shown to afford a marked 
decrease in circulating homocysteine in a mouse model of homocystinuria 
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[43]. This therapeutic approach might be particularly relevant for PLP-
unresponsive patients.  
The 146 C>T transition in exon 1 of the CBS gene generates the 
clinically relevant p.P49L variant, identified in patients with classical 
homocystinuria [44-46]. The mutation results in mild to moderate symptoms 
and sporadic responsiveness to vitamin B6 treatment. When assayed in cell 
extracts or after purification, the protein variant shows impaired or wild type 
(WT)-like canonical activity in the absence or presence of PLP in the assays, 
respectively, and milder to normal responsiveness to AdoMet [36,37,39,40]. 
These findings point to defects in PLP incorporation, although the protein 
variant as purified after recombinant expression in Escherichia coli in the 
presence of suitable chemical chaperones at optimal concentrations exhibits 
unaffected PLP and heme incorporation, and unperturbed circular dicroism 
(CD) or UV-visible absorption spectra in the oxidized state [39].    
Herein we demonstrate that the p.P49L variant of human CBS displays H2S-
synthesizing activity largely sensitive to PLP supplementation along the 
protein purification. The crystallographic structure of a truncated version of 
CBS p.P49L, devoid of the C-terminal Ado-Met binding domain, reveals no 
major differences at the level of the PLP catalytic site with respect to the WT, 
but slightly increased protein flexibility in the heme surroundings. As a novel 
finding we report a markedly increased CO affinity of p.P49L as compared to 
the wild-type enzyme, en route to enzyme inactivation. The obtained 
functional and structural data are discussed in light of the proposal that in 
pathogenic variants of human CBS increased reactivity towards exogenous 
ligands, such CO, represents a further molecular mechanism at the basis of 
classical homocystinuria. 
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MATERIALS AND METHODS 
Protein expression and purification 
Recombinant full-length human CBS p.P49L was expressed and purified as 
previously described for WT CBS [19] either in the absence or presence of 
20 µM PLP, using the herein named pET28b-CBS-p.P49L vector generated 
in [40]. With this vector as template, site-directed mutagenesis was employed 
to obtain also a truncated form of the protein (denoted CBSΔ409-551 p.P49L) 
devoid of the C-terminal 143 residues corresponding to the AdoMet-binding 
domain. The 1227G>A mutant (cDNA numbering) carrying a premature stop 
codon at position 409 was generated from pET28b-CBS-p.P49L using the 
XL Quick Change Kit (Agilent) and the primers 5’-
GAAGAAGCCCTGGTGATGGCACCTCCGTG (forward) and 5’-
CACGGAGGTGCCATCACCAGGGCTTCTTC (reverse). All vectors were 
checked for the correct mutation by DNA sequencing. Expression and 
purification of CBSΔ409-551 p.P49L were carried out as described in [20].   
Purity of the isolated proteins was assessed by SDS-PAGE and their 
concentration was determined by the Bradford method [47], whereas the 
heme concentration in the isolated oxidized proteins was determined using 
ε428nm = 92,700 M
-1
 cm
-1
 [48].  
Unless otherwise stated, the experiments were carried out in 50 mM KPi 
buffer, 300 mM KCl, 10% glycerol, 100 µM EDTA, pH 7.0 (Buffer A). 
 
H2S synthesis assays  
H2S production by recombinant human CBS variants was measured at 37 °C, 
either by amperometry using a H2S-selective electrode (World Precision 
Instruments) or by the lead acetate method [5]. Purified CBS (0.5-1 μM) was 
incubated for 10 minutes with 50 μM PLP, 260 U/ml catalase and 0.4-2.0 
mM homocysteine in the absence or presence of 0.5 mM AdoMet, after 
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which 10 mM cysteine was added to trigger the reaction. Amperometric 
assays were performed using an ISO-H2S-2 hydrogen sulfide sensor coupled 
to an Apollo 4000 Free Radical Analyzer (World Precision Instruments). 
After recording H2S production for 3 minutes, the electrode was internally 
calibrated by adding 4 μM NaHS (corresponding to 2 μM H2S at pH 7.0). 
Finally, 50 μM O-acetylserine and 200 nM Entamoeba histolytica O-
acetylserine sulfhydrylase were added to the reaction mixture to remove H2S 
from solution and bring the signal back to baseline [49]. Activity assays by 
the lead acetate method were carried out in a thermostated cuvette under 
stirring, according to [5]. Lead acetate (400 μM) was added to the reaction 
mix prior to cysteine addition, and H2S production monitored at 390 nm in an 
Agilent Cary-60 spectrophotometer.  
 
CO titrations 
UV-visible absorption spectra of oxidized and reduced CBS p.P49L and WT 
were recorded in an Agilent Cary-60 spectrophotometer. Anaerobic titrations 
of reduced CBS p.P49L with CO were performed at 20 °C in an Agilent 
Cary-60 or a Shimadzu UVPC-1800 spectrophotometer. Gas exchange was 
prevented either by filling the quartz cuvette and sealing it with a rubber-cap 
or by adding mineral oil on top of the aqueous medium. Anaerobic conditions 
were ensured by nitrogen flushing and addition of glucose oxidase (4 
units·ml
-1
), catalase (13 μg·ml-1), superoxide dismutase (12 units·ml-1) and 
glucose (3 mM) to scavenge contaminant oxygen, hydrogen peroxide and 
superoxide anion. CBS p.P49L and WT (1.4-1.6 μM in heme) were reduced 
with 90 μM sodium dithionite, diluted from a 45 mM stock solution 
(quantitated using ε314nm = 8,043 M
-1
·cm
-1
 [50]). CO stock solutions were 
prepared by equilibrating thoroughly degassed buffer A with the pure gas at 1 
atm, yielding 1 mM CO at 20 °C. After each CO addition with gas-tight 
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Hamilton syringes, the spectral changes were visually inspected in real time 
and a new addition was immediately made when no more changes were 
observed.  
According to [16,19,20,51], two apparent Kd (Kd,1 and Kd,2) were used to 
satisfactorily fit the CO affinity data. The Kd,1 and Kd,2 values were obtained 
by fitting the data to Equation 1, where PL is the concentration of CO-bound 
CBS p.P49L, PT and LT are, respectively, the total CBS p.P49L and CO 
concentrations, and α1 and α2 are, respectively, the protein fractions binding 
CO at higher (Kd1) and lower (Kd2) affinity.  
 
𝑃𝐿 =
α1[(𝑃𝑇 + 𝐿𝑇 + 𝐾𝑑1) − √(𝑃𝑇 + 𝐿𝑇 + 𝐾𝑑1)2 − 4𝑃𝑇𝐿𝑇] + α2[(𝑃𝑇 + 𝐿𝑇 +𝐾𝑑2) − √(𝑃𝑇 + 𝐿𝑇 + 𝐾𝑑2)2 − 4𝑃𝑇𝐿𝑇]
2
 
Equation 1. 
 
Stopped-flow measurements 
Time-resolved absorption spectroscopy experiments were carried out in a 
thermostated stopped-flow instrument (DX.17MV, Applied Photophysics), 
equipped with a photodiode-array (light path, 1 cm). To avoid light-induced 
artifacts, the intensity of the white-light incident beam was decreased and a 
filter cutting UV light at λ < 360 nm was employed. Absorption spectra were 
recorded with an acquisition time of 10 ms per spectrum according to a 
logarithmic time scale. All reactions were carried out at 25 °C in buffer A. 
CBS p.P49L was thoroughly flushed with nitrogen, after which glucose 
oxidase (4 units·ml
-1), catalase (13 μg·ml-1), superoxide dismutase (12 
units·ml
-1
) and glucose (3 mM) were added to scavenge oxygen, hydrogen 
peroxide and superoxide anion. The protein was then placed on ice, protected 
from light to prevent possible damaging photoreactions. When indicated, 
CBS p.P49L was incubated with AdoMet for ≥10 minutes, prior to reduction 
with 90 µM sodium dithionite. CO association kinetics were studied by 
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mixing in the stopped-flow apparatus reduced CBS p.P49L, in the absence or 
presence of AdoMet, with CO solutions and the spectra recorded over time. 
CO dissociation kinetics were evaluated by mixing the Fe(II)-CO adduct of 
CBS p.P49L with NO• stock solutions, prepared by equilibrating degassed 
ultra-pure water with NO• gas at 1 atm, further kept on ice protected from 
light. 
 
Spectral data analysis 
CO affinity titrations and CO binding and dissociation kinetic data were 
analyzed with the software MATLAB (Mathworks). Global fit analysis of 
spectral data was performed by singular value decomposition analysis 
combined with curve fitting [52]. 
 
Protein crystallization 
Initial crystallization screenings for CBSΔ409-551 p.P49L were performed in 
96-well plates at 293 K using a Cartesian mini-Bee nanoliter-drop dispensing 
robot (Genomic Solutions). These screenings allowed for the identification of 
one hit for CBSΔ409-551 p.P49L from the JCSGplus
TM
 screen (Molecular 
Dimensions): G10 (0.15 M KBr, 30% w/v PEG 2000 MME). Crystals were 
optimized at the microliter scale using sitting-drop vapor diffusion with a 
drop composition of 0.5 µl protein solution (27.4 mg·ml
-1
 in Buffer A with 
20 µM PLP) and 0.5 µl reservoir solution (0.15 M NaBr, 35% PEG 2000 
MME) equilibrated against 500 µl precipitant solution in the well. Dark 
orange colored small needles as well as big rod-shaped crystals appeared 
after 12 h at 20 °C. 
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Data processing and refinement 
Cryoprotection conditions for diffraction experiments were achieved by 
transferring the crystals to a 5 μl drop of 35% (w/v) PEG 2000 MME, 5% 
(v/v) glycerol, 0.15M NaBr. The crystals were flash-cooled by quick 
plunging into liquid nitrogen. A single crystal was used for data collection 
under a nitrogen-gas stream (Oxford Cryosystems 700) on beamline ID30A-3 
at the ESRF synchrotron (Grenoble, France) using a PILATUS 6M detector 
(Dectris) at a wavelength of 0.9677 Å. After indexing and calculation of a 
data collection strategy using EDNA [53], a wedge of 360° of data was 
collected using a fine-slicing strategy (0.1° rotation per image). The data set 
was indexed and integrated with XDS [54] space-group assignment was 
performed with POINTLESS [55] and scaling was performed with AIMLESS 
[56] all within the autoPROC data-processing pipeline [57]. At this stage an 
Rfree-flag set was created corresponding to 5% of the measured reflections of 
the data-set. Crystals belonged to the monoclinic space group P1 with unit 
cell parameters a = 86.2 Ǻ, b = 86.8 Ǻ, c = 97.8 Ǻ, α = 102.6°, β = 103.1°, γ 
= 111.2°. Data were truncated at 2.80 Ǻ. Data reduction and refinement 
statistics are depicted in Table 1. The structure of the CBSΔ409-551 p.P49L 
variant was solved by molecular replacement using PDB entry 1JBQ devoid 
of any solvent and cofactors as search model using phaser [58] within the 
PHENIX software suite of programs [59]. Based on the Matthews coefficient, 
the search was performed for six molecules. Automated model building was 
performed using the AutoBuild wizard [60], also within PHENIX. Initial 
refinement rounds were carried out with BUSTER-TNT [61] using the macro 
that accounts for missing parts of the model (“-L”). At this point, electron 
density features attributed to the heme moieties were easily identified. 
Iterative cycles of manual model building and refinement were carried out 
with COOT [62] and BUSTER-TNT until convergence. Validation was 
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performed with RAMPAGE [63] and MolProbity [64] as implemented in 
PHENIX.  
 
RESULTS  
Hydrogen sulfide synthesis by CBS p.P49L 
H2S synthesis by the CBS p.P49L variant using homocysteine and 
cysteine as substrates was analyzed in comparison with the WT enzyme by 
amperometric and colorimetric (lead acetate) methods. Two sets of enzyme 
preparations, purified either in the absence or presence of the PLP cofactor, 
were evaluated in assays run in the presence of PLP. As shown in Figure 1, 
the p.P49L CBS variant isolated in the absence of PLP (PLP-‘untreated’) 
displays a basal activity more than 3-fold lower than that of the WT enzyme. 
Despite the markedly impaired enzymatic activity of ‘untreated’ CBS 
p.P49L, activity stimulation by AdoMet is similar between WT and p.P49L 
(respectively 1.5- and 1.4-fold). Conversely, the p.P49L CBS variant purified 
in the presence of PLP (PLP-‘treated’) displays a basal activity similar to the 
WT enzyme, despite presenting impaired activity stimulation by AdoMet 
(1.9-fold for WT to be compared with 1.1-fold for p.P49L). The AdoMet 
activation factor (≤ 2 fold) observed for the WT enzyme was slightly lower 
than usually reported (2-5 fold). This could be related with a fraction of the 
enzyme lacking the C-terminal domain, which was also observed for the CBS 
p.P49L variant (Supplementary Figure S1).  
 
Structure of CBS p.P49L variant 
In an attempt to understand the structural impact of the proline-to-
leucine substitution at position 49 of human CBS, we have determined the X-
ray structure of a truncated form of the p.P49L variant (PDB entry 5MMS), 
lacking the C-terminal 143 residues (henceforth designated as CBSΔ409-551 
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p.P49L), similarly to the reported structure of truncated WT CBS (PDB entry 
1JBQ) [65]. Crystals belong to the triclinic space group P1 with cell 
dimensions a = 86.2, b = 86.8 and c = 97.8 Ǻ, α = 102.6°, β = 103.1° and γ = 
111.2°. XDS as implemented in autoPROC clearly identifies two different 
lattices in the diffraction pattern rotated by 121.4° relative to each other. This 
diminishes the quality of the overall statistics since in some directions an 
almost perfect superposition of reflections makes the integration difficult 
(data collection and refinement statistics are depicted in Table 1). 
There are six molecules in the asymmetric unit corresponding to a 
Matthews coefficient [66] of 2.31 Ǻ3·Da-1 and a solvent content of 
approximately 47%. The structure was refined to 2.80 Ǻ resolution with Rcryst 
of 18.2% and Rfree of 22.1%. The final model comprises the residues from 
R45 to E400 (in chain D), 6 hemes, 6 PLP molecules, 3 sodium ions and 185 
water molecules. The hemes are axially bridged by C52 and H65 and the PLP 
moieties covalently linked to the polypeptide chain through K119. The maps 
are generally of good quality except for two disordered loops (T193 to S199 
and Q295 to T300), for which only in chain D there were complete electron 
densities. This contrasts with the published structure of the truncated human 
CBS WT (PDB entry 1JBQ), where the T193-S199 loop could not be 
modeled. The variant dimeric structure, shown in Figure 2A, displays an 
essentially identical overall fold with respect to the WT enzyme (r.m.s.d. of 
0.4 Å for 344 aligned Cα carbon atoms between chain D of CBSΔ409-551 
p.P49L and chain A of 1JBQ) and highly conserved features in the PLP 
active site and the N-terminally located heme moiety (Figure 2B).  
 
Spectral properties of ferrous p.P49L CBS 
In the absence of clear structural clues for pathogenicity of the p.P49L 
mutation, we sought to evaluate by UV-visible absorption spectroscopy the 
129
Results and Discussion – Paper 2 
 
 
impact of this residue substitution on the protein redox spectra, largely 
dominated by the heme absorption. In WT CBS, heme reduction leads to 
notable changes in the protein absorption spectrum, with a shift of the Soret 
band from 428 nm to 449 nm (Figure 3A). Upon incubation of the enzyme 
with AdoMet prior to reduction, the spectrum of the reduced enzyme is 
affected by a decrease in the 449-nm band intensity and the appearance of a 
feature centered at ~424 nm (Figure 3A, red solid line). Regardless of 
AdoMet, in the oxidized state, p.P49L CBS exhibits no differences in the 
absorption spectrum as compared to the WT protein (Figure 3, dashed lines). 
In contrast, major differences can be noted by comparing the spectra of the 
two proteins in the reduced state, with the mutant displaying markedly more 
pronounced appearance of the 424-nm spectral feature and decrease of the 
449-nm band (Figure 3B, blue solid line), both further elicited in the AdoMet 
bound protein (Figure 3B, red solid line).    
 
Enhanced affinity of p.P49L CBS for CO 
Prompted by the observed spectral differences between reduced 
p.P49L and WT CBS, we analyzed the affinity of the mutated protein for the 
physiologically relevant CO ligand by performing anaerobic CO titrations. 
Similarly to the WT protein, conversion of ferrous CBS p.P49L to the CO 
adduct proved to result in the appearance of a band centered at 422 nm 
(Figures 4A and 4B). Global fit analysis of the spectral data set acquired 
along the titration revealed a much higher CO affinity (>50 fold) of p.P49L 
CBS (Figure 4C, full circles) as compared to the WT enzyme (Figure 4C, 
dotted line). Notably, as previously reported by Vicente et al. [20] for WT 
CBS (Figure 4C, dashed line) and consistent with the effect of AdoMet on 
the spectrum of reduced p.P49L CBS (Figure 3B), pre-incubation of the 
protein variant with AdoMet further enhances the CO affinity (Figure 4C, 
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hollow squares). CO titrations allowed to estimate the following Kd values: 
KdCO,1 = 0.06 ± 0.03 μM  and KdCO,2 = 21 ± 5 μM (with 60%, and 40% 
relative amplitude, respectively) for AdoMet-free p.P49L CBS, and KdCO,1 ≤ 
0.03 μM and KdCO,2 = 1.5 ± 0.6 μM (with 70%, and 30% relative amplitude, 
respectively) for the AdoMet-bound enzyme. It should be noted that the CO 
affinity of the AdoMet-bound p.P49L variant is so high that the KdCO,1 value 
actually represents an upper limit. A possible direct interference of CO with 
AdoMet was ruled out by performing a control experiment where an AdoMet 
solution was equilibrated with CO gas (or N2 as control), yielding no spectral 
changes (not shown). 
 
Kinetics of CO binding and dissociation from p.P49L CBS 
The markedly higher CO affinity of p.P49L CBS as compared to the 
WT enzyme led us to investigate by time-resolved absorption spectroscopy 
the kinetics of CO binding to and dissociation from ferrous p.P49L CBS 
(Figure 5). Upon stopped-flow mixing reduced CBS p.P49L with 1 mM CO, 
the observed spectral changes were identical in shape to those shown for the 
CO titrations in Figure 4, i.e., the predominant 449-nm Soret band and the 
424-nm spectral feature both shifted to 422 nm, with similar optical 
transitions for the AdoMet-free and -bound CBS p.P49L (inset to Figure 5A). 
Global fit analysis of the kinetic data revealed that both AdoMet-free and -
bound p.P49L react with CO according to multiphasic time courses (Fig. 5A), 
as previously shown for WT CBS [19,20,51,67]. Interestingly, despite the 
markedly increased CO affinity of p.P49L with respect to the WT protein, 
under identical experimental conditions CO binding to the either of the two 
proteins in the absence of AdoMet proceeds at comparable rates (t1/2 = 26.2 ± 
9.6 s for CBS p.P49L, Figure 5A, to be compared with t1/2 = 34.5 ± 10.5 s of 
WT, not shown). In the presence of AdoMet, where the spectral changes 
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(Figure 3) and the enhanced CO affinity (Figure 4) of CBS p.P49L point to 
significant effects on the heme properties, a marked increase in CO 
association rates is observed, with the t1/2 decreasing to 5.4 ± 3.1 s (Figure 
5A), to be compared with t1/2 = 17.0 ± 2.7 s for WT CBS (not shown). 
The kinetics of CO dissociation from CBS p.P49L was evaluated by 
anaerobically mixing in the stopped-flow apparatus the CO-bound ferrous 
protein with authentic NO• (900 µM after mixing) and monitoring the 
conversion of the 422-nm hexacoordinate CO-bound adduct spectrum into 
that of the pentacoordinate NO•-bound adduct with a broad absorption band 
centered at 395 nm (Inset to Figure 5B). Global fit analysis of the kinetic data 
revealed that under identical experimental conditions CO is displaced by NO• 
in CBS p.P49L at comparable rates (k1 = 2.0  ± 0.1 s
-1
 and k2 = 0.37  ± 0.05 s
-
1
, with 75%, and 25% relative amplitude, respectively) to the WT enzyme (k1 
= 2.0  ± 0.1 s
-1
 and k2 = 0.33  ± 0.03 s
-1
, with 75%, and 25% relative 
amplitude, respectively; data not shown), and showing no effect of AdoMet 
(Figure 5B). 
 
 
DISCUSSION 
Classical homocystinuria is an inborn error of metabolism associated 
with deficiency in cystathionine β-synthase (CBS), a key enzyme in the 
transsulfuration pathway of methionine metabolism. By catalyzing the 
conversion of homocysteine and serine into cystathionine, the enzyme 
prevents an excessive increase in homocysteine levels, a pathological 
condition associated with oxidative stress and clinical complications in the 
vascular, neurological and skeletal systems. CBS also has a relevant role in 
human physiology by being a major source of H2S, a key endogenous 
signaling molecule whose dysregulation is at the basis of several human 
132
Results and Discussion – Paper 2 
 
 
pathologies, from cardiovascular and neurodegenerative diseases to cancer. 
Thus far, despite decades of research on classical homocystinuria, a full 
understanding of the molecular events at the basis of the pathogenicity of 
several CBS mutations remains elusive, although protein misfolding, 
dysfunctional regulation by AdoMet and impaired enzymatic activity have 
been put forward for some mutations [15,28,33-39].   
This prompted us to investigate in the present study a reportedly mild 
pathogenic mutation associated with classical homocystinuria, a proline-to-
leucine substitution at residue 49 in human CBS [44-46]. The recombinant 
CBS p.P49L variant was expressed in E. coli, purified and characterized both 
structurally and functionally. In line with previous reports focused on the 
canonical cystathionine synthase activity, this variant displayed a H2S 
synthesizing activity remarkably sensitive to PLP supplementation along the 
purification procedure [36,37,39,40]. The functional rescue of p.P49L H2S 
synthesis by PLP is indicative of a decreased affinity of this variant for the 
cofactor, a frequently observed consequence of missense mutations 
potentially associated with protein misfolding. The functional recovery of 
p.P49L observed upon PLP supplementation during protein purification was 
however not fully matched in terms of activity stimulation by AdoMet, as the 
H2S-synthesizing activity of p.P49L showed poor responsiveness to AdoMet 
(Figure 1) as compared to its cystathionine synthase activity [36,37,39,40]. 
This is not surprising since for other CBS variants it has been shown that the 
extent of the stimulatory effect of AdoMet can differ between the canonical 
cystathionine synthase and the H2S-synthesizing activities [28].  
Further attempting to understand the molecular basis of pathogenicity 
of this mutation, the crystallographic structure of a truncated form of the CBS 
p.P49L variant (CBSΔ409-551 p.P49L) was obtained at 2.8 Å resolution and 
compared with that of the truncated WT enzyme (PDB 1JBQ) [65]. Within 
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the obtained resolutions, the structures display highly conserved features 
(Figure 2), particularly inspecting the PLP binding pocket with the cofactor 
covalently bound to K119, the heme ligands C52 and H65, α-helix 8 
(responsible for the heme-PLP communication), the R266 residue forming a 
salt-bridge with C52, and the flexible loop where the mutated P49 residue is 
located. Therefore, at first glance, the structural data do not seem to provide a 
clue for the pathogenicity of the mutation.  
The effect of the mutation on the spectroscopic and ligand-binding 
properties of the heme moiety was also investigated. The first hint for a 
perturbation in the CBS p.P49L heme microenvironment arose from 
inspection of the dithionite-reduced spectrum of this protein variant (Figure 
3). Indeed, in the spectrum of reduced CBS p.P49L, the dominating 449-nm 
band assigned to the hexacoordinate ferrous heme with C52 and H65 as axial 
ligands, shows a significant intensity decrease as compared to the WT 
enzyme, and the appearance of a band at 424 nm (Figure 3B). The latter 
spectral feature has been assigned to a ligand exchange process in CBS 
leading to formation of an enzymatic species (called C-424), in which the 
cysteine thiolate ligand is replaced by a neutral species [14,15], negatively 
impacting the enzymatic activity. In WT CBS, this ligand exchange process 
occurs very slowly (> 48 h at 37 °C, [14]) in the presence of excess reductant. 
Similarly to p.P49L, other CBS variants have been previously reported to 
display an increased propensity to form the C-424 species, particularly CBS 
variants with mutated residues in α-helix 8 [28]. Furthermore, as observed for 
the WT CBS (Figure 3A), incubating the p.P49L variant with AdoMet prior 
to reduction further enhances the conversion of the ‘normal’ 449-nm into the 
ligand-exchanged C-424 species in the reduced protein (Figure 3B). 
Interestingly, among the several CBS variants studied by Yadav and co-
workers [28], p.T257V shows the most similar spectra to CBS p.P49L and, 
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like this variant, it displays WT-like (and PLP-dependent) H2S-generating 
activity and impaired activation by AdoMet [28]. Altogether, the spectral 
data herein reported point to changes at the heme moiety of CBS p.P49L that 
were further explored by evaluating the CO binding properties of the protein 
variant. CBS has been shown to be inhibited in vitro by exogenous ligands 
like CO and NO• [16-20], with different lines of evidence pointing to a 
physiological relevance of this regulatory mechanism in vivo [21-27] (see 
below).  
By performing CO titrations under anaerobic conditions, we observed 
spectral changes (Figure 4) consistent with the formation of the 
hexacoordinate ferrous-CO adduct, with the C52 thiolate or the yet unknown 
‘X’ ligand of the C-424 species being replaced by CO, and the heme 
retaining the H65 endogenous ligand. Notably, the CO affinity, herein 
measured for the first time in a CBS variant, is markedly increased (≥50 fold) 
in CBS p.P49L with respect to the WT enzyme (Figure 4C, [16,20,51]). As 
previously described for WT CBS, the CO titrations followed a biphasic 
profile, which has been previously attributed to heterogeneity in the heme 
micro-environment [16] or anti-cooperativity between hemes within a CBS 
dimer [51]. The remarkably higher CO affinity of CBS p.P49L is essentially 
due to the extremely low KdCO,1 (0.06 ± 0.03 μM), close to the detection limit 
of the experimental setup. Notably, and as previously observed for the WT 
enzyme [20], incubation of CBS p.P49L with AdoMet induced a further 
increase in CO affinity (Figure 4C) and, therefore, only an upper limit value 
for KdCO,1 (≤ 0.03 μM) could be estimated. In the WT enzyme, the increased 
CO affinity observed in the presence of AdoMet is fully matched with an 
enhanced propensity for CO inhibition of the protein H2S producing activity 
[20]. Based on the remarkable increase in CO affinity herein documented for 
CBS p.P49L, this protein variant is expected to be more prone to inhibition at 
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low physiological CO levels. This may represent a more general mechanism 
of pathogenesis in classical homocystinuria, if other pathogenic CBS 
mutations will be demonstrated to lead to enhanced CO affinity, as shown for 
CBS p.P49L in the present study. 
Although direct evidence for ferrous CBS formation in vivo is still 
missing in the literature, several reports have attested the physiological role 
of CBS inhibition by CO (reviewed in [26,27]), which requires the heme to 
be in the ferrous state. Regarding regulation of cerebral microcirculation by 
hypoxia, decreased oxygen levels impair CO production by heme oxygenase 
HO-2 and the release of CBS inhibition by CO promotes H2S synthesis, that 
in turn mediates vasodilation of precapillary arterioles [23]. Stress-inducible 
levels of CO in mice liver cause metabolomic changes consistent with CBS 
inhibition, decrease in hepatic H2S and concomitant stimulation of HCO3
-
-
dependent bile output in wild-type, but not in heterozygous CBS knockout 
mice [22]. Another proposed mechanism concerns the CO-mediated 
regulation of glucose utilization, where CBS inhibition by CO drives the 
demethylation of phosphofructokinase/fructose bisphosphatase type-3 
(PFKFB3), diverting glucose from the glycolytic towards the NADPH-
generating pentose phosphate pathway, with implications in chemoresistance 
and oxidative stress resistance in cancer cells [24]. Moreover, Banerjee and 
co-workers [25] have recently shown that, under endoplasmic reticulum 
stress conditions, CBS inhibition by CO, combined with CSE induction, flips 
the CSE substrate preference from cystathionine to cysteine, transiently 
stimulating H2S production. These multiple lines of evidence provide 
compelling, though still indirect evidence for the formation of ferrous CBS in 
vivo. In line with these observations, an NADPH-dependent diflavin enzyme, 
methionine synthase reductase, has been shown to reduce the CBS heme in 
vitro in the presence of CO or nitrite, generating respectively the ferrous-CO 
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or ferrous-NO CBS adducts [18,67,68]. In light of this evidence, the high 
affinity of CBS p.P49L for CO is fully compatible with the formation of the 
ferrous-CO adduct at physiological CO concentrations.  
To gain mechanistic insight into this high CO affinity, we studied by 
stopped-flow absorption spectroscopy the kinetics of CO 
association/dissociation to/from the reduced heme of this protein variant 
(Figure 5). Similarly to the WT [19,20,51], CO binding to reduced CBS 
p.P49L followed a multiphasic timecourse (Figure 5A). Taking into account 
the markedly increased CO affinity of this protein variant, surprisingly the 
reaction proceeded only slightly faster (t1/2 = 26.2 ± 9.6 s) than for the WT 
enzyme (t1/2 = 34.5 ± 10.5) under identical experimental conditions. Despite 
this minor difference, in the presence of AdoMet the fold increase in the CO 
association rate was overall higher in the p.P49L variant (~4.5 fold) than in 
the WT enzyme (~2 fold) under identical experimental conditions. 
Furthermore, by analyzing the kinetics of CO replacement by NO• in this 
protein variant, we observed essentially identical kinetic traces for the 
AdoMet-free and -bound CBS p.P49L (Figure 5B) and for the WT enzyme 
under the same experimental conditions (not shown).  
The kinetics of CO association and dissociation therefore do not 
provide a clear cut explanation for the markedly higher CO affinity of CBS 
p.P49L, which requires further inspection. In Scheme 1 are represented the 
reaction steps for conversion of the hexacoordinate ferrous CBS, with the 
heme Fe ligated to H65 and either C52 or the unknown ‘X’ ligand in the C-
424 species, into the ferrous-CO adduct. It has been previously postulated for 
the WT enzyme that CO association to the ferrous CBS heme is rate-limited 
by dissociation of C52 [19,20,51]. Since we observed similar CO association 
kinetics for WT and p.P49L, where a fraction of the mutant enzyme is likely 
to be in the ligand-exchanged C-424 state, the CO association appears to be 
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limited by the off-rate of the endogenous ligand regardless of its nature, C52 
or ‘X’ (koff,Cys/X (p.P49L) ≈ koff,Cys/X (WT) in Scheme 1). Taking into account that 
the kinetics of CO dissociation were almost identical for WT and p.P49L 
CBS, regardless of AdoMet being present (koff,CO (p.P49L) ≈ koff,CO (WT) in 
Scheme 1), the dramatic increase in CO affinity of the p.P49L variant 
compared to the WT should be related to a slower rebinding of the 
endogenous ligand, C52 or ‘X’ (kon,Cys/X (p.P49L) << kon,Cys/X (WT) in Scheme 1), 
and/or a faster combination of CO with the transiently generated 
pentacoordinate species (konCO (p.P49L) >> kon,CO (WT) in Scheme 1).  
Regardless of these mechanistic details, the perturbed spectrum of the 
reduced protein and its remarkably higher affinity for CO point to possibly 
subtle structural changes in the CBS p.P49L variant affecting heme 
reactivity. To this end, we further compared the structures of the variant and 
WT enzymes in terms of local flexibility evaluated based on the B factor 
(Figure 6). This analysis interestingly reveals that the differences in 
flexibility are mostly located in specific regions of the protein. The α-helix 8, 
where some mutations have shown to affect the heme spectral properties and 
the H2S-generating activity similarly to p.P49L, displays comparable rigidity 
between CBS p.P49L and the WT enzyme. We thus looked in greater detail 
at the heme binding region (Figure 6) and found in CBS p.P49L an increased 
flexibility of the loop surrounding the C52 ligand, which expands to the 
regions between the C52 and the H65 ligands and even after the latter 
residue. The p.P49L structure therefore displays a higher flexibility in the 
region harboring both heme ligands, which provides a possible structural 
basis for the proposed slower rebinding of the endogenous C52/X ligands 
upon CO dissociation, thereby accounting for the increased affinity of CBS 
p.P49L for CO.  
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CONCLUSIONS  
Cystathionine β-synthase (CBS) is a key enzyme in the 
transsulfuration pathway that prevents oxidative stress conditions, both 
controlling homocysteine levels and promoting the expression of antioxidant 
enzymes through the synthesis of H2S. Being implicated in metabolic, 
oncologic and neurodegenerative diseases, CBS is currently recognized as a 
promising drug target. Mutations in the CBS gene can lead to classical 
homocystinuria, a human disease associated with oxidative stress that affects 
the vascular, neurological and skeletal systems. Protein misfolding, enhanced 
propensity to aggregation, decreased cofactor affinity and dysfunctional 
regulation by the allosteric activator AdoMet, together with impaired 
enzymatic activity, have been proposed to account for the pathogenicity of 
several CBS mutations. As a novel finding, herein we reported that a 
clinically relevant variant of CBS (p.P49L) has markedly increased affinity 
for CO, a known inhibitor of CBS. On this basis, this variant is expected be 
much more prone than WT CBS to be inactivated by CO at the physiological 
levels occurring in vivo, thereby contributing to pathogenicity. The enhanced 
affinity for inhibitory gaseous ligands documented here may represent a new 
pathogenic mechanism at the basis of CBS-related diseases, like classical 
homocystinuria. 
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FIGURES AND LEGENDS 
 
Figure 1 
 
 
 
Figure 1. Hydrogen sulfide production by WT and p.P49L CBS. H2S 
producing activity of CBS purified in the absence (PLP-‘untreated’) or 
presence (PLP-‘treated’) of PLP (20 μM). T = 37 °C. Buffer: 50 mM KPi, 
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300 mM KCl, 10% glycerol, 100 μM EDTA, pH 7.0. Reaction mixture 
contained 50 μM PLP, 0.4-2.0 mM homocysteine, 260 U/ml catalase and 10 
mM cysteine. Assays were carried out in the absence (-) or presence (+) of 
500 μM AdoMet.  
 
Supplementary Figure 1.  
 
 
 
Supplementary Figure 1. SDS-PAGE analysis of CBS preparations. 
Analysis of CBS samples employed in this study, corresponding to full-
length CBS WT and p.P49L purified in the absence (‘untreated’) or presence 
(‘treated’) of PLP (20 µM). Truncated WT and p.P49L CBS lacking the C-
terminal AdoMet-binding domain were analyzed for comparison with the 
full-length protein. Denatured protein samples were loaded onto a pre-cast 
NuPAGE TM 10% Bis-Tris gel (Invitrogen) and ran at 200 V. Protein bands 
were stained with InstantBlue TM (Expedeon) according to the 
manufacturer’s instructions. Protein marker: NZYColour Protein Marker II 
(Nzytech). 
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Figure 2 
 
Figure 2. Structure of CBS p.P49L. X-ray crystallographic structure of 
CBSΔ409-551 p.P49L solved at 2.80 Å resolution (PDB entry 5MMS). Panel A, 
cartoon representation of the protein dimer, each monomer being represented 
in a different color. Pyridoxal 5’-phosphate (PLP) and heme moieties shown 
in stick representation. Panel B, structure superposition of CBSΔ409-551 
p.P49L (PDB entry 5MMS) and truncated WT CBS (PDB entry 1JBQ), both 
colored in grey except for most relevant regions and residues, where 
CBSΔ409-551 p.P49L is colored in red and CBSΔ409-551 WT in blue; zoom in on 
the PLP and heme moieties, highlighting the proline to leucine substitution, 
as well as the R266 residue and α-helix 8 proposed to mediate 
communication between the heme and the PLP active site. Figure generated 
with Pymol 1.8.2 (The PyMOL Molecular Graphics System, Version 1.8 
Schrödinger, LLC).  
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Figure 3 
 
Figure 3. Absorption spectra of WT and p.P49L CBS. Absorption spectra 
of WT (Panel A) and p.P49L (Panel B) CBS (1.4-1.6 µM in heme) recorded 
at 20 °C, in degassed buffer A (50 mM KPi, 300 mM KCl, 10% glycerol, 100 
μM EDTA, pH 7.0), containing glucose oxidase (4 units·ml-1), catalase (13 
μg·ml-1), superoxide dismutase (SOD, 12 units·ml-1) and glucose (3 mM). 
Spectra were collected in the oxidized state (dashed lines) and upon protein 
reduction (solid lines) by addition of 90 μM sodium dithionite, in the absence 
(blue lines) and presence (red lines) of AdoMet (500 μM). Arrows highlight 
direction of the spectral changes caused by AdoMet in the reduced proteins.   
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Figure 4 
 
Figure 4. Enhanced CO affinity of p.P49L CBS. Absorption spectra 
collected upon anaerobic titration of reduced CBS p.P49L (1.4-1.6 μM in 
heme) with CO, in the absence (Panel A) or presence (Panel B) of AdoMet. T 
= 20 °C. Panel C, titration profiles obtained by global fit of the spectral data 
acquired in the absence (full circles) or presence (hollow squares) of 500 μM 
AdoMet. Data were best fitted according to Equation 1, yielding: KdCO,1 = 
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0.05 μM (60%) and KdCO,2 = 22.0 μM (40%) for AdoMet-free CBS p.P49L 
and KdCO,1 ≤ 0.03 μM (70%) and KdCO,2 = 2.1 (30%) for the AdoMet-bound 
enzyme. Gray lines represent titration curves for WT CBS in the absence 
(dotted line) and presence (dashed line) of 500 μM AdoMet. 
 
Figure 5 
 
Figure 5. Kinetics of CO binding to ferrous CBS p.P49L. Panel A, 
Reaction time courses measured in the absence (dotted line) or presence of 
AdoMet (500 μM before mixing; solid line). Spectral data collected over 
1000 s after stopped-flow mixing 1 mM CO with reduced CBS p.P49L (1.5 
μM in heme) at 25 °C, in 50 mM potassium phosphate, 300 mM KCl, 10% 
glycerol, pH 7.0, containing 2 mM glucose, 4 units·ml
-1
 glucose oxidase, 13 
μg·ml-1 catalase and 6 units·ml-1 SOD. Fitted rate constants (% reaction 
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amplitude): k1 = 0.48 s
-1
 (25%), k2 = 0.05 s
-1
 (30%) and k3 =  0.006 s
-1
 (45%) 
for AdoMet-free CBS p.P49L (t1/2 = 19.5 s) and k1 = 2.55 s
-1
 (35%), k2 = 0.26 
s
-1
 (30%) and k3 =  0.022 s
-1
 (35%) for the AdoMet-bound enzyme (t1/2 = 2.3 
s). Inset, optical transitions obtained by global fit analysis of the spectral data 
acquired in the absence (dotted line) or presence of AdoMet (solid line). 
Panel B, time courses of CO displacement from ferrous CBS p.P49L by 900 
μM NO•, acquired in the absence (dotted line) or presence of AdoMet (solid 
line; 500 μM before mixing). Traces were best fitted with the following rate 
constants (% reaction amplitude): k1 = 1.93 s
-1
 (75%) and k2 = 0.035 s
-1
 
(25%) for AdoMet-free CBS p.P49L; k1 = 1.96 s
-1
 (75%) and k2 = 0.038 s
-1
 
(25%) for the AdoMet-bound enzyme. Inset, optical transitions obtained by 
global fit analysis of the spectral data acquired in the absence (dotted line) or 
presence of AdoMet (solid line). 
 
Figure 6 
 
Figure 6. Increased flexibility of heme binding loop in p.P49L CBS. 
Representation of B factor variation along the structure of CBS p.P49L (PDB 
entry 5MMS) and WT (PDB entry 1JBQ) monomer, displaying in first plane 
the regions encompassing the proline to leucine mutation (sticks) and the 
heme ligands C52 and H65. Flexibility can be visualized both by the 
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thickness of the structural element and the respective color: highest flexibility 
represented in red (hot) thick elements; lowest flexibility in thin blue (cold) 
elements (color scale: red>orange>yellow>green>blue). Figure generated 
with Pymol 1.8.2 (The PyMOL Molecular Graphics System, Version 1.8 
Schrödinger, LLC). 
 
Scheme 1 
 
 
Table 1. Data reduction and refinement statistics of CBS p.P49L structure 
 
 p.P49L CBS variant 
PDB entry 5MMS 
Data collection 
Synchrotron ESRF (Grenoble – France) 
Beamline ID30A-3 
Wavelength (Ǻ) 0.968 
Space group P1 
Unit cell  
   a, b, c (Ǻ) 86.2, 86.8, 97.8 
   α, β, γ (o) 102.7, 103.1, 111.2 
Resolution range
a
 (Ǻ) 76.35 - 2.80 (2.90 - 2.80) 
Total no. of reflections 121227 (1141) 
No. of unique reflections 58862 (571) 
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Completeness (%) 98.5 (95.6) 
Multiplicity 2.1 (2.0) 
<I/σ(I)> 4.8 (1.5) 
Rmeas
b
 (%) 17.4 (68.7) 
Rpim
c
 (%) 11.2 (45.1) 
CC1/2
d
 (%) 97.6 (62.1) 
Wilson B-factor (Ǻ2) 41.8 
Refinement 
Rcryst
e
 (%) 18.2 (27.2) 
Rfree
f
 (%) 22.1 (33.1) 
No. of non-H atoms 16452 
   Protein 15916 
   Ligands 351 
   Waters 185 
r.m.s.d bonds (Ǻ) 0.010 
r.m.s.d. angles (
o
) 1.12 
Protein residues 2077 
Ramachandran plot  
   Most favoured (%) 96.6 
   Allowed (%) 3.2 
   Outliers (%) 0.3 
Rotamer outliers (%) 0.3 
Clashscore 0.46 
MolProbity Scoreg 0.88 
B-factors (Ǻ2) 45.4 
   Protein 41.3 
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   Ligands 29.7 
 
a
  Information in parenthesis refers to the last resolution shell. 
b
  Rmeas = Σh (nh/nh − 1)
1/2
 Σi|<Ih> − Ih,i|/Σh Σi Ih,I, where nh denotes multiplicity 
c
  Rpim = Σh [1/(/nh − 1)]
1/2
 Σi|<Ih> − Ih,i|/Σh Σi Ih,i 
d
  CC1/2 is as described previously [69] 
e
 Rcryst=∑hkl||Fobs(hkl)|−|Fcalc(hkl)||/∑hkl|Fobs(hkl)|, where Fobs(hkl)|−|Fcalc(hkl) are the observed and 
calculated structure factors for reflection (hkl), respectively. 
f
  Rfree was calculated as Rcryst but using only 5% of reflections randomly selected and omitted 
from refinement. 
g 
MolProbity score provides a single number that represents the central MolProbity protein 
quality statistics; it is a log-weighted combination of Clashscore, Ramachandran not favored 
and bad side-chain rotamers, giving one number that reflects the crystallographic resolution 
at which those values would be expected. 
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ABSTRACT 
Hydrogen sulfide (H2S) has emerged as a key molecule in human 
(patho)physiology, able to play crucial regulatory functions at physiological 
low concentrations or exert toxicity at higher levels. H2S is synthesized 
through known enzymatic pathways and mainly metabolized by a 
mitochondrial sulfide-oxidizing pathway, comprising sulfide:quinone 
oxidoreductase (SQR) and a few other enzymes. Under hypoxic conditions, 
H2S has expectedly higher stability and was reported to be synthesized at 
higher level with protective effects for the cell. Here, working on SW480 
colon cancer cells, we evaluated the effect of hypoxia on the ability of cells to 
dispose H2S at the mitochondrial level. The mitochondrial sulfide-oxidizing 
activity was assessed by quantitatively evaluating by high-resolution 
respirometry the stimulatory effect of sulfide on rotenone-inhibited cell 
respiration in the presence or absence of antimycin A. We report that, as 
compared to cells grown under normoxic conditions (air O2), cells exposed 
for 24 h to hypoxia (1% O2) display a significant reduction in their basal 
respiration (~65%) and maximal mitochondrial sulfide-oxidizing activity 
(~25%), consistent with the reduced mitochondrial content (~55%) assessed 
by citrate synthase activity assays. This notwithstanding, hypoxia-treated 
cells display a slightly (~40%) higher expression of SQR, as evaluated by 
immunoblotting. Based on these observations, we posit that the lower sulfide-
detoxifying ability induced by hypoxia may contribute to ensure higher 
protective H2S levels, but also increase the risk of sulfide toxicity. 
 
INTRODUCTION 
Hydrogen sulfide (H2S), along with nitric oxide (NO) and carbon 
monoxide (CO), belongs to a small group of gaseous signalling molecules 
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known as ‘gasotransmitters’. H2S is involved in many important 
physiological and patho-physiological processes (Paul, 2015; Kimura, 2015; 
Olson, 2015). While playing key regulatory functions at low (nM) 
concentrations, at higher (μM) levels it exerts toxic effects via inhibition of 
complex IV (cytochrome c oxidase, CcOX) in the mitochondrial electron 
transport chain (Cooper & Brown, 2008) and derivatization of haemoglobin 
to a form named ‘sulhemoglobin’ with a covalent modification of the heme 
porphyrin ring, resulting in reduced O2 affinity (reviewed in Pietri, 2011). It 
is therefore crucial that cells actively keep H2S at low physiological levels to 
prevent toxicity.  
In humans, several enzymes implicated in H2S metabolism are 
currently known (reviewed in Kabil, 2014 and Szabo 2014). At least three are 
directly involved in H2S synthesis: the two pyridoxal 5’-phosphate (PLP)-
dependent enzymes cystathionine β-synthase (CBS) and cystathionine γ-lyase 
(CSE), belonging to the transulfuration pathway, and the mitochondrial 
enzyme 3-mercaptopyruvate sulfurtransferase (MST) (Kabil, 2014; Singh 
2011,). H2S breakdown is afforded by a mitochondrial enzymatic pathway 
that couples the oxidation of H2S (to sulfate, SO4
2-
, and thiosulfate, S2O3
2-
) to 
ATP synthesis (Hildebrandt & Grieshaber 2008). The first step of sulfide 
breakdown is catalyzed by the membrane-associated enzyme sulfide:quinone 
oxidoreductase (SQR). This flavoprotein couples the oxidation of H2S to the 
reduction of coenzyme Q, thus injecting sulfide-derived electrons to the 
mitochondrial electron transfer chain, making H2S the first inorganic 
substrate to sustain mitochondrial respiration (Goubern, 2007). 
Concomitantly, SQR transfers the H2S sulfur atom to a sulfur acceptor, 
leading to formation of glutathione persulfide (GSSH) (Mishanina 2015, 
Landry 2017) or, less likely, S2O3
2-
 (Jackson, 2012). Three additional 
enzymes, persulfide dioxygenase (ETHE1), thiosulfate sulfur transferase 
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(TST) and sulfite oxidase (SOX), cooperate with SQR in the mitochondrial 
sulfide oxidation pathway, leading to formation of SO4
2-
 and S2O3
2-
. To 
oxidize 1 H2S molecule, the mitochondrial sulfide-oxidizing pathway overall 
consumes ~0.75 O2 molecules (0.25 by CcOX plus 0.5 by ETHE1, (Lagoutte 
2010). 
In vivo, H2S can therefore exert a dual effect on cell bioenergetics, at 
lower concentrations stimulating via SQR mitochondrial respiration and thus 
ATP synthesis (Goubern, 2007), or causing a reversible inhibition of CcOX 
at higher concentrations (Cooper & Brown 2008). Notably, the sulfide 
oxidizing activity varies between different cell types and tissues, spanning 
from undetectable, as e.g., in neuroblastoma cells, to high, as observed in 
colonocytes (Goubern, 2007; Lagoutte, 2010; Mimoun, 2012). This is 
perhaps not surprising because colonocytes are physiologically exposed to 
the fairly high levels of H2S produced by the gut microbiota and, particularly, 
by sulfate-reducing bacteria (reviewed in Blachier, 2010).  
 Several diseases, including cancer (Hellmich & Szabo 2015 and 
Hellmich, 2015), were found to be associated with alterations of H2S 
metabolism. In particular, CBS has been shown to be overexpressed in 
colorectal cancer (CRC) (Szabo, 2013) and other cancer types (Panza, 2014; 
Zhang, 2005; Bhattacharyya, 2013). In CRC cell lines, CBS-derived H2S was 
demonstrated to promote cell proliferation and angiogenesis, and to sustain 
cellular bioenergetics by stimulating both oxidative phosphorylation and 
glycolytic ATP synthesis. The enzyme is therefore currently recognized as a 
drug target (Druzhyna, 2016; Chao, 2016, Hellmich, 2015).  
Hypoxia is a common factor in the microenvironment of solid 
tumours that has been recognized to be associated to drug-resistance 
(reviewed in Muz 2015) and malignance phenotype. The effect hypoxia has 
on cellular metabolism has been extensively investigated (reviewed in 
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Masson & Ratcliffe 2014). Among other changes, hypoxic cells undergo a 
reduction in mitochondrial mass, resulting from reduced biogenesis of this 
organelle and enhanced mitophagy (Zhang, 2008; Wu, 2015) and reviewed in 
(Solaini, 2010). Because mitochondria are the main site of sulfide oxidation, 
in the absence of compensatory mechanisms, a reduced ability to detoxify 
sulfide is expected for hypoxic cells. The intricate interplay between H2S and 
O2 has been extensively investigated (reviewed in Olson, 2015). In particular, 
as O2 facilitates both the chemical and enzymatic oxidative decomposition of 
H2S into persulfides and polysulfides, at low O2 tension a higher stability of 
H2S is expected. Furthermore, hypoxic/ischemic conditions have been 
reported to enhance H2S synthesis, primarily through up-regulation of the 
sulfide-synthesizing enzymes (Takano, 2014; Kolluru, 2015). Moreover, 
under hypoxia the H2S-generating enzymes CBS and CSE were shown to 
accumulate in the mitochondria, likely enhancing the H2S mitochondrial 
levels (Teng, 2013; Fu, 2012). Hypoxia is thus expected to increase H2S 
bioavailability, a condition that can have opposite physiological 
consequences. Indeed, while H2S has been shown to be protective against 
ischemia injuries (Kolluru, 2015; Morikawa, 2012; Takano, 2014, Hine, 
2016) the enhanced biosynthesis and chemical stability of H2S, combined 
with the reduced content in mitochondria (the main sites of sulfide disposal), 
may increase the risk of H2S toxicity in hypoxic cells.  
This information prompted us to investigate in the present study the 
effect of hypoxia/reoxygenation on the mitochondrial sulfide-oxidizing 
activity in colorectal cancer cells. Here, we provide evidence that, after 
exposure to hypoxia, these model cells show reduced mitochondrial sulfide-
oxidizing activity consistent with their lower content in mitochondria.  
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MATERIALS AND METHODS 
Materials 
The human colon cancer cell line SW480 was purchased from the American 
type Culture Collection (ATCC no. CCL228™). Sodium sulfide nonahydrate 
(Na2S·9H2O, 431648), 5,5’-dithiobis-(2-nitrobenzoic acid) (DTNB), acetyl 
coenzyme A, oxaloacetate, CelLytic
TM
MT cell lysis reagent, protease 
inhibitor cocktail (P8340), anti-SQR antibody (HPA017079) and the 
bicinchoninic acid assay (BCA) kit were purchased from Sigma. Cell culture 
media and antibiotics were from Sigma, Euroclone or Gibco. Mini-
PROTEAN TGX Stain-Free Precast Gels, the Clarity Western ECL substrate 
and the Laemmli protein sample buffer were purchased from Bio-Rad. 
Bovine serum albumin was from AppliChem. 
 
Preparation of sulfide stock solutions  
Stock solutions of Na2S were prepared by quickly washing with degassed 
Milli-Q water the surface of a Na2S crystal, and then dissolving it in degassed 
Milli-Q water under a N2 atmosphere. The concentration of Na2S in solution 
was measured spectrophotometrically using 5,5’-dithiobis-(2-nitrobenzoic 
acid) (DTNB) according to (Nashef, 1977) in a Cary 60 UV-VIS 
spectrophotometer. The concentration of Na2S was then adjusted to 3-5 mM 
by dilution with degassed Milli-Q water in a gas-tight glass syringe.  
 
Cell culture 
The human colon cancer cell line SW480 was maintained in Dulbecco's 
Modified Eagle Medium (DMEM) containing 4.5 g·L
-1
 glucose, 
supplemented with 2 mM L-glutamine, 10% (v/v) heat-inactivated fetal 
bovine serum (FBS), 100 U·mL
-1
 penicillin and 100 µg·mL
-1
 streptomycin. 
Cells at 37 °C and 5% CO2 in 25 cm
2
 or 75 cm
2
 flasks were grown under 
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normoxic conditions (air O2) or incubated for 24 h under hypoxic conditions 
(1% O2) in a Galaxy 14 S incubator (Eppendorf). After trypsinization, the 
cells were washed in the culture medium, counted using the trypan blue dye 
exclusion test, centrifuged at 1.000 X g for 5 min and resuspended in fresh 
medium at a final density of 8 x 10
6
 cells·mL
-1
. Trypan blue-positive cells 
were always less than 5%. Henceforth, cells grown under normoxic 
conditions or exposed to hypoxia will be respectively referred to as 
‘normoxic’ and ‘hypoxia-treated’ cells. 
 
Measurements of the mitochondrial sulfide-oxidizing activity 
The mitochondrial sulfide-oxidizing activity of tested cells was evaluated as 
described in [(Abou-Hamdan et al., 2015)], by measuring the stimulatory 
effect of sulfide on cellular O2 consumption. Measurements were carried out 
at 37 °C, using a highresolution respirometer (Oxygraph-2k, Oroboros 
Instruments, Innsbruck, Austria), equipped with two 1.5-mL chambers and a 
micropump (TIP-2k) for sulfide injection. According to [Abou-Hamdan 
2015], in these assays sulfide was injected into a cell suspension at increasing 
flux (determined by the pump rate) and sulfide-mediated stimulation of 
cellular O2 consumption was measured until the concentration of injected 
sulfide became inhibitory for CcOX. To prevent reverse electron transfer 
through Complex I in SW480 cells [Lagoutte 2010], measurements were 
carried out in the presence of 10 µM rotenone. The assays were typically 
conducted in FBS-supplemented cell medium under stirring as it follows. 
After addition of cells (4.0 x 10
6
), basal respiration was measured for ~10 
min. Afterwards, following the addition of rotenone resulting in O2 
consumption inhibition, a solution of 3 - 5 mM sulfide was injected for time 
intervals (180 s) at increasing rates (10 nL·s
-1
, 20 nL·s
-1
, 40 nL·s
-1
, 80 nL·s
-1
 
and 160 nL·s
-1
) and the effect on O2 consumption was measured. Some 
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control experiments were carried out not only in the presence of rotenone, but 
also of antimycin A (5 µM), an inhibitor of quinol:cytochrome c reductase 
(Complex III). The latter assays allowed us to evaluate the effect of sulfide 
on extra-mitochondrial and non-enzymatic O2 consumption and thus obtain 
by subtraction (from the experiments performed in the absence of antimycin 
A) the genuine mitochondrial sulfide-oxidizing activity.   
 
Citrate synthase assay 
Cells were harvested and lysed using the CelLytic
TM
MT cell lysis reagent 
and protease inhibitor cocktail from Sigma according to the manufacturer 
instructions. Cell extracts were assayed spectrophotometrically for citrate 
synthase in 100 mM Tris-HCl, 0.3 mM acetyl-CoA, 0.1 mM DTNB and 0.1 
mM oxaloacetate, as described in (Srere, 1969). 
 
Immunoblotting assays 
Cells were harvested, lysed as described in the previous section and, after 
total protein content determination by BCA assay, proteins (20 µg per lane) 
were separated by SDS-PAGE using Mini-PROTEAN TGX Stain-Free 
Precast Gels (from Bio-Rad). The formulation of these gels includes trihalo 
compounds which lead to UV fluorescence emission on reaction with 
proteins (Rivero-Gutiérrez, 2014; Short & Posch, 2011), allowing to estimate 
and normalize the total loaded protein, using a ChemiDoc MP imaging 
system (Bio-Rad) without resorting to any staining procedure. The proteins 
were transferred onto polyvinylidene difluoride (PVDF) membranes using a 
Trans-Blot SD Semi-Dry Electrophoretic Transfer Cell (from Bio-Rad) at 
10V, 180 mA for 30 min. The membranes were blocked with PBS-T 
(phosphate buffered saline with 0.1% Tween 20 [v/v]) containing 3% bovine 
serum albumin (BSA, w/v) and then incubated overnight at 4 °C with rabbit 
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polyclonal antibody against human SQR (1:150, in PBS-T with 3% BSA 
(w/v)). After three washing steps of the membrane with PBS-T (15 min), the 
membranes were incubated with horseradish peroxidase-conjugated 
secondary antibody (1:5000, in PBS-T with 3% BSA [w/v]), followed by 
three washing steps with PBS-T (15 min) and detection by enhanced 
chemiluminescence (Clarity Western ECL Substrate, Biorad). Finally, the 
blotted membranes were subjected to densitometric analysis using Image Lab 
software (Biorad), followed by normalization of the target protein band 
intensity to total protein. 
 
Data analysis 
Oxygen consumption rates were calculated using the software DatLab4 
(Oroboros Instruments, Austria). Data are reported as mean ± standard error 
of the mean (SEM). Statistical significance (P) was estimated using the 
Student’s t-test in Microsoft Excel. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 and 
****P ≤ 0.0001 were considered significant.  
 
 
 
RESULTS 
Colorectal cancer cells (SW480) were either grown under normoxic 
(air O2) conditions or exposed for 24 h to hypoxia (1% O2), and their sulfide-
oxidizing activity was assayed by high resolution respirometry according to 
(Abou-Hamdan 2015) as described in the Material and Methods section. A 
representative oxygraphic trace acquired with untreated (‘normoxic’) cells is 
shown in Fig.1A. The trace clearly shows that most (~80%) of cell 
respiration was blocked by addition of the Complex I inhibitor rotenone, 
added to prevent reversal of Complex I activity upon sulfide injection, as 
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described in (Lagoutte, 2010; Helmy, 2014). Following respiration inhibition 
by rotenone, sulfide was injected into the oxygraphic chamber via a 
micropump following the protocol described in (Abou-Hamdan, 2015). 
Overall, five injections of 3 minutes were carried out at increasing injection 
rates (increasing by a factor of 2 from 10 nL·s
-1
 to 160·nL s
-1
). The first four 
injections led to stimulation of O2 consumption, pointing to a fully operative 
mitochondrial sulfide-oxidizing pathway in the tested cells. The stimulation 
persisted for the entire duration (3 minutes) of sulfide injection, after which 
the O2 consumption rate declined back to the value measured in the absence 
of sulfide. The decline took a few minutes, as if some sulfide persisted in 
solution enhancing cell respiration even after the injection was stopped. In 
line with (Abou-Hamdan, 2015), the extent of O2 consumption stimulation by 
sulfide increased with the rate of sulfide injection (up to 80 nL s
-1
, Fig.1A). 
However, by further increasing the injection rate (to 160 nL s
-1
) a decline in 
the O2 consumption rate was observed during sulfide injection, likely due to 
CcOX inhibition by sulfide, as previously suggested (Abou-Hamdan, 2015).  
For comparison, the experiments described above were carried out on 
the same cells after 24 h-exposure to hypoxic conditions. As shown in 
Fig.1B, the hypoxia-treated cells displayed a lower basal respiratory activity 
compared to untreated cells (25.1 ± 2.0 nM O2 s
-1 
vs 68.3 ± 4.5 nM O2 s
-1
). 
Yet, similarly to normoxic cells, after rotenone addition a progressive 
stimulation of cell respiration was observed by injecting sulfide at increasing 
rate, until the amount of injected sulfide exceeded the detoxifying activity of 
the cells, and CcOX inhibition occurred, impairing cell respiration (see last 
sulfide injection in Fig.1B). By comparing normoxic and hypoxia-treated 
cells, it can be appreciated that in the latter cells, at any sulfide injection rate, 
stimulation of O2 consumption by sulfide was lower than in normoxic cells, 
possibly in line with their lower basal respiration (Fig.1C). Consistently, at 
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the highest non-inhibitory sulfide injection rate, in hypoxia-treated cells 
sulfide sustained an O2 consumption approximately 30% lower than observed 
in untreated cells even (see sulfide injection #4 in Fig.1C).  
In order to evaluate the contribution of mitochondria to the observed 
sulfide-oxidizing activity, we used antimycin A. This well-known inhibitor of 
Complex III indeed blocks quinol oxidation in the respiratory chain and thus 
prevents sulfide oxidation by mitochondria (Abou-Hamdan, 2015). As shown 
in Fig.2, in the presence of rotenone, antimycin A largely prevented O2 
consumption stimulation by sulfide in both normoxic and hypoxia-treated 
cells, proving that under the tested conditions sulfide oxidation occurs mostly 
at the mitochondrial level. The effect of sulfide on the mitochondrial (not the 
total) O2 consumption was quantitatively evaluated by subtracting the O2 
consumption rates measured during sulfide injection in the presence of both 
rotenone and antimycin A (Fig.2C) from those measured at identical sulfide 
injection rates in the presence of rotenone only (Fig.1C). According to this 
analysis, in line with the lower basal respiratory activity of hypoxia-treated 
cells, stimulation of mitochondrial O2 consumption by sulfide was lower in 
hypoxia-treated than in untreated cells: at the highest non-inhibitory (for 
CcOX) injection rate, after subtracting the O2 consumption rate measured in 
the presence of rotenone only, sulfide sustained a mitochondrial O2 
consumption of 38.6 ± 3.5  nM O2 s
-1
 and 29.2 ± 3.0  nM O2 s
-1
, in normoxic 
and hypoxia-treated cells, respectively. Taking into account that 
measurements were carried out with 4 million cells and that the 
mitochondrial sulfide-oxidizing pathway overall consumes ~ 1.33 molecules 
of H2S per O2 molecule (Lagoutte, 2010), a mitochondrial sulfide-oxidizing 
activity of 12.8 ± 1.5 and 9.7± 1.1 nM H2S s
-1 
per million cells can be 
calculated for normoxic and hypoxia-treated cells, respectively (Fig.3A). In 
an attempt to evaluate the effect of hypoxia on the cell mitochondrial content, 
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we carried out citrate synthase activity assays, commonly used as a marker of 
mitochondrial mass (Pereira, 2011). Interestingly, based on these assays, 
hypoxia-treated cells were found to display an ~ 1.8-fold lower citrate 
synthase activity, indicating a lower mitochondrial content compared to 
normoxic cells (Fig.3B). The reduced mitochondrial mass observed in 
hypoxia-treated cells is in agreement with the literature (Solaini, 2010) and 
likely accounts for the lower basal respiratory activity shown by these cells 
compared to normoxic cells (Fig.1C). The measured citrate synthase activity 
was used to normalize the calculated mitochondrial sulfide-oxidizing activity. 
After normalization, this activity proved to be in hypoxia-treated cells ~ 1.4-
fold higher than in normoxic cells (Fig.3C). Finally, we have assayed in cell 
extracts the SQR expression levels by immunoblotting combined with ‘stain-
free’ imaging technology for total protein quantitation (Rivero-Gutiérrez, 
2014; Short & Posch, 2011). We resorted to this technology because proteins 
commonly used as housekeepers, such as GAPDH and β-actin, are known to 
change their expression levels under hypoxia (Heerlein, 2005; Zhong, 2009). 
By performing immunoblotting assays, we found that hypoxia-treated cells 
display a ~40% higher SQR protein level as compared to normoxic cells.     
 
DISCUSSION 
Oxygen (O2) and hydrogen sulfide (H2S) and are key molecules in 
living systems, being able to control each other’s availability and being 
involved in numerous processes in human physiology and patho-physiology. 
As reviewed in (Olson, 2015), the interplay between H2S and O2 is very 
intricate and relies on different mechanisms that include: i) direct reaction 
between the two species; ii) O2-dependent breakdown of H2S at the 
mitochondrial level; iii) H2S-dependent stimulation or inhibition of 
mitochondrial O2 consumption; iv) O2-dependent expression and cellular re-
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localization of sulfide-synthesizing enzymes, as CBS and CSE, and v) O2-
dependent control of CO-mediated inhibition of H2S production by CBS. 
Indeed, this close relationship is such that H2S has been recognized as an O2 
sensor (Olson, 2006). Numerous studies have been successfully carried out 
thus far to shed light on the interplay between H2S and O2 and their highly 
intertwined biologic effects (Olson, 2008 a-c; Olson, 2013). Despite these 
efforts, however, to our knowledge no studies have been conducted yet to 
explore the effect of prolonged exposure to hypoxia on the cell ability to 
dispose H2S, that was the main objective of the present study.  
Under hypoxic conditions, the H2S levels are increased with 
beneficial effects for the cell. H2S plays indeed a key protective role against 
ischemia/reperfusion damages as demonstrated in different model systems 
(Morikawa, 2012; Takano, 2014; Kolluru, 2015). The molecular mechanisms 
underlying H2S protection are only partly understood and include induction 
of antioxidant and vasorelaxation effects on microcirculation. In neuronal 
ischemia/reperfusion models, the protective effect of H2S was interestingly 
found to be mediated by thiosulfate, a product of sulfide oxidation (Muratani, 
2015).  In this context it is interesting to note that H2S is also able to mimic 
hypoxia-induced responses such as vasodilation (Zhao, 2011), neo-
angiogenesis (Papapetropoulos, 2009) and expression of the hypoxia 
inducible factor (HIF-1α; Beaumony, 2016), a master gene regulator 
promoting cell survival under hypoxic conditions. The increased H2S levels 
occurring under hypoxic conditions are therefore part of a more general 
adaptive response adopted by the cells to ensure survival and protection from 
damages at low O2 tensions (and possible reoxygenation).   
In hypoxic cells, H2S bioavailability therefore needs to be finely 
regulated through a correct balance between biosynthetic and catabolic 
pathways so that this gaseous signalling molecule can occur at higher 
173
Results and Discussion – Paper 3 
 
 
(physiologically protective) levels with no risk for the cell to be poisoned. In 
this regard, it seems relevant to gain insight into the regulation of H2S 
production and breakdown at low O2 tensions. Previous studies addressing 
this issue have shown that under hypoxic conditions the sulfide-synthesizing 
enzymes are up-regulated (Takano, 2014; Kolluru, 2015) and CBS 
accumulates in the mitochondria, due to reduced proteolytic activity of the 
mitochondrial LON protease (Teng, 2013). As a result, H2S synthesis is 
enhanced (Olson, 2015). On the contrary, H2S breakdown via both chemical 
and mitochondrial enzymatic reaction pathways is negatively affected by low 
O2 tensions. Evidence for a lower mitochondrial sulfide-oxidizing activity at 
lower O2 concentrations was initially provided in (Matallo, 2014) working on 
immortalised cells derived from alveolar macrophages and, then, 
corroborated by Abou-Hamdan et al. in a more recent investigation on CHO 
cells (Abou-Hamdan, 2016).  
In the present study, using SW480 colorectal cancer cells as a model, 
we tested the effect of prolonged (24 h) exposure to 1% O2 on the cellular 
ability to consume sulfide at mitochondrial level. The sulfide-oxidizing 
activity of normoxic and hypoxia-treated cells was assayed by high-
resolution respirometry, following the approach described in (Abou-Hamdan, 
2015). The method allows to indirectly assess the mitochondrial sulfide-
oxidizing activity from the stimulation of cell O2 consumption by sulfide 
administered with a micropump at increasing injection rates. In these assays 
we made use of rotenone to prevent reversal of Complex I activity upon 
sulfide injection, according to (Helmy, 2014), and antimycin A to subtract the 
effect of sulfide autoxidation and extra-mitochondrial O2 consumption. Also, 
we comparatively evaluated in normoxic and hypoxia-treated cells both the 
mitochondrial content, with citrate synthase assays, and the expression level 
of SQR, by immunoblotting using ‘stain-free’ imaging technology for protein 
174
Results and Discussion – Paper 3 
 
 
normalization. As a major finding, we found that exposure to hypoxia leads 
to a significant reduction in the basal respiration (~65%) and maximal 
mitochondrial sulfide-oxidizing activity (~25%) of treated cells, consistent 
with their reduced mitochondrial content (~55% less than in untreated cells). 
The observed reduction in mitochondrial mass in hypoxic cells has been 
previously documented and suggested to result from enhanced mitophagic 
activity and reduced organelle biogenesis (Zhang 2008). Finally, we made the 
somewhat puzzling observation that hypoxia-treated cells, though displaying 
slightly reduced mitochondrial sulfide-oxidizing activity, have modestly 
(~40%) increased SQR levels. This result is intriguing in that it suggests that 
mitochondria in hypoxic cells are less numerous, but probably enriched in 
SQR. In light of this observation, it is tempting to speculate that the increased 
SQR levels in mitochondria could have a protective role in hypoxic cells 
preventing the organelle to be poisoned by enhanced in situ production of 
sulfide.  
Summing up, this is to our knowledge the first study in which the 
effect of hypoxia on the mitochondrial sulfide-oxidizing activity has been 
evaluated. The collected evidence shows that, following prolonged exposure 
to hypoxia, the cells retain their ability to metabolize sulfide but with reduced 
efficacy, in line with their lower mitochondrial content. Whereas 
physiologically this may represent a regulatory mechanism to ensure higher 
protective H2S levels, under pathological conditions resulting in chronic 
hypoxia the lower ability to detoxify sulfide may lead to higher risk of sulfide 
toxicity. 
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FIGURE LEGENDS 
Figure 1 
 
Figure 1. Effect of sulfide on cell O2 consumption. Panels A and B: 
Representative oxygraphic traces (blue) acquired with normoxic (A) or 
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hypoxia-treated SW480 cells (B), following the addition of 4 x 10
6
 cells 
(yellow line), 10 µM rotenone (green line) and subsequent injection of a 3-5 
mM sulfide stock solution at increasing infusion rates (10 nL·s
-1
, 20 nL·s
-1
, 
40 nL·s
-1
,
 
80 nL·s
-1
, 160 nL·s
-1
). Red traces: O2 consumption rate. Panel C: 
O2 consumption rate measured with normoxic (n = 9; white bar) or hypoxia-
treated cells (n = 8; black bar) under basal conditions and after addition of 
rotenone at increasing sulfide injection rate. 
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Figure 2 
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Figure 2. Effect of sulfide on antimycin A-insensitive O2 consumption. Panels 
A and B: Representative oxygraphic traces (blue) acquired with normoxic (A) 
or hypoxia-treated SW480 cells (B), following the addition of 4 x 10
6
 cells 
(yellow line), 10 µM rotenone (green line), 5 µM antimycin A (purple line) 
and subsequent injection of a 3-5 mM sulfide stock solution at increasing 
infusion rates (10 nL s
-1
, 20 nL s
-1
, 40 nL s
-1
,
 
80 nL s
-1
, 160 nL s
-1
). Red 
traces: O2 consumption rate. Panel C: O2 consumption rate measured with 
normoxic (n = 3; white bar) or hypoxia-treated cells (n = 3; black bar) after 
addition of both rotenone and antimycin A at increasing sulfide injection rate.  
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Figure 3 
 
Figure 3 Effect of hypoxia on mitochondrial sulfide consumption. Panel A: 
maximal mitochondrial sulfide consumption activity calculated for normoxic 
(n = 9, white bar) and hypoxia-treated (n = 8, black bar) cells. Panel B: citrate 
synthase activity in normoxic (n = 13, white bar) and hypoxia-treated (n = 10, 
black bar) cells. Panel C: maximal mitochondrial sulfide consumption 
181
Results and Discussion – Paper 3 
 
 
activity detected in normoxic (white bar) and hypoxia-treated (black bar) 
cells, normalized to the citrate synthase activity (*P ≤ 0.05, **P ≤ 0.01 and 
***P ≤ 0.001).  
 
Figure 4. 
 
Figure 4. Effect of hypoxia on SQR expression. Panel A: representative 
immunoblot of SQR. Panel B: corresponding cell lysates analyzed by ‘stain-
free’ SDS-PAGE technology for total protein determination (see Materials 
and Methods for details). Panel C: SQR levels normalized to total protein in 
normoxic (n = 4 in triplicate, white bar) and hypoxia-treated cells (n = 4 in 
triplicate, black bar). *P ≤ 0.05. 
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Abstract: A genetically engineered human ferritin heavy chain (HFt)-based 
construct has been recently shown by our group to efficiently entrap and 
deliver doxorubicin to cancer cells. This construct, named HFt-MP-PAS, 
contained a tumor-selective sequence (MP) responsive to proteolytic 
cleavage by tumor proteases (MMPs), located between each HFt subunit and 
an outer shielding polypeptide sequence rich in proline (P), serine (S) and 
alanine (A) residues (PAS). HFt-MP-PAS displayed excellent therapeutic 
efficacy in a xenogenic pancreatic cancer model in vivo, leading to a 
significant increase in overall animal survival in treated mice. Here we report 
a new construct obtained by the genetic insertion of two glutamate residues in 
the PAS sequence of HFt-MP-PAS. Such new construct, named HFt-MP-
PASE, efficiently encapsulate the anti-cancer drug mitoxantrone (MIT), and 
the resulting MIT-loaded nanoparticles proved to be more soluble and 
monodispersed than the HFt-MP-PAS counterparts. Importantly, in vitro 
MIT-loaded HFt-MP-PASE nanoparticles kill several cancer cell lines of 
different origin (pancreatic, colon, sarcoma and breast) at least as efficiently 
as the free drug. 
 
Keywords: protein-cage nanocarrier; pasylated ferritin; mitoxantrone; drug-
encapsulation; drug-delivery; cancer 
 
Introduction 
Human ferritin heavy chain (HFt)-based constructs have been shown to 
efficiently entrap and deliver chemotherapeutics (e.g., cisplatin, doxorubicin, 
5-fluorouracil and gefitinib) to cancer cells.[1–9] HFt is a multimeric protein-
cage consisting of 24 identical subunits that self-assemble into a symmetric 
shell-like sphere, with external and internal diameters of 12 and 8 nm, 
respectively.[10–16] Drug molecules are usually encapsulated inside the HFt 
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internal cavity. An important advantage of the HFt system is the ability to 
effectively bind to and enter many types of tumor cells via the transferrin 
receptor 1 (TfR1, CD71). A wide number of tumors express up to 100 times 
higher levels of TfR1 than healthy cells and actively internalize the HFt:TfR1 
ligand-receptor complex to accumulate the large amount of iron required for 
unrestrained cancer cell growth.[17,18] 
Recently, to increase both the in vivo half-life of native HFt and the 
stability of HFt-drug complexes, we have developed novel HFt-based 
constructs, named HFt-MP-PAS, suitable for drug delivery. In these 
constructs the N-terminus of each HFt subunit is genetically fused to: i) a 
PAS polypeptide sequence, i.e., a sequence rich in proline (P), alanine (A) 
and serine (S) residues;[5,19] and ii) a tumor-selective sequence (MP) 
responsive to proteolytic cleavage by tumor proteases (MMPs), inserted 
between each HFt subunit and the outer PAS polypeptide.[20] The PAS 
shield was aimed at hampering the interaction between drug-loaded HFt and 
TfR1 in healthy tissues and reducing internalization by normal cells, already 
limited by the low expression of the receptor. The MP sequence allows the 
PAS shield to be selectively removed by stimuli present in the tumor 
microenvironment (i.e., MMPs specific for this sequence) so that the 
resulting unmasked HFt can freely interact with and be internalized by TfR1 
overexpressed in cancer cells.  
The HFt-MP-PAS constructs proved to i) encapsulate in the internal 
cavity three times more doxorubicin (DOXO) than wild-type HFt, ii) form 
more stable complexes (i.e., drug leakage was negligible) and iii) possess 
higher in vivo circulation time. Importantly, DOXO-loaded HFt-MP-PAS 
(HFt-MP-PAS-DOXO) displayed excellent therapeutic efficacy in a human 
pancreatic cancer model in vivo, significantly increasing overall animal 
survival.[19] The nanocarriers efficacy was even superior to the novel 
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albumin-based DOXO delivery system (INNO-206), currently in phase III 
clinical trials. We ascribed to the PAS shield the increase in DOXO 
encapsulation, protein-drug complex stability and circulation time with 
respect to HFt. The higher in vivo efficacy of HFt-MP-PAS-DOXO with 
respect to other DOXO delivery systems is likely due to both effective PAS 
removal by tumor specific MMPs and efficient DOXO delivery into the cell 
nucleus, as revealed by confocal microscopy studies.[19]  
The goal of the present study was to improve and widen the use of HFt 
as drug-delivery system and in particular to exploit these nanocarriers as 
delivery system for drugs with solubility problems or high nonspecific 
toxicity (i.e. lower therapeutic index). So far, HFt-based constructs have been 
demonstrated to efficiently entrap cisplatin, doxorubicin, 5-fluorouracil and 
gefitinib as chemotherapeutic molecules.[1–8] Here we report the first 
encapsulation of the anti-cancer drug mitoxantrone (MIT) in HFt-based 
constructs. MIT is a synthetic anthracenedione developed to improve the 
therapeutic profile of anthracyclines and a clinically well-established 
anticancer agent which targets DNA topoisomerase I and ubiquitin-specific 
peptidase 11 (USP11) enzyme, a component of the DNA repair complex. 
Despite some limitations, MIT shows high efficacy in several types of 
cancer.[21,22] To widen MIT applicability and improve its therapeutic index, 
a selective delivery system is needed. Here we found that, although the 
previously designed HFt-MP-PAS construct is able to bind several MIT 
molecules, stability and homogeneity of the complex are lower than those 
obtained with DOXO. To obtain higher yields and monodispersed materials, 
we genetically re-engineered HFt-MP-PAS by adding glutamate residues (E) 
in the PAS sequence and obtained a new construct, named HFt-MP-PASE. 
Thanks to this modification, MIT-loaded HFt-MP-PASE nanoparticles (HFt-
MP-PASE-MIT) proved to be both more soluble and monodispersed than the 
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HFt-MP-PAS counterpart, yet displaying high in vitro killing efficacy against 
cancer cells and preferential drug delivery into the cell nucleus. The novel 
HFt-MP-PASE construct herein described further extends the array of drugs 
deliverable by HFt-based nanosystems for therapeutic purposes.  
 
 
 
Material and methods 
 
Protein design 
MIT-loaded HFt-MP-PAS complexes (HFt-MP-PAS-MIT) were found in the 
present work to be less stable and homogeneous than the previously reported 
HFt-MP-PAS-DOXO complexes. Therefore, as an attempt to reduce protein 
aggregation and increase stability, we decided to introduce negatively 
charged residues in the outer shield-forming PAS sequence fused to each HFt 
subunit. Indeed, analysis of the previously obtained HFt-MP-PAS 
construct[20] suggested that introduction of two glutamate residues in the 
PAS sequence would cause sufficient electrostatic repulsion to prevent 
aggregation between different 24-meric assemblies, without affecting subunit 
assembly within the 24-mer. To distribute the negative charges on the surface 
of the construct as much as possible, glutamic acid residues were placed after 
12 residues of the PAS sequence repeat reported previously: 
ASPAAPAPASPAEPAPSAPAASPAAPAPASPAEPAPSAPA. 
Protein structure visualization and modelling of PAS chains were performed 
using the software InsightII (Accelrys Inc). 
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Cloning, overexpression and purification of HFt-MP-PASE constructs 
The HFt-MP-PASE gene was obtained by genetically adding two glutamate 
(E) residues, at positions 21 and 42, to the previously designed 40-residue 
long HFt-MP-PAS gene.[20]  
The expression vector pET-11a containing the HFt-MP-PASE gene was 
assembled by GENEART AG (Germany). Gene synthesis was performed 
taking into account codon-optimization for high level expression in 
Escherichia coli. The recombinant proteins HFt-MP-PAS and HFt-MP-PASE 
were expressed in E. coli, purified and quantified as previously described.[5]  
Native agarose gel electrophoresis 
Protein mobility was assessed by agarose gel electrophoresis under native 
conditions. The 1% agarose gels were run in TAE buffer (40 mM Tris-acetate 
and 2 mM EDTA, pH 8.0) and stained with Coomassie. 
MIT encapsulation in HFt-based nanocarriers  
MIT (MedKoo Biosciences, USA) was encapsulated using the HFt 
disassembly/reassembly procedure previously described for DOXO[5] 
(Scheme 1). Briefly, solutions of HFt-MP-PAS or HFt-MP-PASE in 0.1 M 
NaCl were incubated for 10 min at pH 2.0 (pH adjusted with HCl). Then, 
MIT was added to the solution at 250:1 molar ratio with respect to the 
protein. The pH was initially maintained at 2.5 for 5 min and then increased 
to 7.5 using NaOH. The resulting solution was stirred at room temperature for 
30 min, filtered and dialyzed o.n. vs phosphapte buffer saline (PBS) at pH 7.4 
to remove unbound MIT. After dialysis, solutions were centrifuged at 15.000 
rpm for 30 min at 4°C. Supernatant was collected, concentrated with 30 kDa 
Amicon Ultra-15 centrifugal devices, sterile filtered and stored at 4°C in the 
dark. HFt and MIT content of the samples was determined by the Lowry 
method and UV-vis spectroscopy, respectively, after extracting MIT in 1 N 
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HCl, 95% ethanol. MIT was quantified by using the calculated molar 
extinction coefficient ε = 19200 M−1cm−1 at 610 nm. 
Size exclusion chromatography (SEC) and dynamic light scattering 
(DLS) analyses 
SEC experiments were performed using a Superose 6 gel-filtration column 
equilibrated with PBS. 
DLS experiments were carried out with a Zetasizer Nano S (Malvern 
Instruments, Malvern, U.K.) equipped with a 4 mW He–Ne laser (633 nm). 
Measurements were performed at 25°C with an angle of 173° with respect to 
the incident beam. The average hydrodynamic diameters (Z-average 
diameter) of the scattering particles were determined by peak intensity 
analyses. Results are the average of at least five measurements of samples 
from three different syntheses. All samples were prepared at 1 mg/mL in 
filtered H2Odd. 
Data from both SEC and DLS experiments were analysed with Origin 8.0 
(Originlab Corporation, Northampton, MA). 
Stability of MIT-loaded HFt-based nanocarriers (HFt-MP-PASE-MIT) 
MIT release from HFt-based nanocarriers was evaluated every 7 days for 2 
months in PBS at 4°C and 37 °C. Drug release was evaluated by SEC, 
simultaneously following the optical contributions of the protein and the drug 
at 280 nm and 610 nm, respectively. 
Cell-binding of HFt-based nanocarriers 
Fluorescence Activated Cell Sorting (FACS) experiments were carried out 
after incubation of SW480 and SW620 cell lines (ATCC, Manassas, VA, 
USA) with 0.8, 4 and 8 μM HFt-MP-PASE-MIT at 37°C for 1 h or 3 h. Cells 
(3.5 × 10
5
) were grown in a 6-well plate and incubated at 37°C with 2 ml 
198
Results and Discussion – Paper 4 
 
 
medium (Dulbecco’s Modified Eagle Medium + 10% fetal bovine serum, 
Invitrogen-Gibco). After washing with PBS, cells were detached by trypsin-
EDTA solution and samples were assayed in a flow cytometer (CyAN ADP; 
Dako Italia S.p.a., Milan, Italy) using the Summit 4.3 software (Beckman 
Coulter, Milan, Italy) for data acquisition and analysis. 
Cell-localization of HFt-based nanocarriers 
In confocal microscopy experiments, cells grown on round glass slides were 
treated with 20 μM MIT and HFt-MP-PASE-MIT using the same protocol  
described for the cell-binding assays and then fixed in 4% formaldehyde in 
PBS. After washing with PBS, slides were incubated for 30 min with 1:100 
Lamin A/C (4C11) mouse monoclonal antibody (Cell Signaling #4777) in 
PBS/1% BSA, stained with goat anti-mouse IgG (H+L) secondary antibody, 
Alexa Fluor 488, and mounted with Vectashield (Vector Labs, Burlingame, 
CA, USA). Cells were examined with a Leica TCS SP2 fluorescence 
confocal microscope (Leica Microsystems, Wetzlar, Germany) using 
excitation wavelengths of 488 nm (argon laser) and 633 nm (helium-neon 
laser). Photomicrographs were acquired with the LAS AF Software (Leica 
Microsystems, Wetzlar, Germany). 
Antiproliferative effects of HFt-MP-PASE-MIT construct in vitro  
Human cells from fibrosarcoma (HT1080), triple-negative breast (MDA-MB-
231), prostatic (PC3) and colorectal (SW480 and SW620) cancer were grown 
in Dulbecco’s Modified Eagle Medium; pancreatic PaCa44, Capan-1 and 
MiaPaCa2 cell lineswere grown in RMPI 1640 medium. All growth media 
were also added with 2 mM glutamine, 10% of FBS and antibiotics. Cancer 
cells (5 x 10
3
) were seeded in 90 µL of complete medium in 96-well culture 
microplates. The day after, cells were incubated in triplicate with 10 µL of 
serially diluted free MIT or HFt-MP-PASE-MIT. After 72 hour-incubation at 
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37 °C with drugs, the medium was replaced with fresh medium w/o phenol 
red supplemented with XTT (2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-
2H-Tetrazolium-5-Carboxanilide) reagent (Sigma-Aldrich, St Louis, MO, 
USA), according to the manufacturer’s instructions. Finally, after a variable 
time ranging from 1 to 3 hours of incubation at 37°C cell viability was 
measured at 450 nm by a microplate reader (VERSAmax, Molecular 
Devices, Sunnyvale, CA, USA). The percentage of cell viability was 
estimated by comparing cells treated with free MIT or HFt-MP-PASE-MIT 
to mock treated cells. To compare the killing efficacy, we evaluated the IC50, 
i.e., the compound concentration yielding 50% cell viability. 
 
Results and discussion 
 
MIT encapsulation in HFt-MP-PAS  
MIT encapsulation inside HFt-MP-PAS was achieved following the 
disassembly/reassembly procedure reported previously.[5] The encapsulation 
efficiency, however, was slightly lower than reported previously for DOXO 
(about 90 molecules entrapped per construct) [5]: only about 55 MIT 
molecules were indeed found by UV-visible spectroscopy and size-exclusion 
chromatography (SEC) to be bound by a HFt-MP-PAS 24-mer. HFt-MP-
PAS-MIT complex recovery and drug loading capacities are reported in 
Table 1.  
Sample polydispersity was assessed by SEC and dynamic light scattering 
(DLS). Both techniques showed the presence of slightly higher molecular 
species as compared to monodispersed HFt-MP-PAS-MIT complex (Figure 
1). In particular, DLS revealed the presence of larger particles (mean 
diameter of 20.5 nm) as compared to the monomeric form of the protein 24-
mer (mean diameter of 17.0 nm). The MIT-encapsulating product is thus less 
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homogenous than previously reported for DOXO due to the presence of 
higher molecular weight species (likely dimers) in solution.[5]  
 
 
Design and production of novel HFt-MP-PASE fusion protein 
In order to improve the construct yield and homogeneity, we 
genetically re-engineered the HFt-MP-PAS fusion protein by inserting two 
glutamate residues (E) in the PAS sequence (HFt-MP-PASE). This 
modification was aimed at reducing HFt-MP-PAS aggregation following 
MIT incorporation, through insertion of negative charges in the outer shield 
of the assembly surface. 
The fusion protein HFt-MP-PASE was obtained via recombinant protein 
technology and purified from the cellular soluble fraction at high yield, 
similar to HFt-MP-PAS (about 150 mg per liter of E. coli cell culture). The 
effect on protein mobility of the negatively charged glutamate residues (48 
per protein) inserted on the protein surface was assessed by performing 
agarose gel electrophoresis under native conditions (supporting Figure 1). At 
variance with denaturant SDS-PAGE, in native electrophoresis protein 
mobility depends on both protein charge and molecular mass. Assuming the 
latter to be comparable for HFt-MP-PAS and HFt-MP-PASE, the observed 
difference in protein mobility has to be ascribed to the additional negative 
charges in the HFt-MP-PASE construct (Figure 2). 
MIT encapsulation in HFt-MP-PASE 
As shown in Figure 1 and Table 1, the efficiency of MIT 
encapsulation in HFt-MP-PASE was comparable to that one in HFt-MP-PAS. 
MIT-loaded HFt-MP-PASE constructs, however, were more soluble and 
monodispersed than the HFt-MP-PAS counterparts, displaying no higher 
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molecular weight species in solution (Table 1 and Figure 1). DLS 
experiments indicated that HFt-MP-PASE-MIT samples have approximately 
the same size as our previously reported HFt-MP-PAS-DOXO, with a mean 
diameter of 17.0 nm (Figure 1B).[5] These results indicate that insertion of 
the glutamate residues in HFt-MP-PASE-MIT leads to higher protein 
solubility and homogeneity compared to the HFt-MP-PAS counterpart, likely 
preventing MIT-mediated protein-protein interactions in solution. In addition, 
the slightly higher number of MIT molecules per 24-mer observed for HFt-
MP-PAS in comparison to HFt-MP-PASE (56.0 vs 47.0) can be likely 
ascribed to a significant presence of MIT molecules on the surface of the 
former construct.  
Stability of HFt-MP-PASE-MIT nanocarrier 
HFt-MP-PASE-MIT complex was tested by storing the nanoparticles 
for 2 months in PBS at 4°C or 37°C and evaluating their MIT content by SEC 
analysis every 7 days. HFt-MP-PASE-MIT showed excellent stability, with 
less than 10% MIT being released after 2 months storage at 4°C (Figure 3) 
and no sign of turbidity or precipitation.  
Cell internalization and localization of HFt-based nanocarriers 
To determine whether MIT-containing HFt-based constructs undergo 
cell surface binding and/or internalization, they were incubated with colon 
cancer cells SW480 and SW620 at 37°C for 1 or 3 h and MIT-associated 
fluorescence was visualized by confocal microscopy.  
Figure 4 shows HFt-MP-PASE-MIT localization in the SW480 (upper panel) 
and SW620 (lower panel) cell lines. After 3 hour-incubations HFt-MP-
PASE-MIT massively accumulate in the nuclei of both cell lines, as shown 
by staining with the nuclear membrane marker Lamin A/C (in green). In 
particular, MIT localizes in intranuclear structures assumed to be nucleoli on 
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the basis of size, position and shape, as previously proposed for colon 
carcinoma and breast cancer cells.[23,24] A comparison between cells treated 
with free MIT, HFt-MP-PAS-MIT or HFt-MP-PASE-MIT is shown in Figure 
5. In all cases MIT localizes inside the cell nuclei, but in the case of free MIT 
and HFt-MP-PAS-MIT the drug is partly present also in the cytoplasm. 
Overall, cells treated with HFt-MP-PASE-MIT showed the highest 
accumulation of MIT in the nuclei. In both cell lines tested HFt-MP-PASE-
MIT accumulation was time- and dose-dependent, the accumulation being 
more pronounced in SW480 than in SW620 cells (Figure 6). 
In vitro antiproliferative effects of HFt-MP-PASE-MIT nanocarriers 
To assess the ability of MIT-loaded HFt-MP-PASE to kill cancer cells 
in vitro, we have performed XTT viability assays on a wide range of human 
cancer cells of different origin: fibrosarcoma HT1080; triple-negative breast 
MDA-MB-231; pancreatic PaCa-44, Capan-1 and MiaPaCa2; colorectal 
SW480 and SW620 cancer cells.  
Not only MIT preserved its pharmacological activity after encapsulation in 
HFt-MP-PASE constructs, but the MIT-loaded nanocarrier display IC50 
values similar to those of naked MIT in all cell lines tested, and even lower in 
some cases (see Table 2). This is remarkable in that naked drugs can freely 
diffuse into cells, whereas the HFt-MP-PASE constructs can only deliver 
MIT by undergoing rate-limiting receptor-mediated uptake. Moreover, the 
new nanosystem HFt-MP-PASE-MIT showed, on the pancreatic cell lines, a 
killing efficacy of about ten time higher than the currently used drug 
Gemcitabine (i.e. 0.43 vs 6.75 µM, 0.10 vs 2.8 µM and 0.07 vs 1.15 µM, for 
Paca44, Capan-1 and MiaPaCa2 cells respectively). 
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Conclusion 
We have generated the first, to our knowledge, HFt-based protein 
nanocarrier able to encapsulate the MIT anti-cancer drug. To achieve this 
result, we have re-engineered our previously reported HFt-MP-PAS 
nanocarriers by inserting negatively charged aminoacid residues (glutamates) 
in the outer shield-forming PAS sequence. The novel system (HFt-MP-
PASE) has higher solubility because of reduced drug-mediated protein-
protein interactions, due to electrostatic repulsion between negative surface 
glutamates. Like the previously reported HFt-MP-PAS system, HFt-MP-
PASE is a genetic construct that can be expressed and purified at high yield 
in E. coli as a single protein product, without requiring additional coupling 
and/or separation steps.  
HFt-MP-PASE is able to stably encapsulate up to approximately 50 MIT 
molecules in the internal cavity. MIT encapsulation was shown to preserve 
the pharmacological activity of the drug against a panel of different cancer 
cells, as demonstrated by performing viability assays in vitro. This is 
noteworthy in that the construct needs to undergo receptor-mediated 
internalization, as opposed to free diffusion of the naked drug into the cell. 
This result can be ascribed, at least in part, to the considerable nuclear, likely 
nucleolar, accumulation of the delivered drug, as revealed by confocal 
microscopy experiments. We also shown that HFt-MP-PASE-MIT 
internalization into the cell is time- and dose-dependent, and that SW480 
colorectal cancer cells incorporate slightly higher MIT amounts than SW620 
cells.  
All together these results strongly support the HFt-MP-PASE construct 
herein described as a suitable nanocarrier to be exploited for mitoxantrone-
based cancer therapy in vivo. 
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FIGURES AND TABLES 
 
Figure 1 
 
Figure 1 Gel-filtration elution profiles and particle size distribution of HFt-
based constructs. (A) SEC analysis of MIT-loaded HFt-MP-PAS (black) and 
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HFt-MP-PASE (red) constructs. Elution profiles obtained following 
simultaneously protein and MIT contributions at 280 nm (solid) and 610 nm 
(dotted), respectively. (B) DLS profiles of the same constructs. 
 
Figure 2 
 
 
Figure 2 Native agarose gel electrophoresis band migration profiles. Lane 
HFt-MP-PAS (15 µg); Lane 2, HFt-MP-PASE (15 µg). 
 
Figure 3 
 
 
Figure 3 Drug release from HFt-MP-PASE-MIT complexes. MIT-loaded 
nanocarriers were stored at 4 °C and 37 °C in PBS and assayed for their MIT 
content by SEC at given times. The percentage of MIT leakage was assessed 
206
Results and Discussion – Paper 4 
 
 
by comparing the elution profiles simultaneously collected at 280 nm and 
610 nm. 
 
 
Figure 4 
 
 
 
Figure 4 HFt-MP-PASE-MIT (20 μM MIT concentration) localization in 
SW480 (upper panel) and SW620 (lower panel) colon cancer cell lines after 3 
h-incubation. Left panels: Lamin A/C staining (nuclear membrane marker, 
green); central panels: MIT (blue); right panels: merge. The white bar 
indicates a 10 μm length.  
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Figure 5 
 
Figure 5 Localization of MIT (panels A, B), HFt-MP-PAS-MIT (panels C, 
D) and HFt-MP-PASE-MIT (panels E, F) in SW480 (panels A, C and E) and 
SW620 (panels B, D and F) colon cancer cell lines after 3 h incubation. MIT 
concentration is 20 μM in all experiments. The white bar indicates a 20 μm 
length. Representative images are shown. 
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Figure 6 
 
Figure 6 Cellular uptake of HFt-MP-PASE-MIT nanocarriers by FACS 
analysis. FACS experiments were carried out after incubation of SW480 (left 
panels) and SW620 lines (right panels) with 0.8, 4 and 8 μM of MIT-
containing HFt-MP-PASE at 37°C for 1 or 3 h. Graphs show the mean 
fluorescence intensity (MFI) upon incubation with different doses of HFt-
MP-PASE-MIT. 
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Scheme 1 
 
 
 
Scheme 1. Schematic representation of the synthesis of HFt-MP-PASE-MIT. 
For clarity purposes, only 4 out of the 24 modified HFt N-termini are shown. 
 
 
Table 1 
Protein  Protein recovery (%)  Number of MIT 
molecules per 24-mer 
HFt-MP-PAS 65±4  56±4  
HFt-MP-PASE 90±3 47±5  
 
Table 1. MIT encapsulation by HFt-based nanocarriers. Mean ± standard 
deviation (n = 3) 
 
 
Table 2 
 
Cancer cells  IC50 (µM) 
Free MIT 
IC50 (µM) 
HFt-MP-PASE-MIT 
SW480 0.005 ± 0.001 0.004 ± 0.001 
SW620 0.004 ± 0.001 0.005 ± 0.001 
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MDA-MB-231 0.03 ± 0.009 0.02 ± 0.007 
HT1080 0.01 ± 0.008 0.009 ± 0.005 
PaCa44 0.43 ± 0.12 0.43 ± 0.34 
Capan-1 0.72 ± 0.23 0.10 ± 0.04 
MiaPaCa2 0.11 ± 0.06 0.07 ± 0.02 
 
Table 2. Killing efficacy of MIT and HFt-MP-PASE-MIT against human cell 
lines PaCa-44, Capan-1 and MiaPaCa2 (pancreatic carcinoma), HT1080 
(fibrosarcoma), MDA-MB-231 (breast cancer) and SW480 and SW620 
(colorectal cancer). Mean ± S.E.M. (n =3) 
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Conclusions 
 
 
 
The results obtained along this thesis work allowed to gain insight 
into H2S metabolism (synthesis and catabolism), particularly regarding the 
interplay between this key gaseous signalling molecule, CO and O2 in 
homocystinuria and colon cancer. Moreover, a novel human ferritin-based 
drug delivery system was obtained able to carry the anticancer drug 
mitoxantrone and kill colon cancer cells with high efficacy. The acquired 
knowledge will hopefully set the basis for the discovery of new 
pharmacological targets and therapeutic interventions in diseases associated 
to altered H2S metabolism, such as colon cancer.   
 
Conclusion 1 
Classic homocystinuria is rare metabolic disease caused by mutations 
in the gene of cystathionine β-synthase (CBS). To gain insight into the 
molecular bases of classic homocystinuria, the pathogenic p.P49L CBS 
protein variant was investigated. P49L mutation in CBS causes a mild form 
of homocystinuria with sporadic responsiveness to vitamin B6 treatment. We 
found that the p.P49L CBS variant, recombinantly produced in E. coli and 
purified, displays impaired H2S-generating activity, rescued by PLP 
supplementation along the protein purification. Surprisingly, the investigated 
protein variant displayed a markedly increased affinity for CO binding to the 
protein ferrous heme, resulting into a much higher susceptibility of p.P49L 
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CBS to CO inhibition, compared to the wild-type protein. In light of the 
enhanced susceptibility to CO inhibition documented here, the p.P49L CBS 
variant could be inhibited in vivo by physiological CO concentrations, 
thereby contributing to pathological accumulation of homocysteine. We 
suggest that this may represent a novel, possibly more general, pathogenic 
mechanism in classical homocystinuria. 
 
Conclusion 2 
O2 and H2S are key molecules in living systems, able to control each 
other’s availability and biologic effects with interesting consequences in 
human physiology and patho-physiology. Under hypoxic conditions, H2S 
stability and synthesis are enhanced, and the resulting higher H2S levels are 
known to protect cells against hypoxia and ischemia/reperfusion damage. We 
assessed the effect of hypoxia on the ability of the cells to dispose H2S at the 
level of mitochondria, the main site of H2S detoxification. The maximal 
mitochondrial sulfide-oxidizing activity was measured by quantitatively 
evaluating by high-resolution respirometry the stimulatory effect produced on 
cell respiration by sulfide injection. By comparing SW480 colon cancer cells 
grown under normoxic conditions (air O2) or exposed to hypoxia (1% O2), 
we found that, following 24 h-exposure to hypoxia, the cells retain their 
ability to metabolize sulfide but with reduced efficacy compared to untreated 
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cells. The lower mitochondrial sulfide-oxidizing activity observed in 
hypoxia-treated cells likely originates from the reduced mitochondrial 
content of these cells, independently assessed by performing citrate synthase 
activity assays. Whereas physiologically this may represent a regulatory 
mechanism to ensure higher protective H2S levels at low O2 tension, under 
pathological conditions of chronic hypoxia the observed lower sulfide-
detoxifying activity could lead to higher risk of sulfide toxicity. 
 
Conclusion 3 
We reported the first human ferritin (HFt)-based protein nanocarrier 
able to encapsulate the anti-cancer drug mitoxantrone (MIT). A new Hft 
construct, named HFt-MP-PASE, was obtained by engineering a previously 
designed construct (HFt-MP-PAS, Falvo 2016). The new construct proved to 
be monodispersed and more soluble than the parental HFt-MP-PAS 
construct. Of relevance, HFt-MP-PASE displayed preferential drug delivery 
into the cell nucleus, as revealed by confocal microscopy, and high in vitro 
killing efficacy against colorectal cancer cells. We also showed that cell 
internalization of HFt-MP-PASE loaded with MIT (HFt-MP-PASE-MIT) is 
time- and dose-dependent, and that, following HFt-MP-PASE-MIT 
administration, the SW480 colorectal cancer cells incorporate slightly higher 
MIT amounts than SW620 cells. The collected evidence shows that the new 
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HFt-MP-PASE construct herein described is a suitable nanocarrier to be 
exploited for mitoxantrone-based cancer therapy in vivo. This new construct 
further extends the array of drugs deliverable by HFt-based nanosystems for 
therapeutic purposes. 
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1. Materials 
 
1.1.Chemical reagents 
Trypan blue, sodium sulfide nonahydrate (Na2S·9H2O), 5,5’-dithiobis-(2-
nitrobenzoic acid) (DTNB), acetyl coenzyme A (acetyl-CoA), oxaloacetate, 
CelLytic
TM
MT Cell lysis reagent, protease inhibitor cocktail (P8340), anti-
SQR antibody (HPA017079), thiazolyl blue tetrazolium bromide (MTT), 2,3-
bis-(2-methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide 
(XTT), Luria Bertani broth (LB), -aminolevulinic acid, ampicillin, 
superoxide dismutase, catalase, homocysteine, S-adenosyl-L-methionine 
(AdoMet), glucose oxidase, dithionite, pyridoxal-5’-phosphate (PLP), DNase 
I and bicinchoninic acid (BCA) assay kit were purchased from Sigma. The 
secondary antibody, the polyvinylidene difluoride membrane and the 
nitrocellulose membrane were from GE Healthcare Life Sciences. The Mini-
PROTEAN TGX stain-free precast gels, the Clarity Western ECL Substrate, 
the Laemmli protein sample buffer, the running buffer 10X Tris/Glycine/SDS 
and the Bradford protein assay solution were purchased from Bio-Rad. 20X 
MOPS SDS running buffer, 4X NuPage LDS sample buffer, Bis-TRIS 
NuPage gels and Coomassie brilliant blue was from Life Technologies. 
Tween20 was from Chemik. Bovine serum albumin (BSA) and lysozyme 
were from AppliChem. Kanamycin, chloramphenicol, isopropyl-1-thio-ß-D-
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galactopyranoside (IPTG) were purchased from Nzytech. The 
phenylmethylsulfonyl fluoride (PMSF) was from Merck, Terrific Broth (TB) 
was Fisher Scientific and mitoxantrone (MIT) was from MedKoo 
Biosciences. NucleoSpin RNA buffer set was ordered from Macherey-Nagel; 
Maxima First Strand cDNA synthesis kit (Thermo Scientific); SYBR Green 
qPCR master mix 2X Thermo Scientific. Cell media, non-essential 
aminoacids, glutamine and the antibiotics used for human cell culture were 
purchased from Sigma, Euroclone or Gibco. 
 
1.2. Human cell lines 
The human colon cancer cell lines SW480 and SW620 were purchased 
from the American type Culture Collection (ATCC
®
). The cell lines present 
different grades (Broders classification) and stages  (Dukes classification) of 
cancer development (Dukes, 1932) (Broders,1925). The grading is a measure 
of histological differentiation of cancer and helps to understand how quickly 
a cancer may grow and spread, whereas the staging is a measurement of the 
extent of cancer in the body, i.e., the tumour size and if it has spread 
[reviewed in (Wu, 2007)]. 
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The SW480 and SW620 cell lines are considered good model of colon 
cancer progression (Hewitt, 2000). SW620 cells are lymph node metastatic 
Broders grades Differentiation Prognosis 
1 well differentiated Good 
2 moderately differentiated both good and bad 
3 poorly differentiated Bad 
4 undifferentiated (anaplasia) Bad 
Dukes stages Localization Prognosis 
A mucosa Good 
B extra-rectal tissues both good and bad 
C lymph nodes metastases Bad 
D distant metastases Bad 
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cells derived from the same patient from which the primary adenocarcinoma 
cells SW480 were derived one year before (Leibovitz, 1976).  
SW480 cell line 
Number ATCC
®
: CCL-228
™
; organism: Homo sapiens, human; 
tissue: colon; morphology: epithelial; disease: colorectal adenocarcinoma; 
gender: male; age: 50; ethnicity: Caucasian; Dukes stage: B; Broders grade: 
3-4. According to (Leibovitz, 1976). 
SW620 cell line 
Number ATCC
®:
 CCL-227
™
; organism: Homo sapiens, human; 
tissue: colon; derived from metastatic site: lymph node; morphology: 
epithelial; disease: colorectal adenocarcinoma; gender: male; age: 51 years; 
ethnicity: Caucasian; Dukes stage: C; Broders grade: 4. According to 
(Leibovitz, 1976). 
 
1.3. Expression vectors 
pET28b-CBS 
pET28b plasmid containing human CBS cDNA and restriction sites 
for NdeIand XhoI, yielding an N-terminally His-tagged protein. The plasmid 
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confers kanamycin and chloramphenicol resistance and encodes for the full-
length wild-type CBS.  
pET28b-CBS p.P49L 
pET28b plasmid containing human CBS cDNA with 146 C>T 
transition in the CBS gene exon 1 and restriction sites for NdeI and XhoI, 
yielding an N-terminally His-tagged protein. The plasmid confers kanamycin 
and chloramphenicol resistance and encodes for the full-length CBS mutant 
p.P49L. 
pET28b- CBS409-551-p.P49L 
pET28b plasmid containing human CBS cDNA with 146 C>T 
transition in the CBS gene exon 1, restriction sites for NdeI and XhoI and a 
premature stop codon at position 409, yielding an N-terminally His-tagged 
protein devoid of the C-terminal 143 residues corresponding to the AdoMet 
binding domain. The plasmid confers kanamycin and chloramphenicol 
resistance and encodes for the truncated CBS409-551 mutant p.P49L. 
pET11a- HFt-MP-PASE 
pET11a plasmid containing the HFt-MP-PASE gene, with two glutamate 
(E) residues at positions 13 and 33 with respect to the previously designed 
40-residue long HFt-MP-PAS gene (Falvo, 2016). The expression vector 
pET-11a containing the HFt-MP-PASE gene confers ampicillin resistance 
and was assembled by GENEART AG (DE). 
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2. Methods 
 
2.1. Human cell cultures and treatments 
In order to prevent bacteria, fungi, mycoplasma and virus contaminations, 
standard operating procedures and good laboratory practices were followed. 
 
2.1.1. Human cell cultures 
The human colon cancer cell lines SW480 and SW620 were grown in 
Dulbecco's Modified Eagle Medium (DMEM) containing 4.5 g·L
-1
 glucose, 
supplemented with 2 mM L-glutamine, 10% (v/v) heat-inactivated fetal 
bovine serum (FBS), 100 U·mL
-1
 penicillin and 100 µg·mL
-1
 streptomycin.  
Cells were cultured in 25 cm
2
 or 75 cm
2
 flasks at 20% O2 (v/v), 37°C, 5% 
CO2 (v/v) and were subcultured every two/three days at approximately 70-
80% confluence. 
 
2.1.2. Hypoxic treatment 
At a confluence of 50-60%, cells were incubated in the Galaxy 14 S 
(Eppendorf) incubator at 1% O2 (v/v), 37°C, 5% CO2 (v/v) for 24 h. After 
incubation, the cells had reached approximately 70-80% confluence. After 
trypsinization, the cells were washed in the culture medium, counted using 
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the trypan blue dye exclusion test, centrifuged at 1.000 g for 5 min and 
resuspended in fresh medium at a final density of 8 x 10
6
 cells·mL
-1
. 
  
2.1.3. Trypan blue dye exclusion test 
Trypan blue is a commonly used assay to stain dead cells. A 1:1 (v/v) 
mixture of cell suspension and 0.4% trypan blue dye was placed into a 1.5 
mL-eppendorf tube, mixed gently and left at room temperature for 5 min. 
Cells were then counted using a counting chamber (hemocytometer). Viable 
cells do not incorporate the dye, whereas nonviable cells can be easily 
identified from their distinctive blue colour. Trypan blue-positive cells were 
always less than 5%. 
 
2.1.4. Mycoplasma detection test using RT-PCR 
Possible contamination of cell cultures by mycoplasma was 
periodically tested by real time-polymerase chain reaction (RT-PCR) assays. 
  
Primers Sequences 
Myc F 5’ TCCAGGWCAYGCTGACTA 3’ 
Myc R 5’ ATTTTWGGAACKCCWACTTG 3’ 
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Under sterile conditions and using RNase-free materials, SW480 and 
SW620 cells (70-80% confluence) were harvested by trypsinization and 
centrifugation (1.000 g for 5 min at 20 °C). The cell pellet was then washed 
twice with PBS, centrifuged (1.000 g for 5 min at 20 °C) and the supernatant 
discarded. The pellet was used to carry out RNA extraction and purification 
using NucleoSpin RNA buffer set, according to the manufacturer’s 
instructions. The purity of extracted RNA was assessed using a Cary 60 UV-
VIS spectrophotometer (Agilent) by measuring the 260/280 nm absorbance 
ratio (A260/A280). RNA was considered pure when the A260/A280 ratio was 1.9 
- 2.1 in 10 mM Tris-HCl (pH 7.5). Absorption at 235 nm, if detected, 
indicated the presence of contaminants. Possible contamination by phenol or 
urea would result in absorption bands at 230 nm or 270 nm, respectively. 
Protein contamination would result in a high absorption at 280 nm and thus 
lower A260/A280 ratio. The total RNA was used as a template for the cDNA 
synthesis. Reverse transcription was performed using 1-2 µg RNA and the 
Maxima First Strand cDNA synthesis kit, using a RT-PCR machine 
(Mx3000P, Agilent). The samples were incubated at 25°C for 10 min, and 
then 15 min at 50°C. The reaction was terminated by incubating the samples 
at 85°C for 5 min. The resulting cDNA was stored at -20°C.  For quantitative 
RT-PCR assays, SYBR Green qPCR master mix 2X has been used. SYBR 
green is an intercalating-dye which is able to bind double-stranded DNA and 
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upon excitation emit light (excitation at 470 nm; emission at 510 nm). Thus, 
fluorescence increases as a PCR product accumulates. The cDNAs were 
amplified using initial denaturation step (95 °C for 10 min) and then 45 
cycles of amplification step (95 °C for 10 sec, 60 °C for 30 sec and 72°C for 
30 s). 
Reaction Mixture 
Reagent Starting conc Volume Final conc 
qPCR Master Mix 2X 12.5 µl 1X 
F Primer 3 µM 3 µl 0.3 µM 
R Primer 3 µM 3 µl 0.3 µM 
cDNA - - ~ 500 ng 
Water - up to 25 µl - 
 
 
2.1.5. Protein extraction 
Cells were harvested by trypsinization and centrifugation (1.000 g for 5 
min at 20 °C), washed with PBS and then lysed using the CelLytic
TM
MT cell 
lysis reagent in the presence of the 100X protease inhibitor cocktail. After 
15-min incubation at 4°C, the cells were centrifuged at 20.000 g for 10 min 
and the resulting supernatant was stored at -80°C. Cell lysates were then 
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assayed for their citrate synthase activity (see 2.6) and by Western blotting 
(2.5.3.). 
 
2.2. Cell proliferation assays 
  The thiazolyl blue tetrazolium bromide (MTT) and the 2,3-bis-(2-
methoxy-4-nitro-5-sulfophenyl)-2H-tetrazolium-5-carboxanilide (XTT) 
assays are commonly used methods to assess cell viability and proliferation. 
MTT is a water-soluble yellow tetrazolium salt which is reduced by 
mitochondrial dehydrogenase enzymes leading to formation of a purple 
formazan dye. XTT is a yellow tetrazolium salt which forms, instead, an  
orange formazan dye. These conversions occur only in metabolically active 
and viable cells and can be detected spectrophotometrically. A linear 
relationship exists between the signal produced and the number of viable 
cells; therefore, both MTT and XTT are widely accepted assays to measure 
cell proliferation and, in this thesis work, they were performed on SW480 
and SW620 cell lines. Briefly, 200 µL of cell suspension with a density of 25 
cells µL
-1
 (yielding 5.000 cells) were seeded in wells of a 96-well plate. After 
24 h-incubation at 37°C and 5% CO2, the medium was replaced with fresh 
medium and the cells were incubated with increasing concentrations (from 
0.0001 to 10 µM, logarithmic scale) of free mitoxantrone and HFt-MP-
PASE-MIT. After 72 hour-incubation at 37°C and 5% CO2, the medium was 
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supplemented with 20 µL MTT (0.33 ng mL
-1
 final) or was replaced with 
fresh medium w/o phenol red supplemented with XTT. Finally, after a 
variable time ranging from 1 to 3 hours of incubation at 37°C and 5% CO2, 
100 µl of DMSO were added in order to dissolve the coloured formazan 
crystals produced by reduction of the tetrazolium salts. The cell viability 
tested with the XTT assay was measured at 450 nm in a microplate reader 
(VERSAmax, Molecular Devices, Sunnyvale, CA, USA) or at 570 nm (after 
subtracting the absorbance at 690 nm) when viability was assessed by MTT 
using an Appliskan plate-reader. The percentage of cell viability was 
estimated by comparing cells treated with free MIT or HFt-MP-PASE-MIT 
to mock treated cells. To compare the killing efficacy, we evaluated the IC50, 
i.e., the compound concentration yielding 50% cell viability.  
 
2.3. Bacterial cell cultures 
In order to prevent bacteria, fungi, mycoplasma and virus contaminations, 
standard operating procedures and good laboratory practices were followed. 
 
2.3.1. Generation of competent cells 
Competent cells were obtained as follows. 1 mL of BL21-Gold (DE3) 
cells was grown overnight at 37°C in 100 mL Luria Bertani broth (LB). The 
cells were then incubated at 37°C under shaking for 1.5-3 h until the optical 
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density at 600 nm (OD600) reached 0.4-0.6. Cells were then incubated for 30 
min on ice and centrifuged at 4.000 g for 20 min at 4°C. The supernatant was 
discarded, the pellet gently resuspended in 10 mL of a cold solution of 0.1 M 
CaCl2 and then incubated on ice for 2 hours. Finally, the cells were 
centrifuged at 4.000 g for 20 min at 4°C, the supernatant discarded and the 
pellet was resuspended in 20% glycerol and frozen at -80°C in 100 µL 
aliquots. 
 
2.3.2. Transformation of competent cells 
Competent cells were transformed as it follows. 1 µL of the plasmid 
of interest (see 1.3) was gently added to 100 µL of competent BL21-Gold 
(DE3) cells and the mix was incubated on ice for 30 min before undergoing 
the thermic shock at 42°C for 1 min, followed by 2-min incubation on ice. 
Afterwards, 900 µL of sterile LB broth were added and the cells were 
incubated at 37°C for 1 h (200 rpm). Finally, 200-300 µL of transformed 
cells were plated on LB-agar plates containing the appropriate antibiotics, 
and incubated at 37°C overnight. 
 
2.4. Recombinant proteins expression and purification 
Recombinant human proteins full-length CBS wild-type, full-length 
CBS mutant p.P49L, truncated CBS409-551  mutant p.P49L, modified ferritin 
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(HFt-MP-PASE) have been expressed in Escherichia coli and purified. The 
vectors used to transform Escherichia coli BL21(DE3) competent cells were 
reported in 1.3. 
 
2.4.1. Expression and purification of full-length CBS wild-type and p.P49L 
mutant  
According to (Vicente, 2014) , transformed cells were grown at 37°C 
in LB broth containing 25 mg L
-1
 kanamycin and 34 mg L
-1
 chloramphenicol 
until A600nm reached 0.4–0.5. Gene overexpression was induced by the 
addition of 0.5 mM isopropyl-1-thio-ß-D-galactopyranoside (IPTG), whereas 
heme biosynthesis was stimulated by the addition of -aminolevulinic acid 
(final concentration of 75 mg L
-1
) to the culture medium. After incubation at 
120 rpm and 22 °C for 4 h, cells were harvested by centrifugation and the 
pellet was resuspended in the buffer A containing 50 mM potassium 
phosphate buffer (KPi), 300 mM KCl, 10% glycerol pH 7.0, supplemented 
with 1 mg mL
-1
 lysozyme, 1 mM phenylmethylsulfonyl fluoride (PMSF), and 
a few grains of DNase I (10 ml per litre of culture).  The resuspended cells 
were incubated on ice for 30 min and then disrupted by sonication. After 
centrifugation at 8.200 g for 5 min at 4°C, 10 mM imidazole was added to the 
cleared supernatant. Purification of the His-tagged protein was performed by 
affinity chromatography using a 1-mL HisTrap FF crude column (GE 
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Healthcare). Chromatography was carried out in an ÅKTA Prime fast 
performance liquid chromatography system (GE Healthcare). The column 
was washed with 15 volumes of buffer B (Buffer A containing 10 mM 
imidazole with or without 20 µM pyridoxal-5’-phospate [PLP]) at a rate of 1 
mL min
-1
, and the protein was then eluted in 20 volumes of a linear imidazole 
gradient up to a final concentration of 500 mM. The imidazole was then 
removed using a PD10 desalting column (GE Health- care) and the purified 
protein was concentrated in a Vivaspin 15R 30-kDa tube (Sartorius). Purity 
of the isolated proteins was assessed by SDS-PAGE and their concentration 
was determined by the Bradford method (see Quantification and biochemical 
detection of proteins), whereas the heme concentration in the isolated 
oxidized proteins was determined using ε428nm = 92.700 M
−1
 cm
−1 
(Carballal, 
2008). 
 
2.4.2. Expression and purification of truncated CBS409-551 mutant p.P49L 
According to (Vicente, 2016), transformed cells were grown at 37°C 
in LB broth containing 25 mg L
-1
 kanamycin and 34 mg L
-1
 chloramphenicol 
until A600nm reached 0.4–0.5. Protein overexpression was induced by the 
addition of 0.5 mM isopropyl-1-thio-ß-D-galactopyranoside (IPTG), whereas 
heme biosynthesis was stimulated by the addition of -aminolevulinic acid to 
the culture medium to a final concentration of 35 mg L
-1
. After incubation for 
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16 h at 120 rpm and 22 °C, cells were harvested by centrifugation and the 
pellet was resuspended in buffer A which contained 50 mM potassium 
phosphate buffer (KPi), 300 mM KCl, 10% glycerol (pH 7.0), supplemented 
with 1 mg mL
-1
 lysozyme (AppliChem), 1 mM phenylmethylsulfonyl 
fluoride (PMFS), and a few grains of DNase I (10 ml per litre of culture).  
Following a 30-min incubation on ice, cells were lysed by sonication and 
centrifuged at 8.200 g for 10 min at 4°C. The cleared supernatant was 
supplemented with 10 mM imidazole and loaded at 2.5 mL min
-1
 onto a 5-ml 
HisTrap FF crude column (GE Healthcare) previously equilibrated with 15 
volumes of buffer B (Buffer A containing 10 mM imidazole) at a rate of 5 
mL min
-1
. Protein purification was carried out in an ÅKTA Prime fast 
performance liquid chromatography system (GE Healthcare) and the protein 
was eluted in 20 volumes of a linear imidazole gradient up to a final 
concentration of 500 mM. The pooled fractions were concentrated with an 
Amicon Ultra-15 centrifugal filter unit with an Ultracel-30 membrane 
(Millipore), and the protein was further purified by size exclusion 
chromatography, using a HiLoad 26/600 Superdex S200 column (GE 
Healthcare) previously equilibrated with buffer A as such or supplemented 
with 20 µM pyridoxal-5’-phospate (PLP) (buffer C). The protein was loaded 
onto the column and eluted with buffer A or buffer C at a rate of 0.5 ml/min. 
Purity of the isolated proteins was assessed by SDS-PAGE and their 
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concentration was determined by the Bradford method (see Quantification 
and biochemical detection of proteins), whereas the heme concentration in 
the isolated oxidized proteins was determined using ε428nm = 92.700 M
−1
 cm
−1 
(Carballal, 2008). 
 
2.4.3. Expression and purification of the PASE-derivative of human ferritin 
(HFt-PASE) 
 According to (Falvo, 2016), cells harboring the designed plasmid 
were grown at 37°C in 1 L ampicillin-containing Terrific Broth (TB) until 
OD600 reached 0.6. Gene overexpression was induced by addition of 0.5 mM 
isopropyl-1-thio-ß-D-galactopyranoside (IPTG) and cells were further grown 
overnight at 22°C. Cells were then harvested by centrifugation (6.000 rpm for 
20 min), resuspended in 50 mM Tris-HCl (pH 7.5), 0.5 mM dithiothreitol 
(DTT), 1 mM ethylenediamine tetra-acetic acid (EDTA), and 300 mM NaCl 
and then disrupted by sonication in the presence of 1 mM 
phenylmethylsulfonyl fluoride (PMFS). The lysate was centrifuged at 16.000 
rpm for 45 min and the supernatant containing the soluble fraction was 
incubated at 37 °C for 40 min with 0.1 mg mL
-1 
DNase supplemented with 10 
mM MgCl2, heated to 55 °C for 8 min and finally centrifuged to remove 
denatured proteins. The recovered supernatant was heated to 72 °C for 8 min, 
and then centrifuged to remove denatured proteins. The recovered 
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supernatant was precipitated using an ammonium sulphate cut at 75% 
saturation (w/v). The pellet was resuspended and dialyzed overnight against 
phosphate saline buffer (PBS) pH 7.5 and then loaded on a strong anion 
exchange HiTrap Q HP column (Q Sepharose High Performance GE 
Healthcare, Boston, USA), previously equilibrated with the same buffer. In 
these conditions, HFt samples eluted from the column, whereas other E. coli 
proteins and DNA contaminants did not. The recovered HFt samples were 
ultracentrifuged at 35.000 rpm for 55 min at 6°C using a Beckman L8-70M 
ultracentrifuge (Beckman Coultier). The recovered supernatant was then 
precipitated using ammonium sulphate at 65% saturation (w/v). The pellet 
was resuspended and dialyzed overnight against PBS pH 7.5, pooled, 
concentrated using concentration tubes with cut-off 30 KDa Amicon Ultra-15 
centrifugal filter devices (Millipore, Billerica, MA, USA), sterile filtered, and 
finally stored at 4 °C. Typical yields were 100 mg of pure proteins per 1 L 
culture. The purity of all the preparations was assessed using SDS-PAGE 
electrophoresis and Coomassie brilliant blue staining (see Quantification and 
biochemical detection of proteins). Protein concentration was determined 
spectrophotometrically at 280 nm, using a molar extinction coefficient (on a 
24-mer basis) of 4.56 x 10
5
 M
-1
 cm
-1
 (ProtParam sofware, www.expasy.org). 
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2.4.3.1. Encapsulation of mitoxantrone in the HFt-based nanocarriers 
The chemotherapeutic agent mitoxantrone (MIT) was encapsulated 
using the previously reported HFt disassembly/reassembly method used for 
doxorubicin (DOXO) (Falvo 2016). Briefly, solutions of HFt-MP-PASE (see 
2.3) in 0.1 M NaCl were incubated for 10 min at pH 2.0 (pH adjusted with 
HCl). Then, MIT was added to the solution at a 250:1 molar ratio with 
respect to the protein. The pH was initially maintained at 2.5 for 5 min and 
then increased to 7.5 using NaOH. The resulting solution was stirred at room 
temperature for 30 min, filtered and dialyzed overnight vs phosphate buffer 
saline (PBS) at pH 7.4 to remove unbound MIT. After dialysis, solutions 
were centrifuged at 15.000 rpm for 30 min at 4°C. The supernatant was 
collected, concentrated with 30 kDa Amicon Ultra-15 centrifugal devices, 
sterile filtered and stored at 4°C in the dark. HFt and MIT content of the 
samples was determined by the Lowry method and UV-VIS absorption 
spectroscopy, respectively, after extracting MIT in 1 N HCl, 95% ethanol. 
MIT was quantified by using the calculated molar extinction coefficient ε610  
=19.200 M
−1 
cm
−1
. 
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2.5. Preparation of gasotransmitters stock solutions 
 
2.5.1. Sulfide solution 
Stock solutions of Na2S were prepared by quickly washing with 
degassed Milli-Q water the surface of a Na2S crystal, and then dissolving it in 
degassed Milli-Q water under a N2 atmosphere. The concentration of Na2S in 
solution was measured spectrophotometrically using 5,5’-dithiobis-(2-
nitrobenzoic acid) (DTNB) according to (Nashef, 1977) in a Cary 60 UV-VIS 
spectrophotometer. DTNB is widely used for thiol quantitation using the 
extinction coefficient ε412=13.600 M
-1
 cm
-1
. The reaction between DTNB and 
H2S generates two molecules of the yellow compound 5-thio-2-nitrobenzoate 
anion (NTB
-
) and this stoichiometry was taken into account for the 
calculation of the H2S concentration. Briefly, 100 µL of 5 mM DTNB 
solubilised in 100 mM HEPES, pH 7.1, was added to 850 µl of ultrapure 
water in a 1mL-quarz cuvette. After blank determination, three consecutive 
kinetic runs were collected, each following the addition of 3 µL of the Na2S 
solution. The observed absorption change values (ΔA) were used to 
determine the concentration of the Na2S solution using ε412 = 13.600 M
-1
 cm
-1 
and dividing the resulting value by 2 (Nashef, 1977). The Na2S working 
solutions was prepared diluting a ~1 M freshly prepared stock solution with 
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degassed ultrapure water in a syringe and were stored on ice and protected 
from light before the use.  
 
2.5.2. Carbon monoxide solution 
Carbon monoxide (CO) stock solutions were prepared by thoroughly 
equilibrating degassed buffer (50 mM KPi, 300 mM KCl 10% glycerol, 100 
µM EDTA, pH 7.0) with the pure gas at 1 atm, yielding 1mM CO at 20°C.  
 
2.5.3. Nitric oxide solution 
 Nitric oxide (NO) solution was prepared by equilibrating degassed 
ultra-pure water with NO∙ gas at 1 atm and 20°C using a tonometer. In these 
conditions, the solubility of NO∙ is 2 mM. The concentration of NO∙ in 
solution was determined by titrating CcOX. The reduced enzyme indeed 
binds NO∙ according to a 1:1 stoichiometry leading to a characteristic 
absorption spectrum. Finally, NO∙ solution was kept on ice and protected 
from light before the use. 
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2.6. Protein quantification and immunodetection 
 
2.6.1. Bicinchoninic acid (BCA) and Bradford assays  
Total protein content in the extracts derived from the cultivated 
SW480 cells (see 2.1.4) and the concentration of the purified recombinant 
proteins (see 2.3) were obtained by bicinchoninic acid (BCA) and Bradford 
assays, respectively. BCA assays were carried out using the BCA Kit. A 
standard curve was obtained using a series of dilutions of bovine serum 
albumin (BSA) (0, 0.3, 0.6, 0.9, 1.2, 1.5, 1.8, 2 µg µL
-1
). Then, 5 µL of 
sample and standard protein were diluted in 200 µL of BCA working solution 
(obtained mixing solutions A and B in a 50:1 ratio) in a 96-well plate. After 
incubating the plate at 37°C for 30 min, the absorbance at 562 nm was 
measured using a plate-reader (Appliskan Multimode). Protein concentration 
in the sample was calculated with reference to the BSA standard curve. To 
perform the Bradford method the Protein Assay Solution was used. A series 
of dilution of the BSA stock solution were made in order to obtain a standard 
curve (0, 2, 6, 8, 10 µg µL
-1
). Then, 5 µL of sample and standard were diluted 
in 200 µL of the Bradford solution in a 96-well plate. After incubating the 
plate at 25°C for 5 min, the absorbance at 595 nm was measured using a 
plate-reader (Appliskan Multimode). The protein concentration of the sample 
was calculated with reference to the BSA standard curve. 
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2.6.2. SDS-electrophoresis 
Purified proteins (see 2.3) were analyzed by SDS polyacrylamide gel 
electrophoresis (SDS-PAGE). We used precast Bis-Tris NuPage gels at 10% 
or 4-12% acrylamide. The running buffer was the 20X MOPS SDS running 
buffer and the sample were loaded using the 4X NuPage LDS sample buffer. 
The electrophoretic run was performed at 100-120 V. The proteins were 
stained using Coomassie brilliant blue. 
 
2.6.3. Western blot analysis 
 For Western blotting assays, SW480 cells were lysed as described 
previous (see 2.1.1, 2.1.2 and 2.1.4). After total protein content determination 
by BCA assay, proteins (20 µg) were mixed with 4X Laemmli protein sample 
buffer and separated on 10% SDS-PAGE using Mini-PROTEAN TGX stain-
free precast gels and the running buffer 10X Tris/glycine/SDS. The 
formulation of these gels includes trihalo compounds which lead to UV 
fluorescence emission on reaction with proteins (Rivero-Gutiérrez, 2014; 
Short & Posch, 2011), allowing to estimate and normalize the total loaded 
protein, using a ChemiDoc MP imaging system (Bio-Rad) without resorting 
to any staining procedure. Proteins were then transferred onto a 
polyvinylidene difluoride (PVDF) or a nitrocellulose membrane. The 
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membranes were blocked by PBS containing 0.1% (v/v) Tween 20 and 3% of 
BSA for 1 h at room temperature and then incubated overnight at 4°C with 
rabbit polyclonal antibody against human SQR (1:150), followed by 
incubation with horseradish peroxidase-conjugated secondary antibody. 
Afterwards, membranes were washed and developed using Clarity Western 
ECL substrate. Finally, the intensity of the target protein band was 
normalized to total protein content assessed as described above. 
 
2.7. Citrate synthase activity determination 
SW480 cell lysates obtained as described in 2.1.1, 2.1.2 and 2.1.4 were 
assayed for their citrate synthase activity (Srere, 1969). Citrate synthase is an 
enzyme of the mitochondrial matrix, commonly used as a quantitative marker 
of mitochondrial mass. This is an enzyme of the Krebs cycle which catalyses 
the reaction between acetyl coenzyme A (acetyl CoA) and oxaloacetic acid 
(OAA) to form citric acid. The hydrolysis of the thioester of acetyl CoA 
results in the formation of CoA with a thiol group (CoA-SH). The thiol reacts 
with the 5,5’-dithiobis-2-nitrobenzoic acid (DTNB) to form the yellow 
product 5-thio-2-nitrobenzoic acid (TNB). TNB formation was assessed 
spectrophotometrically using a Cary 60 UV-VIS spectophotometer and 
ε412=13.600 M
-1
 cm
-1
. The assay was performed at 30°C under stirring using 
a 1mL-cuvette and the following reaction mixture: 
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Reagent Starting conc Volume Final conc 
Buffer Tris-HCl 100 mM 910 µl 100 mM 
Acetyl-CoA 30 mM 10 µl 0.3 mM 
DTNB 10 mM 10 µl 0.1 mM 
OAA 10 mM 50 µl 0.1 mM 
Lysates  20 µl  
 
Finally, the activity was normalized to million cells. 
 
2.8. H2S consumption measurements 
 
2.8.1. Respirometric method 
O2 consumption measurements were carried out at 37°C under stirring 
by high resolution respirometry using an Oxygraph-2k (OROBOROS 
Instruments, Innsbruck, Austria). The instrument allows to measure the O2 
concentration (µM) and the O2 consumption rate (OCR) (nM s
-1
) in real time 
through an O2 Clark-type electrode. The probe of this electrode is a platinum 
wire coated with Ag/AgCl. The gas selectivity is achieved by a gas-
permeable membrane isolating the probe from the other redox-active non-
gaseous molecules and by setting the applied polarization voltage to 0.67 V, 
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specific for O2 reduction to H2O (1/2 O2 + 2 e
-
 + 2 H
+
  H2O). The oxygen 
electrode was calibrated by recording the signal in air-equilibrated buffer 
(corresponding to [O2] in the range 200-300 μM, calculated from the 
solubility of the gas in the experimental conditions used) and subtracting the 
signal measured on addition of sodium dithionite ([O2] = 0). The instrument 
is equipped with two 1.5 mL-chambers and a titration-injection microPump 
(Tip-2k) used to perform controlled sulfide injections directly into the 
measuring chambers. 
 
 
Figure 1. a) The OROBOROS Oxygraph 2k with the titration-injection microPump (Tip-2k) 
on top. b) Inside view of the instrument. Image from Oroboros Oxygraph 2k Instruction 
Manual. 
To carry out respirometric assays, SW480 cells were harvested as 
described in 2.1 and 2.2. After equilibration and calibration of the instrument 
with complete cell medium, 4 x 10
6
 cells were added into each chamber at a 
final density of 2.6 x 10
6
 cells mL
-1
. Basal respiration was monitored for ~ 10 
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min and then 10 µM rotenone was added. In a set of control experiments, 
performed to determine the sulfide autoxidation and sulfide-induced extra-
mitochondrial O2 consumption to be subtracted, both 10 µM rotenone and 5 
µM antimycin A were added to the chamber. After stabilization of O2 
consumption in the presence of rotenone (or rotenone and antimycin A), a 
solution of sulfide (3-5 mM) was injected at increasing rate (10 nL s
-1
, 20 nL 
s
-1
, 40 nL s
-1
, 80 nL s
-1
 and 160 nL s
-1
). Each sulfide injection lasted 180 s 
and was restarted only after restoration of the O2 consumption rate measured 
in the absence of sulfide. 
According to (Abou-Hamdan, 2015), the mitochondrial sulfide-oxidizing 
activity in a cell suspension can be evaluated from the stimulatory effect 
produced on cell respiration by sulfide injection. The protocol provides: 
- Addition of rotenone (a specific inhibitor of complex I) to prevent 
complex I from working in a reverse mode, as reported for colon 
cancer cells; 
- Addition of rotenone and antimycin A (a specific inhibitor of complex 
III) to block mitochondrial sulfide oxidation.  
- Injections of Na2S at increasing flow rates in order to stimulate 
mitochondrial respiration. The injections were repeated at increasing 
injection rate until inhibition of complex IV occurred. 
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The maximal sulfide-oxidizing activity was calculated from the maximal 
oxygen consumption stimulation by Na2S (occurring at the highest injection 
rate non inhibitory for CcOX) taking into account the H2S/O2 stoichiometric 
coefficient (1.33) reported in (Lagoutte, 2010). Finally, data were normalized 
to millions of cells and citrate synthase activity. 
 
 
2.9. H2S synthesis measurements 
 
2.9.1. Amperometric methods 
In order to detect the H2S production, the amperometric assays were 
performed using an ISO-H2S-2 hydrogen sulfide-selective sensor coupled to 
an Apollo4000 Free Radical Analyzer (World Precision Instruments).  
 
 
Figura 2. ISO-H2S-2 sulfide selective electrode. Image from ISO-H2S-2 Instruction 
Manual. 
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Hydrogen sulfide (H2S) diffuses through a selective membrane covering the 
sensor and is oxidized, resulting in an increase in electrical current. The 
changes in electrical current, expressed in pA, are proportional to the 
concentration of hydrogen sulfide in the sample. ISO-H2S-2, therefore, has 
been used for measuring H2S concentrations in samples. It is important, to 
keep the pH constant during the measurements and acquire calibration curves 
under similar conditions. Briefly, according to (Vicente, 2017), H2S 
production by recombinant human CBS variants was measured at 37°C in the 
presence of 50 mM potassium phosphate buffer (KPi), 300 mM KCl, 10% 
glycerol and 100 µM EDTA (pH 7.0). Purified CBS (0.5–1 µM) was 
incubated for 10 minutes with 50 µM PLP, 260 U mL
-1
 catalase and 0.4–2.0 
mM homocysteine in the absence or presence of 0.5 mM AdoMet, after 
which 10 mM cysteine was added to trigger the reaction. After monitoring 
H2S production for 3 minutes, the electrode was internally calibrated by 
adding 4 µM NaHS (corresponding to 2µM H2S at pH 7.0). Finally, 50 µM 
o-acetylserine and 200 nM Entamoeba histolytica o-acetylserine 
sulfhydrylase were added to the reaction mixture to remove H2S from 
solution and bring the signal back to baseline  
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2.9.2. Lead acetate assay 
H2S activity assays by the lead acetate method were carried out in a 
thermostated cuvette under stirring, according to (Chiku, 2009). H2S 
production by the recombinant human CBS p.P49L variant was measured at 
37°C in a reaction buffer containing 50 mM potassium phosphate buffer 
(KPi), 300 mM KCl, 10% glycerol and 100 µM EDTA (pH 7.0). Purified 
CBS (0.5–1µM) was incubated for 10 minutes with 50 µM PLP, 260 U mL-1 
catalase, and 0.4–2.0 mM homocysteine in the absence or presence of 0.5 
mM AdoMet. Afterwards, 10mM cysteine was added to trigger the reaction. 
Lead acetate (400 µM) was added to the reaction mix prior to cysteine 
addition. The reaction of H2S with lead acetate generates a brown precipitate 
of lead sulfide, detected as an absorption increase at 390 nm using an Agilent 
Cary-60 UV-VIS spectrophotometer. The molar extinction coefficient for lead 
sulfide under these conditions was determined to be 5.500 M
-1
 cm
-1
. NaHS 
was used as standard. 
 
2.10. Equilibrium titrations 
 UV-visible absorption spectra of oxidized and reduced p.P49L and 
WT CBS (see 2.3) were recorded in a Cary-60 UV-VIS spectrophotometer 
(Agilent). Anaerobic titrations of reduced CBS p.P49L with CO were 
performed at 20°C in the same spectrophotometer. Gas exchange was 
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prevented either by filling the quartz cuvette and sealing it with a rubber-cap 
or by adding mineral oil on top of the aqueous medium. Anaerobic conditions 
were ensured by nitrogen flushing and addition of glucose oxidase (4 U 
mL
−1
), catalase (13 µg mL−1), superoxide dismutase (12 U mL−1), and 
glucose (3 mM) to scavenge contaminant oxygen, hydrogen peroxide, and 
superoxide anion in the reaction buffer (50 mM potassium phosphate buffer 
(KPi), 300 mM KCl, 10% glycerol, 100 µM EDTA, pH 7.0, with or without 
PLP (see 2.3). p.P49L and WT CBS (1.4–1.6 µM in heme, as determined 
using ε428nm = 92.700 M
−1
 cm
−1
 (Carballal, 2008) were reduced with 90 µM 
sodium dithionite, diluted from a 45 mM stock solution (quantitated using 
ε314nm= 8.043 M
−1⋅cm−1 (Dixon,  1971). CO stock solutions were prepared as 
reported in 2.4. After each CO addition with a gas-tight Hamilton syringe, the 
spectral changes were visually inspected in real time and a new addition was 
immediately made when no more changes were observed. According to 
(Puranik et al., 2009), two apparent Kd (Kd,1 andKd,2) were used to 
satisfactorily fit the CO affinity data. The Kd,1 and Kd,2 values were obtained 
by fitting the data to:  
 
𝑃𝐿 =
α1[(𝑃𝑇 + 𝐿𝑇 + 𝐾𝑑1) − √(𝑃𝑇 + 𝐿𝑇 + 𝐾𝑑1)2 − 4𝑃𝑇𝐿𝑇] + α2[(𝑃𝑇 + 𝐿𝑇 +𝐾𝑑2) − √(𝑃𝑇 + 𝐿𝑇 + 𝐾𝑑2)2 − 4𝑃𝑇𝐿𝑇]
2
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Where PL is the concentration of CO-bound CBS p.P49L, PT and PL are, 
respectively, the total CBS p.P49L and CO concentrations, and Kd,1 and Kd,2 
are, respectively, the protein fractions binding CO at higher (Kd,1) and lower 
(Kd,2) affinity. 
 
2.11. Stopped-flow absorption spectroscopy measurements 
Time-resolved absorption spectroscopy experiments were carried out in a 
thermostated stopped-flow instrument (DX.17MV, Applied Photophysics), 
equipped with a photodiode-array (light path = 1 cm). To avoid light-induced 
artifacts, the intensity of the white-light incident beam was decreased and a 
filter cutting UV light at < 360 nm was employed. Absorption spectra were 
recorded with an acquisition time of 10 ms per spectrum according to a 
logarithmic time scale.  
 
 
Figure 3. Schematic representation of a stopped-flow instrument. In this apparatus, two 
solutions (A and B) can be mixed in equal volume or, prior to data recording, A and B can 
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pre-mixed and, after a pre-set delay time, further mixed with an equal volume of a third 
solution (C). Image from DX.17MV Stopped Flow Instruction Manual. 
 
All reactions were carried out at 25°C in the reaction buffer 
containing 50 mM potassium phosphate buffer (KPi), 300 mM KCl, 10% 
glycerol, 100 µM EDTA (pH 7.0), in the presence or absence of PLP (see 
2.3). CBS p.P49L was thoroughly flushed with nitrogen, and then glucose 
oxidase (4 U mL
−1
), catalase (13 µg mL−1), superoxide dismutase (12 U 
mL
−1
), and glucose (3 mM) were added to scavenge oxygen, hydrogen 
peroxide and superoxide anion. The protein was then placed on ice, protected 
from light to prevent possible damaging photoreactions. When indicated, 
CBS p.P49L was incubated with AdoMet for ≥ 10minutes, prior to reduction 
with 90 µM sodium dithionite. CO association kinetics were studied by 
mixing in the stopped-flow apparatus reduced CBS p.P49L, in the absence or 
presence of AdoMet, with CO solutions and the spectra were recorded over 
time. CO dissociation kinetics were evaluated by mixing the Fe(II)-CO 
adduct of CBS p.P49L with NO∙ stock solutions (see 2.4). 
 
2.12. Data Analysis 
CO affinity titrations and CO binding and dissociation kinetic data 
were analyzed with the software MATLAB (Mathworks). Global fit analysis 
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of spectral data was performed by singular value decomposition analysis 
combined with curve fitting. Oxygen consumption rate (OCR) was acquired 
using DatLab software (Oroboros Instruments). Densitometric analysis of 
blotted membranes and of total protein load on gel was carried out with 
Image Lab software (Bio-Rad). IC50 values were calculated using OriginLab 
software (OriginLab Corporation).  
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CoA: coenzyme A  
AdoMet: S-adenosyl-L-methionine 
AOAA: aminooxyacetic acid 
ATP: adenosine triphosphate 
BCA: bicinchoninic acid  
BSA: bovine serum albumin 
CBS: cystathionine β-synthase 
CoQ: coenzyme Q 
CRC: colorectal cancer 
CSE: cystathionine γ-lyase 
DAO: D-amino acid oxidase 
DOXO: doxorubicin  
DTNB: 5,5’-dithiobis-(2-nitrobenzoic acid) 
EDTA: ethylenediamine tetra-acetic acid  
ETC: electron transport chain 
ETHE1: persulfide dioxygenase or ethylmalonic encephalopathy 1 
Ft: ferritin 
GHS: glutathione 
hCBS: human cystathionine β-synthase 
HFt: heavy chains ferritin  
HIF: hypoxia-inducible factor 
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IPTG: isopropyl-1-thio-ß-D-galactopyranoside  
KPi: potassium phosphate buffer 
LB: Luria Bertani broth 
LFt: light chains ferritin 
MIT: mitoxantrone 
MMP: metalloproteinase 
MST: 3-mercaptopyruvate sulfurtransferase 
MTT: thiazolyl blue tetrazolium bromide  
NAD: nicotinamide adenine dinucleotide 
NP: nanoparticle 
OAA: oxaloacetic acid  
PBS: phosphate buffered saline  
PLP: pyridoxal 5’-phosphate 
PMSF: phenylmethylsulfonyl fluoride   
SAM: S-adenosyl-L-methionine 
SOU: sulfide oxidizing unit 
SQR: sulfide:quinone oxidoreductase 
TfR1: transferrin receptor 1  
TNB: 5-thio-2-nitrobenzoic acid  
XTT: 2,3 – bis - (2-methoxy-4-nitro-5-sulfophenyl) - 2H – tetrazolium – 5 - 
carboxanilide  
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